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Abstract  
Events during wound repair are reminiscent of developmental events such as cell migration, 
redifferentiation and proliferation. Factors controlling these processes in the early embryo may 
therefore be important regulators in adult wound healing. Fibrosis is a disease of dysregulated 
wound healing with fibroproliferative disorders accounting for 45% of deaths in developed nations. 
Despite this, effective antifibrotic therapy is limited. Understanding factors regulating wound repair 
process will aid identification of potential therapeutic targets.   
This project first explored how activation of developmental signalling pathways influences regulation 
of myofibroblast transdifferentiation and behaviour in liver fibrosis, focusing on the Wnt signalling 
pathway. Wnt signalling was upregulated in activated myofibroblasts, with significantly increased 
expression of non-canonical ligands. Wnt stimulus did not provoke a canonical/β-Catenin mediated 
response, with myofibroblasts responding through non-canonical associated signalling instead. 
Inhibition of Wnt signalling reduced classic markers of fibrosis, suggesting a profibrotic role for Wnt 
signalling during liver fibrosis. Stimulus with the non-canonical ligand Wnt5a did not directly affect 
expression of fibrotic markers in myofibroblasts. Instead it appeared to act as a prosurvival factor 
and increased expression of profibrotic cytokines in resident liver macrophages.      
Dynamic changes in DNA methylation pattern also regulate embryonic development. This project 
next explored whether inheritance of epigenetic marks could alter early DNA methylation patterns 
and affect response to injury in adult, focusing on the histone variant H2A.Z. H2A.Z is thought anti-
correlative to DNA methylation and has been shown to be enriched in the sperm of injured animals 
in a model of transgenerational adaptation to wound healing. H2A.Z expression was depleted via 
morpholino injection in early zebrafish embryos, resulting in significant mortality and phenotypic 
abnormality. Injected animals displayed significant hypermethylation of DNA during early embryonic 
periods. This suggests that alteration of epigenetic marks can influence methylation status of DNA.   
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Chapter 1: INTRODUCTION 
1.1 Wound healing and Fibrotic Disease 
 
Tissue injury and the resulting epithelial cell damage triggers a highly co-ordinated, multicellular 
response, facilitating repair and restoration (1). Wound healing can be broadly divided into three 
different phases: the inflammatory, the proliferative and the resolving phase and is summarised by 
Figure 1.1. General mechanisms of wound healing are conserved throughout the body and are vital 
for restoration of normal tissue architecture and protection from external pathogens. Most 
vertebrates cannot completely regenerate lost or damaged tissue, healing instead through the 
process of scar formation (2). 
 
The initial inflammatory phase occurs rapidly after injury. Damaged epithelial cells release damage 
associated molecular pattern molecules (DAMPs) promoting the recruitment of inflammatory cells 
to the site of injury. Infiltrating immune cells clear the injury site of debris and release a multitude of 
growth factors and cytokines, stimulating migration of the fibroblasts and smooth muscle cells 
critical for the second proliferative phase(3). Major cytokines directing the wound healing response 
include Platelet Derived Growth Factor (PDGF) and TGFβ1(4) 
 
Repair of injury requires increased production and deposition of extracellular matrix, producing a 
fibrotic scar to replace lost or damaged tissue. Fibroblasts are the major cell type involved in the 
secretion of matrix components  with Type 1 collagen the major component of the fibrotic scar(5, 6). 
Upon wound closure, activated fibroblasts are cleared from the injury site and there is a shift 
towards the resolution phase and a gradual remodelling of the collagen scar(1). 
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This highly sequential process can become disrupted under conditions of chronic injury. Fibrosis is a 
disease of dysregulated wound healing. Repeated insult leads to the persistent activation of 
profibrogenic myofibroblasts, the excessive deposition of fibrotic matrix and the subsequent 
disruption of organ function(7). Fibroproliferative diseases involving a number of organs include 
idiopathic pulmonary fibrosis (IPF), diabetic nephropathy, hepatic cirrhosis and systemic 
scleoderma(SSC) account for approximately 45% of deaths in developed nations(8). Effective anti-
fibrotic therapy is currently limited making fibrotic disease a significant health issue for the modern 
world 
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Figure 1.1  Summary of Wound Healing  
Tissue injury and resulting epithelial cell damage triggers inflammation and fibroproliferation, 
promoting repair through deposition of scar. Chronic injury results in persistent activation of 
fibroblasts and excessive deposition of matrix  
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1.2 Myofibroblast Activity and Regulation 
 
A hallmark of fibrosis is the activation of profibrogenic myofibroblasts. Myofibroblasts are not 
normally detected in healthy tissue and are activated only upon injury (7). They are characterised by 
high expression of alpha smooth muscle actin (α-SMA), leading to increased contractility as well as 
other phenotypic traits such as increased proliferation and migratory potential(7). They originate 
from numerous types of precursor such as endothelial cells, epithelial cells, pericytes as well as 
resident fibroblasts. As the major producers of extracellular matrix, myofibroblasts are the ideal 
target for antifibrotic therapy. Fully understanding the pathways that regulate their differentiation, 
activity and clearance will enable identification of targets for pharmacological modulation. 
 
Parallels have been drawn between the events occurring during wound healing and those occurring 
during embryonic morphogenesis such as the highly co-ordinated movements of cells and tissues(9).  
Tissue morphology during embryogenesis is regulated by the morphogen families of signalling 
molecules such as the Hedgehog (Hh), Notch, Wnt, Fibroblast Growth Factor (FGF) and Transforming 
Growth Factor –β (TGF β) families(10). Morphogens function in a concentration specific manner, 
establishing morphogen gradients to govern the response of receiving cells, directing migration, 
differentiation and cell fate specification(11). 
 
In adults, morphogen activity in healthy tissue is limited and is only active when the need arises, 
during cell renewal and regeneration for example(10). If these pathways become irregularly active, 
the subsequent disruption of normal cell adhesion, proliferation and differentiation is a significant 
risk factor for pathology. Activation of embryonic developmental pathways in cancer is well 
established:  mutations in β-Catenin for example,  a downstream effector of the Wnt family, are a 
hallmark of numerous cancers(12). 
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Recent research connects morphogen signalling to wound healing and fibrosis. Reactivation of these 
embryonic signalling pathways has been implicated in promoting activity of myofibroblasts in 
numerous fibrosis models such as SSC, IPF and renal fibrosis(13-17). Furthermore, blockade of 
morphogen activity diminishes myofibroblast activity: knockdown of the Hh transcription factor Gli 
for example attenuates the fibrotic response mice after unilateral ureteral obstruction (UUO) 
injury(18). Manipulating morphogen signalling could therefore be an attractive possibility for 
modulating the fibrotic response. 
1.3 Liver Fibrosis  
 
Although the liver has remarkable potential for regeneration and repair chronic liver disease is a 
major health burden. Approximately one million deaths per year worldwide are attributed to 
cirrhosis, the end stage of liver fibrosis, making it the 14th most common cause of death(19).  Liver 
transplant is currently the only effective treatment with over 5500 transplants performed in Europe 
per year (20). A shortage of donor material however significantly limits the availability and efficacy 
of this treatment. The major cause of liver injury is chronic alcohol abuse although other 
contributing factors include viral infection and metabolic syndrome, damage due to the 
accumulation of fat and impaired lipid metabolism(21) 
The initial insult leads to inflammatory damage, death of parenchymal cells and activation of 
myofibroblasts. Early stages of liver fibrosis are characterised by excessive ECM deposition and scar 
formation but few clinical symptoms.  Evidence suggests that if underlying aetiology is removed at 
this early fibrotic stage, reversion to normal liver function is possible (8). Continuous injury however 
promotes development of advanced fibrosis and cirrhosis. Cross linking of deposited matrix renders 
scars increasingly resistant to degradation, disordering tissue architecture and disrupting liver 
function(22). Increased ECM deposition distorts the hepatic vasculature, gradually increasing the 
hepatic venous pressure gradient (HVPG) and resulting in portal hypertension. Clinical complications 
 6 
 
associated with cirrhosis include variceal bleeding, ascites, renal failure and hepatic 
encephalopathy(23). In addition, there is dysregulation of hepatocyte regeneration and the 
development of regenerating nodules, a significant risk factor for hepatocellular carcinoma 
(HCC)(24). Here, potential for reversion is limited and the only complete treatment is liver 
transplant. 
The liver is composed of multiple cell types with hepatocytes the most abundant, comprising 
between 70-80% of the liver cell mass. They are the primary functional cells in the liver, involved in 
protein synthesis and storage, carbohydrate and lipid metabolism and synthesis and secretion of 
bile(25). In addition, there are Kupffer cells , the liver resident macrophages, sinusoidal endothelial 
cells and the mesenchymal hepatic stellate cell (HSC). The primary source of pro-fibrogenic 
myofibroblasts upon liver injury is thought to the hepatic stellate cell(26). 
1.4 Models of Liver Fibrosis 
Numerous in vivo animal models aid study of these numerous aetiologies.  Toxin- mediated 
induction of liver injury is a widely used method with intraperitoneal administration of carbon 
tetrachloride (CCl4) one well established model(27). Inflammatory response is induced upon 
administration and fibrosis observable after 4-6 weeks of repeated injection. Resolution of scarring 
occurs once injections stop, making CCl4 a good model for all stages of the fibrotic response: initital 
inflammation, fibrogenesis and fibrosis resolution. Bile duct ligation (BDL) is a common model of 
cholestatic injury(28). Non Alcoholic Fatty Liver Disease (NAFLD), a significant contiributor to liver 
disease worldwide, can be modelled by several dietary regimes such as high fat diets or methionine - 
coline deficient (MCD) diets(29). 
In vitro, hepatic stellate cells (HSCs) the primary source of profibrogenic myofibroblasts can be 
isolated by enzymatic digestion and density gradient centrifugation from liver tissue(30). However, 
difficulties encountered with primary cell culture such as limited amount of source tissue and 
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variability between preparations have led to the development of several HSCs cell lines from rat, 
mouse and human. The human LX-2 cell line is the most widely used,  developed from 
spontaneously immortalised human HSCs and considered representative of fully activated 
myofibroblasts(31).  Finally, more sophisticated in vitro culture methods such as precision cut tissue 
slices are increasingly being used. Culture of tissue slices allows study of a multicellular system in 
vitro, where tissue architecture, ECM composition and cell-cell contacts are maintained(32). This is 
far more physiologically relevant than the monoculture of primary HSCs or cell lines which is 
currently the main method of in vitro liver fibrosis study. 
1.5 Hepatic Stellate Cells 
 
Hepatic Stellate Cells are liver specific pericytes and reside in the space of Disse between the 
sinusoidal endothelial cells and the hepatocytes(26). They comprise approximately 15% of the total 
cell population.  In normal, healthy liver they are considered ‘quiescent’ (qHSC). Liver injury however 
stimulates a significant phenotypic change and transdifferentiation into pro-fibrogenic 
myofibroblasts (aHSC). Their embryonic origin is not fully resolved and evidence supports HSCs 
deriving from the endoderm, ectoderm or mesoderm. Typical markers used to identify HSCs include 
vimentin, desmin and  glial fibrillary acid protein (GFAP)(26).  Quiescent HSCs secrete a variety of 
cytokines and growth factors and their major role is in the storage of vitamin A (retinol), acting as a 
store for 80% of the body’s retinol in cytoplasmic lipid droplets. Maintenance of the quiescent 
phenotype involves an adipogenic transcriptional  profile: qHSCs express high levels of the 
adipogenic master regulator PPARγ along with other adipogenic associated transcription factors such 
as CCAAT/enhancer-binding protein (C/EBP) α, C/EBPβ, C/EBPδ and  sterol regulatory element-
binding protein 1c (SREBP-1c). 
Transdifferentiation to  profibrogenic myofibroblasts involves a massive shift in transcriptional 
profile(33). Apidogenic associated gene expression is replaced by profibrogenic mediators such as 
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TNFα, TGFβ and PDGF, several of which are known antagonists of apidogenesis(33). Expression of 
the myofibroblast marker α-SMA is significantly upregulated and as HSCs are the only major liver cell 
type to express α-SMA, this is often used as a definitive identifying marker of aHSCs(34). Clarifying 
the factors regulating this dramatic change in HSC phenotype of critical importance. Activity of 
several key transcription factors during transdifferentiation has been well defined, with roles for the 
NF-κB, KLF6, AP1, E Box binding proteins and the Smad families of transcription factors(35). 
Substantial morphological changes follow this shift in transcriptional profile with HSCs adopting 
typical myofibroblast characteristics including increased contractility, increased proliferation, stress 
fibre formation and increased migratory capacity(26) (Figure 1.2). aHSCs are the major synthesisers 
of ECM components involved in scar deposition. 
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Figure 1.2 HSC transdifferentiation 
 
Diagram detailing phenotypic and transcriptional changes occurring during HSC activation. Injury 
triggers transdifferentiation of the vitamin A storing, adipogenic like quiescent HSCs. They loose 
vitamin A storage and undergo significant phenotypic  changes such as increased contractility, 
proliferation and migration. Expression of adipogenic related genes such as PPARγ and SREBP1 is 
downregulated while expression of profibrogenic genes such as TGFβ is increased.   
 
 10 
 
1.6 Epigenetic regulation of HSC transdifferentiation 
 
Recent work has highlighted the importance of epigenetic factors in regulating myofibroblast 
transdifferentiation and progression of liver fibrosis.  Epigenetics is traditionally defined as: 
‘heritable changes in gene function that occur without changes in DNA sequence’(36). DNA is not 
found naked in the cell, packaged instead by proteins into chromatin which forms chromosomes. 
The three major epigenetic modifications are methylation of DNA, modification of histones and 
microRNA activity. Structural changes resulting from these modifications function in regulation of 
gene expression(37). 
DNA methylation is an extensively studied epigenetic modifications, highly conserved across animals, 
plants and fungi(39). Methylation of DNA is the transfer of a methyl group to the fifth position of a 
cytosine base and in mammals is restricted to cytosines present in CpG dinucleotides. Regions of 
high CpG composition are termed ‘CpG Islands’ and are a typical feature of gene promoters(38). 
When DNA methylation occurs at these regions it is normally associated with transcriptional 
repression (39).  Transfer of methyl groups is mediated by the DNA Methyltransferase (Dnmt) 
enzymes, divided into two functional classes. De novo methyltransferases (Dnmt3a and Dnmt3b) 
initiate methylation on previously unmethylated CpG sites while the maintenance methyltransferase 
(Dnmt1) recognises hemimethylated DNA during DNA replication and copy existing patterns(40, 41). 
Disruption of methylation machinery has drastic consequences for development, depletion of Dnmt 
expression in mice leading to early embryonic or early postnatal death (40, 42). Likewise, in the adult 
perturbation of methylation patterns is implicated in disease, notably in numerous cancers(43). 
Dynamic alterations of DNA methylation patterns are critical for the control of cell behaviour during 
morphogenesis. Epigenetic reprogramming during wound healing can therefore be considered 
another way in which response to injury recapitulates developmental processes(9). 
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DNA methylation can promote gene repression through two mechanisms: decreasing access of 
transcription factors to target sites or targeting repressive complexes to DNA (39). Treatment of 
cultured HSCs with the commonly used demethylating agent, 5-aza-2'-deoxycytidine, halts 
transdifferentiation of HSCs, preventing the morphological and transcriptional changes associated 
with an activated myofibroblast phenotype(44). DNA Methylation therefore has a critical role in 
regulating myofibroblast transdifferentiation. 
Methyl CpG binding protein 2 (MeCP2) is one nuclear protein which preferentially binds methylated 
DNA and is thought to function in the recruitment of corepressor proteins(45). MeCP2 is significantly 
upregulated in aHSC and is shown to regulate the activity of key transcription factors involved in HSC 
transdifferentiation. One major factor required for HSC quiescence is PPARγ, an adipogenic 
associated regulator. MeCP2 binds to the promoter of PPARγ and mediates its repression. PPARγ 
expression in MeCP2 deficient myofibroblasts is significantly increased, moreover CCl4 injured 
MeCP2 knockout animals display a reduced fibrotic response(46). MeCP2 regulates several other 
transcriptional regulators important in HSC transdifferentiation. It is associated with repression of 
IκBα, an inhibitor of the nuclear factor kappa B (NFkB) family of transcription factors necessary for 
HSC transdifferentiation(44). MeCP2 also plays a role in repression of PTCH1, an inhibitory 
component of the morphogen Hh pathway shown important in promoting HSC 
transdifferentiation(47). 
Progression from initial liver injury to the end stage cirrhosis can take between five to fifty years and 
is highly variable:  only a minority of patients with chronic liver disease progress to end stage 
cirrhosis (8). This variability cannot be explained by genetic factors alone suggesting a complex 
interaction of environmental, epigenetic and genetic influences.  A recent study explored 
multigenerational epigenetic adaptation to the wound healing response, where injury in parents led 
to epigenetic changes which can be stably transmitted to offspring(48). In this study, offspring of 
CCl4 injured parents demonstrated decreased fibrotic response when compared with offspring of 
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control, non-injured groups. Differential gene expression was accompanied by corresponding 
changes in DNA methylation status: increased methylation of the pro-fibrogenic TGFβ promoter 
corresponded with reduced mRNA expression whereas decreased methylation of the anti-fibrogenic 
PPARγ promoter corresponded with increased mRNA expression. This suggests that ancestral injury 
may be one factor contributing to population variability. How this information is transmitted 
between parent and offspring has yet to be determined. 
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1.7 Process of HSC activation 
Activation of HSCs is stimulated through receipt of paracrine signals from neighbouring cells. Injury  
dramatically alters hepatic architecture: damaged hepatocytes undergo apoptosis provoking an 
inflammatory stimulus with activation of the resident Kupffer cells and subsequent  infilitration of 
circulating lymphocytes(23). In this altered environment a multide of factors are released which 
promote transdifferentiation such as PDGF,EGF and production of reactive oxygen species mediated 
by Cyp2e1 (cytochrome P450 2E1), a member of the cytochrome P450 family of enzymes (23). 
Increased TGFβ signalling is a major profibrotic stimulus, promoting the recruitment of inflammatory 
cells and fibroblasts to the site of injury as well as stimulating increased expression of extracellular 
matrix components(49). 
This initial activation phase promotes the change in HSCs to a myofibroblast like phenotype with 
increased responsiveness to growth factors and environmental signals. aHSCs are characterised by 
expression of classic markers of activated myofibroblasts such as α-SMA, Type I collagen, Tissue 
Inhibitor of Metalloproteinase 1  (TIMP1) and TGFβ and its associated receptors(26). Once 
transdifferentiation has occurred, HSCs are able to maintain their activated phenotype through 
autocrine signalling as well as receipt of paracrine stimulus. Environmental as well as chemical 
stimuli also play a role, alterations in ECM composition for example where increased amounts of 
fibrosis associated collagens such as Type 1 collagen cause increased stiffening of matrix and further 
enforce the activated phenotype(50). Placing aHSCs on a softer matrix such as Matrigel, promotes a 
reversion to quiescence(51). 
As mentioned, aHSCs major role is in the production of ECM components. They secrete massive 
amounts of Type1 Collagen, one of the best characterised components of the fibrotic scar(52). aHSCs 
are a source of multiple members of the matrix metalloprotineases (MMPs) family involved in 
degradation of matrix, specifically MMP2, MMP9 and MMP13(53, 54). They also secrete increased 
amounts of TIMP1 involved in inhibition of MMPs as well as conferring resistance to apoptosis. This 
increased production of ECM components disrupts regulation of matrix composition: clearance of 
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matrix in early stages by increased MMP activity allows for increased deposition of collagen. This 
leads to a change shift in matrix from a laminin and type IV collagen rich composition to one 
comprising interstitial collagens such as collagens I and II(55).  Degradation of excessive collagen will 
be prevented by increased TIMP1 activity, leading to accumulation of fibrotic matrix. The 
upregulation of α-SMA, a major constituent of stress fibres, enhances their contractility and 
promotes wound closure(56). Excessive production in the chronically injured liver however disrupts 
vasculature, promoting increases in the HVPG. If injury is not resolved and aHSCs not cleared, this 
disruption of ECM will continue leading to the impairment of liver function described previously. 
As well as mediating fibrogenesis, HSCs also contribute to the immune response upon injury, 
stimulated via TLR activity such as LPS induced TLR4 signalling (57). They are highly secretory, 
producing numerous chemokines to promote migration of  inflammatory cells(26). Evidence even 
exists for them being capable of acting as antigen presenting cells (58). 
Resolution of acute injury requires clearance of HSCs, allowing for degradation of excessive matrix 
and a return to a normal hepatic architecture. Apoptosis of aHSCs is thought to be the major 
mechanism of HSC clearance(59). Specifically targeting induction of apoptosis to α-SMA expressing 
cells in the injured liver significantly improves resolution of fibrosis after CCl4 mediated liver injury, 
demonstrating its significance(60). During injury, HSCs receive pro-survival signals derived from 
matrix. Maintaining an intact matrix prevents apoptosis whereas matrix degradation, through 
recombinant MMP9 treatment for example, promotes it(61). Furthermore, increased TIMP1 
expression by aHSCs acts as an autocrine anti-apoptotic signal : liver specific overexpression of 
TIMP1 for example impairs fibrosis resolution compared to control animals in a CCl4 injury model in 
mice(62).  Under conditions of chronic injury, degradation of matrix and reduction of survival signals 
will not occur.  HSCs will therefore remain present and persistently active. 
As well as clearance of HSCs by apoptosis, there is the potential for them to ‘deactivate’, returning to 
a quiescent like phenotype. Decreased expression of activation associated genes has been observed 
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in vitro(33). In vivo studies further confirmed these findings, genetic labelling experiments 
demonstrating cells which had previously been αSMA positive during injury remaining in liver after 
cessastion of injury(63). These cells are termed inactivated HSCs (iHSCs) rather than fully quiescent 
as they demonstrated a more marked response to TGFβ1 stimulus in comparison to quiescent 
controls. Cellular senescence is also thought to contribute to aHSC clearance and fibrosis resolution. 
The accumulation of senescent cells observed in cirrhotic liver thought to be derived from HSCs and 
animals deficient for components of senescent pathway displaying reduced ability to resolve 
fibrosis(64). These studies demonstrate the importance of clearing HSCs for resolution of fibrosis. 
1.8 Morphogens and HSCs 
 
From this it is clear that HSCs are fundamental to fibrosis progression in the liver. The signalling 
events that regulate their activation need to be fully understood to facilitate identification of 
potential therapeutic targets. Regarding the potential for developmental pathway reactivation in 
HSCs, much work has been done on reactivation of Hh signalling observed in aHSCs. Upregulated Hh 
signalling occurs upon liver injury and is associated with regulating metabolism in HSCs, promoting 
glycolysis and stimulating the quiescent to activated HSC transdifferentiation(65). Blockade of Hh 
signalling is able to revert myofibroblasts to a more quiescent like phenotype as well as decreasing 
fibrotic response in a mouse CCl4 injury model(65). Further work has highlighted the importance of 
Notch signalling, again upregulated in HSCs upon injury. Inhibition of Notch in cultured HSCs again 
reduces myofibroblast markers  and inhibition in a BDL injury model attenuated the fibrotic 
response(66).  The importance of cross talk between these two pathways has also been highlighted, 
with inhibition of Notch signalling disrupting Hh activity and vice versa(66). 
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Wnt is one of the major signalling pathways active during development, critical for cell 
differentiation and proliferation(67).  However, the activity of Wnt signalling and potential 
contribution to HSC activation has not yet been fully explored. Wnt signalling is increasingly 
implicated in tissue injury and repair in the adult, observed in simple organisms such as planaria to 
numerous types of injury models in humans including myocardial infarction, bone fracture, skin 
wounding and retinal damage(68). Furthermore,  blockade of Wnt signalling disrupts invertebrate 
regeneration and impairs tissue repair in mammals(68). 
 
Activation of β-Catenin, a key downstream mediator of Wnt signalling is one of the first responses to 
tissue injury in numerous organs (69-71). Furthermore,  elevated Wnt signalling is initially beneficial 
to repair and regeneration, increased Wnt7a expression for example promotes  hair follicle 
neogenesis after wounding in mouse skin(72). However, in the situation of chronic injury, the 
promotion of cell migration and proliferation driven by Wnt activity is likely to contribute to 
pathology of fibrosis.The Wnt pathway is highly complex with numerous ligands, receptors and 
interactors. Identifying Wnt components active in HSCs may therefore identify potential targets for 
modulating HSC behaviour. 
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1.9 Wnt Signalling 
 
Wnt proteins are a family of highly evolutionary conserved secreted glycoproteins. Wnt signalling is 
a key regulator of embryogenesis across the animal kingdom: from the wingless (wg) protein first 
identified in Drosophila to the nineteen different Wnt members currently described in 
mammals(67). The Wnt signalling cascade is outlined in Figure 1.3. In summary, Wnt proteins 
secreted by signalling cells bind to their membrane bound Frizzled (Fzd) receptors, resulting in 
phosphorylation of the downstream mediator Dishevelled (Dvl).  Phosphorylated Dvl then 
propagates Wnt signalling by three potential pathways: the canonical β-Catenin associated pathway, 
the non-canonical Planar Cell Polarity (PCP) pathway or the non-canonical Calcium associated 
(Wnt/Ca2+) pathway.  Wnt ligands can be broadly classified as canonical or non-canonical depending 
on the pathway they initiate(12). 
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Figure 1.3 Summary of the Wnt Pathway  
 
An overview of the Wnt signalling pathway. Wnt ligands bind to Fzd receptors to trigger 
phosphorylation of Dvl and propagation of signal through ‘Canonical’ or ‘Non Canonical’ 
branches. (A) Canonical signalling involves the inhibition of GSK3β and subsequent stabilisation 
of β-Catenin. Stabilised β-Catenin then translocates to the nucleus to activate TCF/LEF 
transcription factors. ‘Non-Canonical’ signalling is independent of  β-Catenin. (B)Wnt/Ca2+ 
associated signalling involves activation of Phospholipase C (PLC), an increase in intracellular 
Ca2+ levels and activation of downstream effectors such as calcium/calmodulin-dependent 
kinase II (CamKii),  Protein Kinase C (PKC) and the nuclear factor of activated T cell (NFAT) family 
of transcription factors. (C)  
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1.10 Canonical/ β-Catenin Signalling 
Canonical/ β-Catenin associated signalling was the first Wnt signalling cascade to be described and 
remains the most extensively studied of the branches. The canonical pathway proceeds by 
stabilisation of the cadherin protein β-Catenin, enabling its nuclear translocation and activation of 
transcriptional targets(12). β-Catenin was initially identified as a membrane bound component of 
adherens junctions. Cytoplasmic β-Catenin has a different role however as a transcriptional 
activator. Under normal conditions, cytoplasmic pools of β-Catenin are regulated through 
phosphorylation by a destruction complex composed of APC, Axin and GSK3β and subsequent 
targeting for ubiquitination and destruction. Upon Wnt stimulus, phoshorylated Dvl is able to inhibit 
destruction complex function, increasing levels of non-phosphorylated β-Catenin. 
In its non-phosphorylated form, β-Catenin is then able to translocate to the nucleus. β-Catenin’s best 
known nuclear targets are the TCF/LEF family members of transcription factors. Mammals have four 
members: TCF1, TCF3, TCF4 and LEF1 and each member has multiple potential isoforms, adding 
significant complexity to the pathway(73). Nuclear β-Catenin displaces the repressor of TCF/LEFs, 
Groucho/TLE, forming a transcriptional activating complex with TCF/LEF members and enabling 
activation of target genes. Known targets of canonical Wnt signalling are summarised in Table 1. The 
vast diversity of targets demonstrates the wide reaching effects of canonical Wnt signalling during 
development. The dramatic effects of early embryonic β-Catenin disruption further enforces this, β-
Catenin deletion in mouse embryos causing  defective anterior-posterior axis formation along with 
defunct initiation of gastrulation(74). 
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Target Genes of Canonical Wnt 
Axin-2 FGF9 mBTEB2 RANK ligand 
BMP4 FGF18 MMP2 Runx2 
Brachyury FGF20 MMP7 SALL4 
bTrCP Fibronectin MMP9 Snail 
CCN1/Cyr61 Follistatin Movo1 Sox2 
CD44 FoxN1 Nanog Sox9 
Cdx1 fra-1 NeuroD1 Sox17 
Cdx4 Gastrin Neurogenin 1 SP5 
c-jun Gbx2 Nkx2.2 Stromelysin 
Claudin-1 Gremlin n-myc Telomerase 
c-myc Hath1 Nr-CAM Twist 
CTLA-4 Id2 Oct4 uPAR 
CyclinD Il8 Osteocalcin VEGF 
Cyclooxygenase-2 Irx3 Osteoprotegerin  
E-cadherin Islet1 Periostin  
EGF receptor ITF-2 Pitx2  
EphB/ephrin-B Jagged1 PPARd  
FGF4 Keratin Proglucagon  
 
Table 1.1 Target genes of β-catenin/Canonical Wnt signalling 
1.11 Non-Canonical Wnt Signalling 
Early experiments identified that treatment of Xenopus embryos with certain Wnt ligands such as 
Wnt1 induced secondary axis formation through β-Catenin activation. Treatment with other Wnts 
such as Wnts4 and Wnt5a either achieved no secondary axis induction or antagonised canonical Wnt 
mediated induction. This suggested certain Wnts are able to function independently of β-Catenin.  β-
Catenin independent Wnt activity, classed as ‘Non-Canonical’ is divided into two main branches:  
Wnt/Calcium signalling and Planar Cell Polarity 
 
The Wnt/Calcium Pathway uses calcium as a second messenger. Here, Dvl  activates phospholipase C 
(PLC), increasing intracellular calcium levels and stimulating activity of effectors such as 
calcium/calmodulin-dependent kinase II (CamKii) or Protein Kinase C (PKC). The nuclear factor of 
activated T cell (NFAT) family are the transcription factors associated with the calcium associated 
pathway(75). 
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The planar cell polarity pathway (PCP) is predominantly associated with regulation of convergent 
extension in embryogenesis. It is a key regulator during gastrulation and neurulation: perturbation of 
germ layer formation and defects in neural tube closure commonly observed with PCP 
disruption(76). In PCP signalling, phosphorylated Dvl activates members of the Rho family of small 
GTPases such as RhoA, Rac and cdc42. This leads to alterations of cytoskeletal arrangement along 
with activation of the phosphorylated JNK mediated signalling cascade(77). In addition to Wnt-Fzd-
Dvl interaction, PCP signalling is regulated by numerous other factors known as the ‘Core PCP 
genes’- CELSR1-3, VANGL1, VANGL2, DIVERSIN and PRICKLE1-4. PCP signalling is also implicated in 
orientation of cell division, left-right determination and orientation of cilia. Significant defects in 
heart, kidney and foregut development are observed in mouse and zebrafish models deficient for 
PCP components(78). 
 
1.12 Wnt Ligands 
 
Different Wnt ligands display varying specifities for different receptors and co-receptors, leading to 
differential activation of canonical vs non-canonical signalling. Structurally, Wnt proteins are very 
similar being cysteine rich, highly glycosylated and sharing a common sequence for secretion(79). 
Extensive post translational modification is necessary before secretion of Wnt ligands due to their 
greatly hydrophobic nature. An essential requirement for Wnt secretion is palmitoylation, the 
addition of palmitic acid onto proteins, mediated here by Porcupine (Porc) a seven pass 
transmembrane protein. Mutations in Porc prevent Wnt signalling and lead to early embryonic 
death, demonstrating its essential function(80). 
 
There are multiple proposed methods of Wnt secretion that aid its morphogen activity,  signalling 
over such long distances of multiple cell diameters. These include lateral diffusion of Wnt ligands 
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aided by heparan sulphate proteoglycans, Wnts secreted on lipoprotein particles, the formation of 
micelles able to shield hydrophobic regions or Wnts secreted by exosomes. The presentation of 
Wnts at points of cell-cell contact has also been proposed(81). 
 
Wnts1, 3a, 10a and 10b are well known as canonical ligands while Wnt5a and Wnt11 are considered 
non-canonical(67). The canonical/non-canonical activities of the other Wnt family members remain 
poorly characterised. In most studies, Wnt3a and Wnt5a are used as prototypical canonical and non-
canonical ligands(82, 83). 
1.13 Wnt Receptors 
 
Regardless of their method of secretion, Wnts function through binding to their cell surface bound 
receptors, triggering their intracellular signalling cascade and the uptake and degradation of Wnt 
ligands themselves. The main class of Wnt receptors are the Fzd receptors: seven transmembrane, G 
protein coupled receptors(84).  They possess two functional domains: a cystine rich domain (CRD) on 
the N terminus involved in ligand binding and a C terminal PDZ (Postsynaptic density 95, Discs Large, 
Zonula occludens-1) domain which binds intracellular effectors. Like Wnts, Fzds are conserved 
throughout the animal kingdom and ten Fzd family members have been identified so far in 
mammals. Fzds are not simply restricted to Wnt ligand binding, their CRD domain allows interaction 
with a variety of ligands including RSpondins, Norrins, connective tissue growth factor (CTGF), Il6, Il8 
and IFNy. The two main interactors with the intracellular PDZ domain are Dvl proteins and the 
heterotrimeric G proteins(85). 
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Figure 1.4 Frizzled Receptor Structure 
 
 
 
Simple binding of Wnt ligands to Fzd receptors is not sufficient for signalling to occur. For complete 
transmission of signal the input of Fzd co-receptors is also required. Several members of the low-
density lipoprotein receptor related protein (LRP) family ( LRP5 and LRP6) are the best characterised 
of these Fzd coreceptors, implicated in mediating canonical Wnt signalling(86). Phosphorylation of 
LRP5/6 by Wnt activated Fzd is thought to contribute to the inhibition of the destruction complex 
and promote stabilisation of β-Catenin.  Recent research has also identified numerous other proteins 
able to act as Fzd coreceptors such as the members of the receptor tyrosine kinase-like orphan 
receptor (ROR) family ROR1 and ROR2, Ryk and PTK7(87). These alternative co-receptors are 
predominantly associated with the non-canonical, β-Catenin independent signalling 
 
Current thinking is that specificity of different Wnts for different receptors and co-receptors governs 
whether cells respond via the canonical or non-canonical pathway. HEK293 cells treated with the 
canonical associated Wnt3a responded through phosphorylation of LRP5/6 and activation of β-
catenin. Conversely, Wnt5a treatment promoted response through phosphorylation of ROR2(82). 
Diagram detailing structure of the Frizzled (Fzd)  receptors. The cysteine rich domain (CRD)on the N 
terminus functions in ligand binding including Wnts, sFRPS and RSpondins. The PDZ (Postsynaptic 
density 95, Discs Large, Zonula occludens-1) domain on the C terminus functions in binding and 
phosphorylation of Dvl.  
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Phosphorylation of co-receptors was achieved through the recruitment of the same cellular 
machinery, suggesting that Wnts are able to instigate significantly different effects through changing 
only the co-receptor they phosphorylate.  Rather than determined by the Wnts available, a cell 
response to Wnt may therefore be governed by its current expression profile of receptors and 
coreceptors. This will allow for the highly cell context specific nature of Wnt signalling. Known Wnt-
Fzd interactions are summarised in Table 2. From this, activities of Wnts3a and 5a appear the best 
characterised. 
Wnt 1 2 2B 3 3A 4 5A 5B 6 7A 7B 8A 8B 9A 9B 10A 10B 11 16 
Fzd1 √ √   √  √    √         
Fzd2       √             
Fzd3  √   √  √             
Fzd4  √ √        √         
Fzd5     √  √   √          
Fzd6     √  √             
Fzd7    √ √               
Fzd8     √               
Fzd9  √                  
Fzd10           √         
 
Table 1.2 Known Wnt-Fzd interactions, as demonstrated by Immunoprecipitation. Adapted from (85) 
1.14 Propagation of Wnt Signalling 
After binding to Fzd receptors and recruitment of associated co-receptors, Wnt signal is transmitted 
by the phosphoprotein Dvl. Dvl has three conserved domains: an N terminal DIX (Dvl,Axin) domain, a 
central PDZ domain and a C terminal DEP (Dvl, Egl-10, Pleckstrin) domain. Dvl proteins interact with 
Fzd receptors through their shared PDZ domains while the DEP domain mediates interaction of Dvl 
with its target proteins(88). Dvl is recruited to Fzds and phosphorylated by the kinases Casein Kinase 
1 (CK1) Casein Kinase 2 (CK2) and PAR1. Vertebrates have three Dvl  members : Dvl1, Dvl2,Dvl3. 
Single or double null mutations in mice result in significant developmental defects, again 
emphasising the critical role of correct Wnt pathway function during development(89). 
 
Dvl activity mediates of all branches of Wnt signalling. In the canonical pathway it inhibits activity of 
the β-Catenin destruction complex, recruiting the scaffolding protein Axin away to the plasma 
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membrane, preventing the GSK3-β mediated phosphorylation and destabilisation of β-Catenin(12). 
In the non-canonical PCP pathway, phosphorylated Dvl interacts with PCP associated proteins at the 
cell membrane such as Diego/Diversin, enabling its interaction with numerous downstream 
effectors(90). Dvl/ RhoA interaction, mediated by the adapter protein Daam1, leads to activation of 
ROCK kinase and instigation of cytoskeletal rearrangement,  Dvl activation of RhoB is associated with 
influencing migration and Dvl activation of Rac1 is associated with stimulation of the JNK signalling 
cascade(88). In the calcium associated pathway, Dvl is attributed with activating phospholipase C 
(PLC) and instigating an increase in intracellular calcium levels(75). 
 
1.15 Extracellular Interactors 
In addition to the multiplicity of Wnt ligands, receptors and downstream effectors, numerous 
secreted interactors of Wnts also exist. This imposes a further layer of regulation to the pathway 
before Wnts even bind to their receptors.  These include Wnt-inhibitory factors (WIF1 and 2), 
sclerostin, Gremlin, Wise and WNT1-inducible-signaling pathway protein 1 (WISP1) (Figure 1.5A)(91). 
The two major families of extracellular modulators of Wnt proteins are the secreted Frizzled related 
proteins (sFRPs) and the Dickkopfs (Dkks). Traditionally, these families are seen as inhibitors of Wnt 
signalling, although recent research suggests potential for expanded roles(92). 
 
The Dkks are small secreted proteins able to disrupt the interaction between Fzd and the Lrp5/6 co-
receptor, preventing subsequent phosphorylation of Dvl and Wnt propagation. The dkk family 
consists of four members, with Dkk1,Dkk2 and Dkk4 highly similar in structure and function (Figure 
1.5B)(93). As Dkk1/2/4 function through binding and preventing Lrp5/6 function, they are mainly 
associated with blockade of canonical activity. Their effects on non-canonical signalling have not yet 
been explored. Dkks have key roles in modulating effects of Wnt during embryogenesis with dkk1 
mutants in mice and zebrafish defective in anterior-posterior patterning and limb development(94, 
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95). Dkk3 is thought a divergent member of the family, both in structure and function and there is a 
evidence it may function in activation rather than inhibition of the pathway (96, 97). 
 
Unlike the Dkks, sFRPs are not limited to the canonical pathway. The family consists of 5 members, 
sFRP1-5. They are structurally similar to the Fzds , sharing a similar CRD, allowing interaction with 
both  Wnt ligands and Fzd receptors but lack the transmembrane domain (Figure 1.5) (98) Again, 
conventionally  they are viewed as Wnt inhibitors: binding to either Wnts or Fzds to antagonise 
signalling. Recent research has challenged this and there is evidence for members able to bind and 
directly activate Fzds or facilitate Wnt-Fzd binding(92).  One important proposed function is in aiding 
Wnt diffusion: sFRPs shown able to bind to Wnt ligands and increase their range of signalling, 
another possible mechanism for establishing morphogen gradients(99). Early papers identified them 
as secreted apoptosis related proteins (SARPs), with a role in modulating apoptosis separate from 
Wnt activity(100).    sFRPs also possess a netrin like domain (NTR), found also in procollagen C 
proteinase enhancer proteins and tissue inhibitors of metalloprotinases (TIMPs)(101), suggesting 
that through this domain they may have Wnt independent roles in regulating extracellular matrix 
composition. 
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From this it is clear that Wnt signalling is far more complex than the summary diagram in Figure 1.3, 
with numerous potential ligands, receptors, downstream effectors and extracellular modulators. 
Specificities between Wnts and their receptors and Wnts and their extracellular modulators have 
not yet been mapped out. Nor has it been fully characterised how the presence of different Wnt 
ligands and extracellar interactors may affect other members of the same family. There is therefore 
much further work required on the mechanisms of the Wnt pathway. 
   
Figure 1.5 Extracellular interactors of Wnt  
 
(A) Examples of proteins capable of interacting with Wnts or Fzd receptors including: Gremlin, Wise,  WNT1-
inducible-signaling pathway protein (WISP), secreted Frizzled related proteins (sFRPs) and the Dickkopfs (Dkks).  
(B) Structural comparison of sFRP, Fzd and Dkk families. sFRPs share a similar cysteine rich domain (CRD) with 
Fzd receptors while lacking the seven transmembrane (7TM) and cytoplasmic domains  (CD). Dkk3 is considered 
a divergent member of the Dkk family due to the presence of the sgy domain not present in Dkks 1/2/4.  
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1.16 Wnts in Embryo and Adult 
As indicated previously, Wnts are one of the main families of morphogens critical for governing cell 
fate specification and cell polarity during embryonic development. Mouse knockout models have 
been invaluable in clarifying the roles of specific Wnt ligands. Importance of the Wnt pathway in 
development is emphasised by the diverse range of phenotypes elicited upon disruption of 
signalling. Abnormal neurulation, gastrulation and somatogenesis are observed along with limb and 
bone deformities(67). Issues of redundancy between different ligands adds further complexity with 
some phenotypes not observed until multiple ligands are knocked down. This further complicates 
elucidating function of specific Wnts. 
 
In the adult, dysregulated Wnt signalling occurs in numerous pathologies such as arthritis, cancer 
and metabolic disease(67, 102, 103). Regarding fibrosis, the current literature primarily focuses on 
the pro-fibrotic influence of canonical/ β-catenin associated signalling.  Upregulated expression of 
classic canonical ligands such as Wnt10b and 3a is observed in multiple models of fibrosis across a 
variety of organs, such as the skin, lung, liver and kidney(104-106). This is accompanied by nuclear 
accumulation of β-catenin in fibroblasts and upregulation of β-catenin target genes such as Axin2, 
PAI-1 and LEF1(107-109). Ectopic Wnt signalling further promotes fibroblast activity. Human dermal 
and lung fibroblasts stimulated with recombinant canonical Wnts such as Wnt1 and Wnt3a 
increased pro-fibrotic gene expression, stress fibre formation and production of ECM(104). 
Overexpression of Wnt10b in mice leads to increased development of spontaneous dermal fibrosis 
in comparison to controls. These animals also display increased susceptibility to bleomycin injury, 
commonly used to model fibrosis, with an intensified fibrotic response(107). Furthermore, 
disruption of canonical signalling can attenuate fibrosis. The Dkk family member Dkk1 is commonly 
used as a method of Wnt blockade. In vivo administration of Dkk1 in a murine UUO model of kidney 
fibrosis decreased nuclear β-catenin accumulation and induction of target genes and subsequently 
reduced fibrotic response(106). 
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How non-canonical Wnts influence fibrosis is more enigmatic. Significant upregulation of non-
canonical ligands is also observed in fibrotic kidney, liver and lung(110-112).  Manipulation of non-
canonical Wnt signalling suggests functional roles, for example  overexpression of the non-canonical 
Wnt11 in renal epithelial cells increased expression of α-SMA(113).  Through the PCP pathway non-
canonical Wnts are able to alter cytoskeletal conformation via interaction with Rho family 
members(114, 115) providing great potential for influencing the increased migration and 
contractility characteristic of activated myofibroblasts. 
 
There is clearly strong bias in the field towards investigating profibrotic potential of the canonical 
pathway. Identifying upregulated canonical signalling is straightforward, achieved by measuring 
nuclear translocation of β-catenin, upregulation of classic canonical targets such as Axin2 or c-Myc or 
using reporter assays such as the TOPFLASH luciferase assay(116, 117). Non-Canonical signalling on 
the other hand is mediated by effectors influenced by numerous other pathways. Therefore no non-
canonical Wnt specific, direct read-out of activity exists. Despite the increased complexity of 
studying non-canonical Wnt signalling there is significant potential for its influence on myofibroblast 
activity. Focusing research only on the canonical renders a vast number of prospective therapeutic 
targets unexplored. 
 
Upregulation of Wnt ligands in activated HSCs has been reported in numerous studies(110, 118-
132). Wnt expression appears absent in quiescent cells, again suggesting that in healthy liver Wnt 
expression is minimal. However, there is significant disagreement as to which ligands are 
upregulated. The non-canonical ligands Wnt5a and Wnt4 are identified in the majority of studies of 
in vitro activated HSCs (110, 119, 121, 122, 130) and analysis of fibrotic ECM isolated from LX-2s 
detected the presence of Wnt5a protein(126). Further validation of increased Wnt5a protein 
expression was demonstrated in murine model of CCl4 induced liver fibrosis, one of the few studies 
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to show protein data in an in-vivo model(126). In addition several studies also identify increased 
expression of canonical Wnts (Wnt3a and Wnt10b)(110, 132).  Establishing whether Wnt activity in 
HSCs is occurring through canonical or non-canonical mechanisms is critically important as their 
signals are transduced by significantly different downstream mediators. 
 
There appears to be general agreement that Wnt signalling is activated in myofibroblasts. How it 
contributes to the fibrogenic phenotype is less well explored. Most studies focus on the role of 
canonical ligands: recombinant Wnt3a shown to promote survival of HSCs(125) and the canonical 
agonist RSpondin2 shown to stimulate upregulation of fibrotic associated markers. As canonical 
Wnts are known to be anti-adipogenic, one group suggests a mechanism by which Wnt antagonises 
the adipogenic transcription factors maintaining HSC quiesence(132). In addition, inhibition of β-
Catenin activity through adenovirus mediated overexpression of the canonical antagonist Dkk1, 
stimulates reversion of in-vitro activated cells to a ‘quiescent like’ phenotype and amelioration of 
fibrosis in a murine model of biliary fibrosis(110). The actions of several anti-fibrotic agents are 
suggested to work through inhibition of canonical/ β-Catenin signalling, such as the plant flavonoid 
Morin (124)and the AMPK activator Metformin(127). However, these agents are attributed to 
influencing survival of HSCs rather than the fibrogenic phenotype. 
 
There are an equal number of studies contradicting the importance of canonical Wnt activity, 
instead supporting non-canonical Wnts and an absence of canonical signalling in the fibrogenic 
myofibroblast.  One of the initial microarray studies identifying upregulated Wnt activity 
demonstrated no increase in expression of either total β-Catenin or its non-phosphorylated, active 
form in in vitro activated cells(121).  Culture activation has shown to initiate upregulation of Wnt5a 
protein accompanied by downregulation of Wnt10b(122). The same study showed treatment with 
an agonist of canonical Wnt pathway stimulating decreased expression of fibrotic markers and a 
shift from a fibroblast like morphology. This suggests that active β-Catenin is associated with 
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maintaining quiescence, in keeping with its role in maintaining stem cell pluripotency(133). 
Disruption of non-canonical Wnt signalling appears to have functional consequences: depleting 
Wnt5a in the LX-2 cell line reduces Collagen I  and TGF-β expression(130) and knockdown of Wnt4 
causes a similar reduction of α-SMA expression in activated rat HSCs(119). Similar direct knockdown 
studies of canonical Wnts have not been published. 
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1.17 General Hypothesis and Main Aims 
 
General hypothesis: 
Similar regulatory mechanisms co-ordinate cell behaviour during embryogenesis and cellular 
response to tissue injury. Exploring these events will allow insight into mechanisms regulating 
myofibroblasts differentiation and wound healing response 
 
Aims 
 To characterise the expression of the  Wnt morphogen pathway in HSCs 
 To explore the effect of canonical Wnt signalling in HSCs 
 To explore the potential for non-canonical Wnt signalling in HSCs 
 Development of zebrafish for study of developmental control of fibrosis. 
 
. 
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Chapter 2: Materials and Methods 
2.1 Primary cell culture 
Hepatic stellate cells (HSCs) were isolated from normal livers of male Sprague- Dawley rats by a 
standard, previously optimised protocol(46). Rats were anesthetised using a combination of 
Ketamine (2µl per gram of body weight) and Xylazine (1µl per gram of body weight). Livers were 
cannulated and flushed through with 300 ml Hank's Balanced Salt Solution without Calcium and 
Magnesium (HBSS -). Livers were then perfused with 3mg/ml Collagenase B (Roche) in HBSS 
containing Calcium and Magnesium(HBSS +) followed by 10mg/ml Pronase (Roche) in HBSS +. 
Following perfusion, livers were dissected out and incubated in 3mg/ml Pronase in HBSS+ for 15 
mins. Livers were then homogenised under sterile conditions using nylon mesh, mixed with  
10mg/ml DNAse in HBSS and centrifuged at  1800rpm for seven minutes. Supernatant was removed, 
pellets resuspended in HBSS + DNase and centrifuged again. HSCs were purified from liver 
homogenate by discontinuous density centrifugation in 11.5% Optiprep (Sigma Aldrich D1556): 
pellets resuspended in a solution of HBBS+ and Optiprep and centrifuged for 23 minutes at 1500g 
(with an acceleration of 7 and a deceleration of 2). Upper layer containing HSCs was removed, 
resuspended in HBSS+ and centrifuged again at 1800rpm for seven minutes. Isolated cells were 
resuspended in Dulbecco’s modified Eagle’s medium (DMEM) and initially plated on plastic T75 
flasks for 20 minutes to allow attachment and separation of Kupffer cells. The non adhered HSCs 
were then washed, centrifuged and seeded onto 10cm2 dishes or 6 well culture plates. Day 0, freshly 
isolated cells are considered quiescent HSCs (qHSCs). Cells were cultured on plastic for up to ten 
days and were considered activated (aHSCs) after Day 7. 
 
Dermal fibroblasts were obtained from freshly harvested rat skin. Skin was briefly sterilised in 70% 
ethanol and washed in serum free medium. Skin was cut into small pieces and digested with  
collagenase A for 2.5 hours at 37°C. Digestion was then filtered, centrifuged, resuspended, strained 
to remove debris and plated onto 10cm dishes or 6 well culture plates. Primary cells were 
maintained in humidified atmosphere of 5% CO2 in air at 37°C. Cells were cultured in DMEM 
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supplemented with 16% fetal bovine serum (FBS), 100 U/mL penicillin, 100µg/mL streptomycin and 
2mM L-glutamine, 
2.2 Cell line Culture 
Cell lines used were the immortalised human HSC cell line, LX-2, or the human embryonic kidney 
(HEK 293).  Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 
10% fetal bovine serum (FBS), 100 U/mL penicillin, 100µg/mL streptomycin and 2mM L-glutamine. 
Again, cells were maintained in humidified atmosphere of 5% CO2 in air at 37°C. 
2.3 Cell Culture Reagents 
Reagent Source 
Cyclosporin A Tocris 
SP600125 Calbiochem 
Recombinant Human Dkk-2 RnD 
Recombinant Human Dkk-3 RnD 
Recombinant Human sFRP-1 RnD 
Recombinant Human sFRP-5 RnD 
Alkaine Phosphatase (CIAP) Promega 
IWP2 Sigma 
ICG001 Tocris 
Dvl-PDZ domain inhibitor Calbiochem 
Mitomycin C Sigma 
Table 2.1 Cell culture treatment reagents 
2.4 RNA isolation and cDNA Synthesis 
Cells were washed with PBS and scraped into RLT buffer (Qiagen) with added β-mercaptoethanol. 
Total RNA was purified from harvested cells using the RNeasy kit (Qiagen), following the 
manufacturer’s instructions. cDNA templates were prepared using Moloney murine leukemia virus 
reverse transcriptase (MMLV-RT) (Promega). A nanodrop was used to quantify isolated RNA and 0.5 
- 1µg was incubated at 37 OC for 30minutes with one unit of RQ1 RNase-Free DNase in 10X DNase 
reaction buffer. DNAse activity was then stopped using 0.5M EGTA solution and 0.5 µg of Random 
Hexamers were added. After a 5 minute incubation at 70 OC, samples were placed onto ice and a 
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reaction mixture of 20units of RNAsin, a mix of dNTPs at 10mM each and one unit of MMLV-RT in 5X 
reaction buffer was added. After a final incubation of 60mins at 42 OC, samples were diluted with 
RNase free water to 10ng/µl of cDNA  
 
2.5 RT-PCR 
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) was performed as follows: an initial 3 
minutes at 94 OC, followed by 35 cycles of denaturation for 20 seconds at 94 OC, annealing at 50 – 60 
OC (depending on primer pair) for 30 seconds and elongation at 72 OC for 30 seconds, followed by a 
final 7 minutes at 72 OC. Reagents used were DreamTaq PCR MasterMix (Life Technologies) 
consisting of Dream Taq DNA polymerase in 2X DreamTaq buffer along with a mix of dNTPs at 0.4 
mM each and 4 mM MgCl2, 20ng of cDNA template and 0.1µM of primers made up to a 25µl 
reaction mix with RNase free water.  Once amplification was complete, 3 µl of 10x loading buffer 
was added to products before loading onto 1% agarose gels stained with 0.5µg/ml of Ethidium 
Bromide . Gels were run for one hour at 0.15A and results visualised under UV. 
2.6 qPCR 
Quantitative polymerase chain reaction (qPCR) was performed using a 7500 Fast system (Applied 
Biosciences). Reagents used were SYBR Green JumpStart Taq ReadyMix (2X) (Sigma), 10ng of cDNA 
and 0.1 µM of primers made up to a 13 µl reaction mix. The program consisted of 40 cycles of 
denaturation for 10 seconds at 95 OC, annealing at 50 – 60 OC (depending on primer pair) for 30 
seconds and elongation at 72 OC for 30 seconds, followed by a final dissociation curve cycle of 95 OC 
for 15 seconds, 60 OC for 60 seconds and 95 OC for 30 seconds. All results were normalised to a 
control housekeeping gene by subtracting average ct for housekeeping gene from the average ct of 
gene of interest, producing Δct. The average Δct obtained from experimental condition was 
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normalised to control conditions using the equation 1/POWER (2,avg Δctx-avg Δcty). Housekeeping 
genes used were : GAPDH (Human) , β-Actin (Rat) or  rppo (Zebrafish). 
2.7 Primers 
Primers for target sequences were designed using Oligo Primer Analysis Software 4.0 (Molecular 
Biology Insights, Inc). Primers were designed to be between20-23 base pairs in lengths, with an 
optimal annealing temperature between 55 and 60 OC. Ideal primers produce a single clear band 
following PCR amplification when visualised on agarose gel. At qRT-PCR level, they produce a 
uniform melting curve with single peak and no contaminating primer dimers. Figure 2.1 
demonstrates examples of ideal and poor melt curve read outs. 
 
 
 
 
 
 
 
 
Figure 2.2 Example Melt Curves (A)Example of ideal melt curve (B) Evidence of primer dimers (C) Example of 
non specific binding 
 
 
 
 
 
 
 
(A) (C) (B) 
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2.7.1Wnt Ligands 
Primer Sequence (5’-3’) Primer Sequence (5’-3’) 
rhWnt1f GCAGTGGCCGATGGTGGGGTAT hWnt6f GAGAGTGCCAGTTCCAGTTCCG 
rhWnt1r CACTCACGCTGTGCAGGATCCC hWnt6r CAGCAGCTCGCCCATAGAACAG 
rWnt3a f TGGGTTGTCTGGCAGGTGTGAG  rhWnt7bf GGACGGCTGTGACACCATGTGC 
rWnt3a r TCC ACCACCATCTCTGAGGCAC rhWnt7br GGTGAAGACCTCGGTGCGCTCG 
hWnt3af GGCTGGAAGTGGGGTGGCTGTA rhWnt9bf CGGCCCAGCAAGTACTCACCTG 
hWnt3a r CCTCGTTGTTGTGGCGGTTCAT rhWnt9br GCACTCCACGTAGCAGCACCAC 
rWnt4f CTGGAGAAGTGTGGCTGTGACC rhWnt10af TCTTCCTACTGCTGCTGGCTGC 
rWnt4r AAGGACTGTGAGAAGGCTACGC rhWnt10ar CATCAGGGTGACGCACACACAC 
hWnt4f GTGGGTCACGCACTGAAGGAGA rWnt10bf CTCGGGATTTCTTGGATTCCAG 
hWnt4r GGGGCTAGGCTCCAAGTACACC rWnt10br CAGGTTTGAATTGGCAGC 
rhWnt5af AACCCTGTTCAGATGTCAGAAG hWnt10bf GACACTTGCATTTCCGCTTCAG 
rhWnt5ar CTGCATGTGGTCCTGATACAAG hWnt10br GACACTTGCATTTCCGCTTCAG 
rWnt6f GGGAGGCTGCGGAGATGATGTC rmhWnt11f TCCCAAGCCAATAAACTGATG 
rWnt6r CAGAGCACAGGAACCCGAAAG C rmhWnt11r CAGGTATCGGGTCTTGAGGTC 
 
Table 2.2 Primer sequences for Wnt ligands 
 
2.7.2 Wnt Receptors 
Primer Sequence (5’-3’) Primer Sequence (5’-3’) 
rFzd1f GCGACGTACTGAGCGGAGTG rRYK F TCCACCCAGACGACCCAGTAT 
rFzd1r TGATGGTGCGGATGCGGAAG rRYK R CTTCACCTTGGCTTTGGCTTC 
rFzd2f CTCAAGGTGCCGTCCTATCTCAG rROR1 F CAGGGGGAAATAGAAAATCAG 
rFzd2r GCAGCACAACACCGACCATG rROR1 R ACAGTATGGGAAGGCGTAGTG 
rFZD4f CCCCACAAAACTCCCATCCAGC rROR2 f CGTGCGGTGGCTGAAGAATG 
rFZD4r CCACACGGCCATCCAAATATCC rROR2 r GCCCGTGTCTGTCGTGTCCA 
rFZD5f CTGGAGTCTTGGCGGCGCTTCA rPTK7 F CCCCTCAGCACCAAACAGAAG 
rFZD5r GCCCGGTCCTGCCAGTGAGTGC rPTK7 R GGACACCTTCACCTGCCTCTG 
rFZD6f AGACCTCCCCAGAAGCATCCCT   
rFZD6r TTCTCCTTCACGGTGCCTGCTC   
rFZD8f GCGAGTACGAGGAGCTGGGTGC   
rFZD8r CCGCCAAGAACCACGTGAGAGA   
Table 2. 3 Primer Sequences for Fzd receptors 
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2.7.3 Extracellular Interactors 
Primer Sequence (5’-3’) Primer Sequence (5’-3’) 
rSfrp1F GCTCAACAAGAA CTGCCACATG rDkk1F GTGCTTTCAACGATGGCTCTCT 
rSfrp1R CCAGTAGAAGCCGAAGAACTGC rDkk1R TACTTGTTCCCGCCCTCATAGA 
rSfrp2F CCTGGAGACAAAGAGCAAGACC rDkk2F ATTGATGGGTTTTGTTGTGCTG 
rSfrp2R TGACCAGATAGGGAGCGT TGAT rDkk2R GGTAGCATCCTTCCACACTTTG 
rSfrp4F CTTCCCACTGTGTGGACCTT rDkk3F ACAACGAGA CCA ACA CGGAGAC 
rSfrp4R CTATCCCTCGAACGCAAGTC rDkk3R CTGGAG AACTGG CAG TAC CTGG 
rSfrp5F GAGATGCTGCACTGCCACAAGT rDkk4F GGTCTGCGTGAATGATGTTTGC 
rSfrp5R ACGAAGTCGCTGGAGCACATCT rDkk4R CCTGTCCCTTAT TGCTTTGTGA 
Table 2.4 Primer Sequences for Wnt Extracellular interactors 
2.7.4 Pathway Components 
Primer Sequence (5’-3’) Primer Sequence (5’-3’) 
rhBcatF AAGGTGCTGTCTGTCTGCTCTA rDvl1f CAGATGAGGAGGACAACACGA 
rhBcatR TTCCATCCCTTCCTGCTTAGTC rDvl1r GTGATGCTGCTGAAGGAGGAT 
rGSK3F CGAGTGGCGAGAAGAAAGATGA rDvl2f GATTTTGGGGTGGTGAAGGAA 
rGSK3R GTGGTTTAATGTCTCGATGGCA rDvl2r AAGGGGGTAATGGTGGAGGTG 
rAPCF CGCTCCCACACACATCCAAACA rDvl3f CACGCCTAATGAGAAGACACA 
rAPCR ATGGGCTAGGTCGGCAGGATAC rDvl3r AGTGGAGTCTGTGATGCTGCT 
rAxinF GCAGGCGTT TGGAGGAAGAAGA   
rAxinR GGGTCCGGTAGGGTATTGGTT C   
rLrp5F AAGTGGACAGGGGAGAAAAGGA   
rLrp5R TTGTCCTGCAACTGTACACCAG   
rLrp6F ACCATCTAATCTCGTCACATCA   
rLrp6R TACTGGATTGACTCTCGACAAA   
Table 2.5 Primer Sequences for Wnt pathway components 
 
2.7.5 Wnt Targets 
Primer Sequence (5’-3’) Primer Sequence (5’-3’) 
rSOX9 F TGGCAGAGGGTGGCAGACAGC hAxin2 1 f CGAGATCCAGTCGGTGATGG 
rSOX9R TTGGGCGGCAGGTATTGGTCA hAxin2  r CCACACACGACCTTTAGGCT 
hSOX9 F AGCGAACGCACATCAAGAC rAXin2f TCCTTACCGCATGGGGAGTA 
hSOX9 R CTGTAGGCGATCTGTTGGGG rAXin2r GTGGGTTCTCGGGAAGTGAG 
rCCND1 F CTACCGCACAACGCACTTTCT rNFATc1 f GCAAAGCCCAAGTCTCTATCC 
rCCND1 R TTCTTCCTCCACTTCCCCTTC rNFATc1 r CATAGTGAGCCCTGTGGTGAG 
hCCND1 F CCAGAGGCGGAGGAGAACAAA rNFATc2 f ACAGTTCCGCTCAGGGCTCTC 
hCCND1 R AGCGTGTGAGGCGGTAGTAGG rNFATc2 r AAGAGGGACGGCTGCTGGTAG 
rcMYC F CCACAGCAAACCTCCACACA rNFATc3 f GAGAAGAGTCCTGGCATCAAC 
rcMyc R ACCCTGCCACTGTCCAACTT rNFATc3 r GAGTGATGGGGTGAAAGAGAG 
rEVI F ATTGGGTCAGTGGCTCATAAG rNFATc4 f ATCAGTATGGAGGACAGGGCT 
rEVI R GATGAAGATGCTGGGTGTGAG rNFATc4 r GAGTGGTGGGGAGGAAGGTAA 
Table 2.6 Primer Sequences for typical Wnt target genes 
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2.7.6 β-Catenin Interactors 
Primer Sequence (5’-3’) Primer Sequence (5’-3’)   
hChibbyf GGTTAGTGGCGGTGTGGAC hPygopus2f GTGAACGATGACCAGGATG   
hChibbyr AAGTGGGATTCAGCAGTGG hPygopus2r TGCCCTCACGGATGTAGAC 
rChibbyf CCGAAGAAGACTCCTCCTC hrBCL9f GGTCCGTCCCCCTACAGTGAT 
rChibbyr CACACCCCCACTAATCACT hrBCL9r CATTTCCAGCCCCATTCTTCA 
hPygopusf GTGGACTGGATGGGTTAGGAG hBCL92F TCTGGGCTGAGGGAGGTGGAC 
hPygopusr GATTCGGTGGTGGAGCATACT hBCL92R TCTGCTGCTGCGGGGTCATCT 
Table 2.7 Primer sequences for nuclear β-Catenin interactors 
2.7.6 Zebrafish Germ Layer Markers 
Primer Sequence (5’-3’) Primer Sequence (5’-3’) 
drneurog1F TCCTTTTCGCACACGGATGA drpitx3F CCGTTATCCCGACATGAGCA 
drneurog1R GTGCACAGTGGTTTCGTTCC drpitx3R CCACACCCGTACTCTTGCTT 
drspry1F CGTGTCTCTCAGGCTGTCA    drcxcr4aF TTTCTCCCAACGGTGTACGG 
drspry1R GGGCCCTCAGTGTATTCGTT    drcxcr4aR TACCAGTCTTTGGCCACGTC 
drntlaF CCACAAGGAAGTCCCAGACC drmyoDF CTCCGAGGTCCTGCGAATTTT 
drntlaR ATTGAACTGAGGAGGGCTGC drmyoDR GGGAAGGGGATATCCGACAA 
drsnai1aF  CCCGGTGCCTGTTATACCTC drctnnb1F ACCAAGAGCAAGTAGCAGACA 
drsnai1aR GCAGGTTGCTGGTAGTCCAT drctnnb1R CGAACTGTGTGGAAGGTATCT 
drfoxa1F  CCCCCAAACTCGGAACTGAA drccnd1F CACTTCCTTGCCAAACTGCC 
drfoxa1R ATGGGGGTCTCCTTTGAGGT drccnd1R ATGAGAGGCAACTGTCGGTG 
drfoxa2F TCAATGACAGGCATGTCCCC drsox9aF GCATGAATCTCCTCGACCCC 
drfoxa2R TAGCTCCTGCGGTAGGTCTT drsox9aR CTGGGTGCATCAGACAGACA 
drsox17F GCATCCGAAGGCCAATGAAC drrpoF CTGAACATCTCGCCCTTCTC 
drsox17R GCTTTCCATGACTTACCAAGC drrpoR  TAGCCGATCTGCAGACACAC 
Table 2.8 Primer sequences for zebrafish germ layer markers 
2.8 Primers Used 
2.8.1 Fibrogenic Targets 
Primer Sequence (5’-3’) Primer Sequence (5’-3’)   
rBActinf AGAGGGAAATCGTGCGTGACA hGAPDHf GTCAGTGGTGGACCTGACCT   
rBActinr ACATCTGCTGGAAGGTGGACA hGAPDHr TGAGCTTGACAAAGTGGTCG 
rαSMAf CATGTCGTCCCAGTTGGTGAT hαSMAf CACTGTTCTCTGTGCCTAAAC 
rαSMAr CGAAGCGCAGAGCAAGAGA hαSMAr GGTTGGCCTTTCCCAGTG 
rTGFβf GAACCCCCATTGCTGTCC hTGFβf TGACAGCAGGGATAACACACT 
rTGFβr TCCGTCTCCTTGGTTCAG hTGFβr CGCACGCAGCAGTTCTTCTCC 
rTIMP1f GCATGGACATTTATTCTCCAC hTIMP1f ACTTCCACAGGTCCACAAC 
rTIMP1r TCTCTAGGAGCCCCGATCTG hTIMP1r CATTCCTCACAGCCAACAGT 
rCollagen1f TTCACCTACAGCACGCTTGTG hCollagen1f CAAGAGGAAGGCCAAGTCGAGG 
rCollagen1r GATGACTGTCTTGCCCCAAGTT hCollagen1r CGTTGTCGCAGACGCAGAT 
rPPARγf ATTTCTGCTCCACACTAT hPPARγf GGGATCAGCTCCGTGGA 
rPPARγr GCTTTATCCCCACAGACT hPPARγr TGCACTTTGGTACTCTTGAAGTT 
Table 2.9 Primer sequences for human and rat fibrogenic targets  
 40 
 
2.9 Protein Lysate Preparation 
Cells were washed with cold PBS and scraped into Radio-Immunoprecipitation (RIPA) lysis buffer (20 
mM Tris-HCL, pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 10% glycerol) with added protease 
inhibitors ( 1 cOmplete Protease Inhibitor Cocktail Tablet (Roche) per 50 mL buffer) and phosphatase 
inhibitors (200µl Phosphatase Inhibitor Cocktail (Pierce) per 50 mL buffer). Samples were sonicated 
for six minutes then centrifuged at 4 OC for 15mins at 13000xg. The supernatant was aspirated and 
stored and the pellet discarded. Protein concentrations were then determined using the Bradford DC 
assay kit (BioRad). Equal amounts of protein sample were added to 5X Laemmli buffer and made up 
to a 20µl reaction mixture with RIPA. 
 
2.10 Cytoplasmic and Nuclear Fractionation. 
For cytoplasmic fractionation cells were washed, scraped into PBS, pelleted by centrifugation for  10 
minutes (6000g) at 4 OC and  resuspended in 650µl of fractionation buffer (10 mM HEPES, 60 mM 
KCl, 1 mM EDTA, 0.075% Igepal, 1mM DTT and 1 mM PMSF, adjusted to pH 7.6). Samples were 
incubated on rotary wheel at 4 OC for 10 minutes. Samples were then vortexed, centrifuged at 
maximum speed for 30 seconds and the resulting supernatant taken. For nuclear fractionation cells 
were washed, scraped into PBS and then pelleted by centrifugation (6000g, 2minutes). Pellet was 
resuspended in 75µl of Dignam A buffer (10mM HEPES (pH7.9), 1.5mM MgCl2,,10mM KCl, 0.5mM 
DTT, 0.2% NP-40) 
, spun at 3000rpm for 10secs and supernatant discarded. This wash was repeated twice and pellet 
then resuspended in 20µl of Dignam C buffer (2mM HEPES(pH7.9),25 % glycerol, 420mM NaCl, 
1.5mM MgCl2,  0.5mM DTT, 200nM EDTA). Samples were incubated on ice for 10minutes and 
vortexed frequently. After incubation, samples were spun for 1 minute at 1300rpm. Supernatant was 
taken and pellet discarded. 
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2.11 Alkaline Phosphatase (ALP) Treatment for dephosphorylation of protein  
Protein lysates from culture activated rat HSCs were incubated with 100 units of ALP (Promega) in  
reaction buffer (5 mM Tris pH 7.9, 10 mM NaCl, 1 mM MgCl2, and 0.1 mM DTT) for 30 minutes at 
room temperature. Samples were then diluted with 5X Laemelli buffer and used for Western 
Blotting.  
2.12 FLAG Immunoprecipitation 
Medium from LX-2 cells overexpressing Flag tagged sFRP4 subjected to immunoprecipitation using 
the FLAG Tagged Protein Immunoprecipitation Kit (Sigma). 1ml of medium was added to 40µl of 
Anti-FLAG M2 affinity gel resin and incubated at 4 OC overnight. After incubation, resin was 
centrifuged, supernatant removed and washed 3 times with 0.5ml of kit specific Wash buffer. 
Protein was then eluted with 3X FLAG Peptide following manufacturer’s instructions. Eluted protein 
then subjected to SDS-PAGE and immunoblotting. 
2.13 SDS PAGE and Western Blotting 
Samples were denatured by incubation at 95 OC for 5 minutes and then separated by electrophoresis 
on 10% sodium dodecylsulfate–polyacrylamide gels. Gels were run for approximately 2 hours at 100 
volts then transferred to nitrocellulose membranes (Amersham). Membranes were first blocked to 
minimise non specific binding using 5% Milk in Tris-buffered saline (TBS)/Tween 20 (TBS-T) solution. 
After 1 hour blocking, membranes were incubated with antibody overnight at 4OC. Membranes were 
washed three times with TBS-T solution before a 1 hour incubation at room temperature with 
horseradish peroxidise (HRP) conjugated secondary antibody at a 1:5000 dilution. Membranes were 
again washed with TBS-T before visualisation by chemiluminescence reaction (Pierce) followed by 
exposure to film. 
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2.13.1 Primary Antibodies Used 
 
Antibody (Clone 
Number) 
Dilution Source Catalogue # Predicted MW 
(kDa) 
CaMKII (pan) 1 in 1000 Cell Signal 3362S 60, 50 
c-Myc (9E10) 1 in 1000 Pierce A1-980 45 
Cyclin D1 (92G2) 1 in 1000 Cell Signal #2978 36 
Dvl2 1 in 1000 Cell Signal #3216 90-95 
DNMT1  (60B1220.1) 1 in 500 Genetex GTX48548 183 
FLAG 1 in 500 Sigma F3165 13 
Fzd4 1 in 500 Abcam ab83042 65 
Fzd8 1 in 1000 Abcam ab75235 73 
GAPDH 1 in 2000 Abcam ab9485 34 
LEF1 (C12A5) 1 in 1000 Cell Signal #2230 25-58 
H2A.Z 1 in 1000 Abcam ab4174 14 
H3K27me3 1 in 1000 Abcam ab6002 17 
p84 (5E10) 1 in 1000 Genetex GTX70220 84 
PJNK Thr183/Tyr185) 1 in 1000 Cell Signal  #9251 46, 53 
sFRP1 1 in1000 Abcam ab4193 37 
sFRP4 1 in 500 Abcam ab32784 50 
TCF1 (C63D9) 1 in 1000 Cell Signal #2203 48, 50 
TCF3 (D15G11) 1 in 1000 Cell Signal #2883 78 
TCF4 (C48H11) 1 in 1000 Cell Signal #2569 58, 79 
TGFβ (56E4) 1 in 1000 Cell Signal #3709 45 to 65 
TJNK 1 in 1000 Cell Signal #9252 46, 54 
Wnt5a 1 in 1000 Abcam ab174100 45 
Wnt5a (C27E8) 1 in 1000 Cell Signal #2530 45 
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αTubulin 1 in 1000 Cell Signal #2144 52 
Βactin (AC-15) 1 in 2000 Abcam (ab6276 45 
β-Catenin (Active) 
(8E7) 
1 in 500 Millipore 05-665 92 
β-Catenin (Total) 1 in 1000 Abcam ab6302 92 
Table 2.10 Primary antibodies used 
 
2.13.2 Secondary Antibodies Used 
Antibody Dilution Source 
Goat Anti-Rabbit 1 in 5000 Cell Signal 
Rabbit Anti-Mouse 1 in 5000 Sigma 
Table 2.11 Secondary Antibodies used 
 
2.14 ELISA for TGFβ1 
Supernatants harvested from primary rat HSCs and assayed using TGFβ1 Quantikine®ELISA kit (R&D 
Systems) as per manufacturer’s instructions. Reagents, standard dilutions, control and experimental  
samples were prepared as directed. 50 μL of Assay Diluent RD1-21added to 50μl of Standard, 
Control or experimental samples and incubated for  2 hours at room temperature. Plate washed 
with wash buffer and 100 μL of TGF-β1 Conjugate added to each well. Samples wereincubated for a 
further 2 hours at room temperature and washed again. 100 μL of Substrate Solution was then 
added to each well and samples incubated for 30 minutes at room temperature in the dark. Finally, 
100 μL  of Stop solution was added and optical density of each well determined using a microplate 
reader set to 450 nm with correction at 540nm.  Supernatants from two separate preparation of 
HSCs used for assay. 
 
2.15 Transformation of competent bacteria 
Plasmid DNA was mixed with 100µl of JM109 competent bacteria and 0.1M CaCl2. After 30minutes 
incubation on ice, bacteria were heat shocked for 45 seconds at 42 OC , returned to ice for five 
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minutes then incubated for 1 hour in 500μl of Luria broth (LB) medium (Sigma) under gentle 
agitation. 100µl of cell suspension was spread onto LB agar plates containing selection antibiotic and 
incubated at 37OC. After overnight incubation, single colonies were picked, placed into 5mls of LB 
medium containing selection antibiotic and again incubated overnight at 37 OC under agitation. 
 
2.16 Purification of Plasmids 
Plasmid DNA was purified via alkaline lysis. QIAprep Spin Miniprep Kit (Qiagen) was used for mini-
preparations of DNA, following manufacturer’s instructions. For maxi-preparations, 1 µl of 
transformed bacteria was added to 300ml LB medium containing selection antibiotic and incubated 
at 37 OC under agitation. After overnight incubation, suspension was centrifuged at 4500 g for 15 
minutes. NucleoBond Xtra Maxi kit (Clontech) was used for purification of plasmid, as per 
manufacturer’s instructions. Plasmid DNA was quantified using a Nanodrop. 
2.17 Cell Transfection 
Cells were transfected with plasmid DNA 24 hours after passage at approximately 40-60% 
confluency. Transfection was mediated via Effectene transfection reagent (Qiagen) following 
manufacturer’s instruction. Standard transfection period was 48 hours before harvest. DNA 
concentration was dependent on vessel size: 1 µg in 10cm dishes, 0.5 µg per well of 6 well plate, 
0.25 µg per well of 12 well plate.  
2.17.1 Constructs used 
Construct Source Resistance 
TOPFLASH Millipore Ampicillin (50µg/ml) 
FOPFLASH Millipore Ampicillin (50µg/ml) 
Renilla Luciferase Promega Ampicillin (50µg/ml) 
hWnt3a Origene Ampicillin (50µg/ml) 
hWnt5a Origene Ampicillin (50µg/ml) 
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hWnt10b Origene Ampicillin (50µg/ml) 
hFzd4 Origene Ampicillin (50µg/ml) 
hFzd8 Origene Ampicillin (50µg/ml) 
hROR2 Origene Ampicillin (50µg/ml) 
hsFRP4 Origene Kanamycin (50ug/ml) 
hBcatenin (S37A) Orford et al(134) Ampicillin (50µg/ml) 
hLEF1 Origene Ampicillin (50µg/ml) 
NFAT Luciferase Jans et al (135) Ampicillin (50µg/ml) 
pGL3 Control Luciferase 
(empty) 
Promega Ampicillin (50µg/ml) 
pcDNA3.1  Invitrogen Ampicillin (50µg/ml) 
Table 2.12 Constructs used  
2.18 Luciferase Assay 
β-Catenin activity was measured by transfection of the  TOPFLASH firefly luciferase TCF-reporter 
construct. NFAT transcriptional activity was measured by transfection of an NFAT firefly luciferase 
reporter plasmid containing nine copies of an NFAT-binding site from the IL-4 promoter. For 
luciferase assays,  0.5µg of plasmid was contransfected with 0.05 µg of Renilla luciferase  plasmid 
serving as a transfection control. TOPFLASH assays were accompanied by a further negative control 
with separate transfection of FOPFLASH reporter constructs with mutant TCF binding sites. TOPflash 
activity was then normalised to the ratio of FOPflash activity. After 48 hours transfection, cells were 
scraped into 1 x Passive Lysis Buffer (Promega), freeze thawed and luminescence measured using 
the Dual Luciferase Reporter Kit (Promega) and a luminometer. Transfections were performed in 
duplicate and data presented as average ratios of firefly to Renilla luciferase activity 
2.19 siRNA Knockdown 
sFRP4 oligo nucleotide sequences 
Oligonucleotide Sequence 
siGENOME siRNA Rat sFRP4 (89803) GGAUAGACAUCACACCAGA 
siGENOME siRNA Rat sFRP4(89803) GCGAUGAGCUGCCUGUCUA 
 
 46 
 
sFRP4 siRNA  oligonucleotides designed and ordered from Thermo Scientific.   Rat HSCs (passage 2 – 
3) transfected with a combination of siRNA at increasing doses using Interferin transfection reagent 
(Polyplus). Cells subjected to second dose of siRNA 24 hours after first and harvested for protein 72 
hours after initial dose. Nonspecific siRNA used as a control. 
2.20 Scratch Wound Assay to assess migration  
90% confluent LX-2 cells seeded in 6 well plates were treated with Mitomycin-C (Sigma) for 30 
minutes to inhibit proliferation and then a single scratch made in each well using a sterile 200µl 
pipette tip. Bright field images of each well were taken using a Zeiss Axio Observer over a period of 8 
hours. At each time point, three fields per scratch were analysed and results presented are averages 
of ten measurements of wound width per field. Experiments were performed in triplicate. For Wnt 
overexpression studies, LX-2s were transfected with Wnt5a or empty control expression vectors 48 
hours before scratch injury. For IWP2 and Wnt Conditioned medium treatment, LX-2s were pre-
treated with IWP2/Wnt conditioned media for 30 minutes before scratch injury. 
2.21 Acridine Orange staining to assess apoptosis 
Apoptosis assays were conducted on cells seeded in 12-well plates at 20 – 30% confluency. 
Apoptotic cells were detected by staining with Acridine Orange (1μg/ml) and visualisation under a 
FITC filter using a Zeiss Axio Observer. Five random fields per well were counted at x20 magnification 
in duplicate wells. 
2.22 MTT Assay to assess proliferation  
Cells were seeded in 96 well plates. After 24 hours treatment, cells were treated with MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (5mg/ml, Sigma) for 4 hours. Medium was 
 47 
 
then aspirated and cells incubated with DMSO (Sigma) for 30 minutes. Plate was read using plate 
reader at 570nm absorbance. 
2.23 Zebrafish Maintenance 
Wild type zebrafish line used was the AB line. Transgenic lines used were the LiPan 
(Tg(fabp10:dsRed, elavl3:GFP) Tg(ngn1:GFP) and Tg(isl1:GFP). Adult fish were maintained on a light 
dark cycle of 14:10 hours at 28oC. Embryos were collected after spawning and incubated at 28oC in 
fish water containing 0.6g/L salt (Crystal Sea Marinemix; Marine Enterprises International)  and 
methylene blue (0.002 g/L) (Sigma). 
2.24 Morpholino injections 
A morpholino was obtained from Gene Tools,  designed using their provided software to target the 
h2afv transcript (CTTTTCCTGCTTTGCCTCCTGCCAT) and obtained from Gene Tools. A standard 
control morpholino (CCTCTTACCTCAGTTACAATTTATA)  with no known targets in the zebrafish 
genome was used as a control. Morpholinos were injected at the 1 – 8 cell stage using a 
microinjector with needles calibrated to inject 4nl per embryo. Viable larvae were defined as normal, 
severe or mildly affected as demonstrated. For coinjection experiments morpholinos targeting 
dnmt1 or p53 were used. 
 
2.25 Genomic DNA Isolation and Slot Blot to assess DNA methylation 
Larvae were collected in lysis buffer (10mM TRIS, 100mM EDTA, 0.5% SDS) with added 10ng/ml 
Proteinase K and incubated at 55 oC for 2hours. Samples were centrifuged at maximum speed for 
five minutes and supernatant used for DNA isolation via Phenol Chloroform extraction. DNA was 
precipitated using 100% ethanol. Pellets were then washed with 75% ethanol, air dried and 
resuspended in 1 x Tris-EDTA (TE) buffer. 600ng of DNA was used for slot blot analysis. DNA was 
diluted in 20µl of TE buffer and denatured with equal volume of denaturing solution at 95 oC. After 
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10min incubation equal volume of ice cold 2M ammonium acetate was added and samples were 
loaded onto a nitrocellulose membrane pre-soaked in 2X SSC buffer. Membrane was then dried and 
baked in vacuum oven at 80 oC. After one hour membrane was blocked in 5% milk/TBST for a further 
hour and then incubated in primary antibody overnight  at 4 oC. After primary incubation, membrane 
was washed 3 times in TBST, incubated with secondary antibody for a further hour then washed and 
visualised using chemiluminescence reaction. Antibodies used were anti-5-MeC (Eurogentech) ( 1 in 
2000) and rabbit anti-mouse (1 in 5000). Samples blotted in parallel were stained with 0.2% 
Methylene blue in 0.3M NaOAc to detect total DNA. The freeware programme GelAnalyzer was used 
to quantify 5MeC and methylene blue intensity and 5MeC levels were determined by normalising to 
total DNA.  
2.26 Touch Response Assay to assess motility  
A single two day post fertilisation (dpf)  fish was placed in a dish marked with concentric rings 1cm 
apart as illustrated by Figure 6.5. Fish were touched once lightly on the head and the zone they 
swam into recorded (Zone 1, 2 or 3). 
2.27 Statistical Analysis  
GraphPad Prism 6 was used to calculate mean and standard error values. Data presented as 
averages ± standard error of the mean (SEM). Statistical analysis was performed using a student’s T-
Test (paired or unpaired where appropriate). A P value of <0.05 was considered statistically 
significant.  (*p<0.05, **p<0.01, ***p<0.001) 
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CHAPTER 3: Wnt Pathway 
Characterisation in Hepatic Stellate 
Cells 
3.1 Introduction 
 
From the current literature there is considerable conflict regarding Wnt signalling and HSCs. This first 
Chapter intended to decipher which patterns of Wnt expression and activity were observable here in 
HSCs. Many previous studies focus predominantly on Wnt ligand expression in HSCs, overlooking the 
potential effects of Wnt receptors and extracellular modulator. A thorough study of how the whole 
Wnt pathway responds upon transdifferentiation will be far more informative. This will enable 
identification of the ligands expressed by HSCs, the receptors which meditate their signal and other 
components able to enhance or repress signalling. 
3.2 Increased Wnt activity accompanies HSC activation 
 
All current literature at least agrees that increased Wnt signalling accompanies HSC activation(110, 
119-122, 126, 130, 132). These studies predominantly infer activation of the Wnt pathway from 
upregulation of Wnt ligand mRNA expression. However the complexity of the pathway means that 
this may not necessarily equate with upregulated Wnt activity. To begin, I first wanted to determine 
increased active Wnt signalling in HSCs based on a reliable downstream indicator. I selected 
phosphorylation of the downstream protein Dvl as a putative marker, Dvl being the first signal 
mediator in the pathway after Wnt/Fzd binding. It mediates all branches of Wnt signalling and 
should therefore function as a marker of both canonical and non-canonical activity(88). When 
visualised on Western blot, two Dvl bands are apparent: a phosphorylated, higher weight form and a 
non-phosphorylated lower weight form. A shift to a  phosphorylated form of Dvl has previously been 
 50 
 
used as a marker of active Wnt and I aimed to reproduce this in primary HSCs(136). Cell lysates from 
activated rat HSCs (seven days in culture) show a clear double band when immunoblotted with an 
anti-Dvl antibody (Figure3.1A). Treatment of lysates with alkaline phosphatase (ALP), a 
dephosphorylating agent, removes the top band, demonstrating its specifity to 
phosphorylation(Figure3.1B). mRNA expression of all members of the Dvl family (Dvl1,Dvl2, DVl3) is 
significantly increased in aHSCs when compared to qHSCs by qRT-PCR (Figure3.1C). 
In vitro culture promotes transdifferentiation of freshly isolated primary HSCs, resulting in 
myofibroblast like cells by Day 7. This spontaneous activation is a commonly used method of 
studying HSC behaviour(30). Protein expression of Dvl is visible by Day 3 of a time course of in vitro 
activation and expression of hyperphosphorylated Dvl is visible by Days 5 and 7 as cells approach a 
fully activated phenotype. I was unable to detect Dvl expression in quiescent HSCs suggesting that 
Wnt signalling is active only upon HSC activation (Figure3.1D). 
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Figure3.1  Increased expression of phosphorylated Dvl in aHSCs 
(A)Two bands are distinguishable upon immunoblot for Dvl2: a lower and a higher weight band corresponding 
to non-phosphorylated, Wnt inactive and phosphorylated, Wnt active forms respectively. GAPDH serves as a 
loading control (B) The higher band can be attributed to phosphorylation as treatment of protein lysates with 
the dephosphorylating agent Alkaline Phosphatase (ALP) removed the higher band. GAPDH serves as a loading 
control (C) mRNA levels of Dvl family members Dvl1,Dvl2, Dvl3 were quantified by qRT-PCR in quiescent rat 
HSCs (qHSC) and HSCs activated after seven days in culture (aHSC) (n=3). (D) Protein lysates from two different 
preparations of rat HSCs at different time points in culture were immunoblotted for Dvl2. Expression of Dvl2 is 
detectable by Day3 and phosphorylated form visible at Day5. βactin serves as a loading control. . qRT-PCR 
results are expressed as fold change normalised to control ± SEM *p<0.05, **p<0.01. Student’s t Test 
(unpaired).  
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3.3 HSCs express predominantly non-canonical ligands 
 
Expression of phosphorylated Dvl convincingly implies active Wnt signalling in aHSCs. I next wanted 
to demonstrate that increased Wnt ligand expression accompanies phosphorylation of Dvl and 
assessed expression of a variety of canonical and non-canonical ligands by RT-PCR in aHSCs and 
whole rat liver (Figure3.2A). Rat brain was used as a positive control due to its diversity in Wnt 
expression(137). Only non-canonical ligands could be detected in aHSCs: Wnt4, Wnt5a and Wnt6. 
Wnt7b and Wnt9b expression was present in whole liver only, suggesting different Wnt expression 
profiles of different liver cell types as previously described(138). Wnt6 expression intriguingly 
appears expressed selectively in aHSCs and not detectable in either whole liver or rat brain. 
Expression of Wnt 4, 5a and 6 were significantly upregulated upon activation when quantified by 
qRT-PCR. (Figure3.2B).  Wnt expression in quiescent HSCs was low (Ct> 30) again suggesting that 
Wnt signalling is activated only during transdifferentiation. Further analysis across a time-course of 
in-vitro activation suggests temporal differences in Wnt expression: Wnt4 upregulated at Day 4 well 
before an increase in Wnt5a at Day 8 (Figure3.2C). This may suggest different requirements for 
specific Wnts ligands at different stages of activation. 
Knowledge of the non-canonical branches of Wnt signalling is lacking in comparison to the well-
defined non-canonical branches. Wnt6 appears to be an interesting candidate for further study due 
to its selective expression in HSCs. However, literature on its targets and mechanisms are limited 
and reagents such as antibodies are of poor quality. Wnt5a however is one of the few examples of a 
well studied non-canonical ligand with a large amount of literature on its roles in influencing cell 
behaviour(103). Furthermore, significant upregulation of Wnt5a by HSCs has previously been 
reported in both in vitro and in vivo models(110, 122, 126, 130). Based on this, I selected Wnt5a as a 
target for investigating the role of non-canonical Wnt signalling in HSCs, despite increases in Wnt4 
and Wnt6 expression appearing more profound. Wnt5a protein expression across a time course of 
activation could not be analysed due to the poor cross reactivity of Wnt5a antibodies with rat. 
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However Wnt5a protein expression and secretion are evident upon analysis of whole cell lysates and 
concentrated medium from the LX-2 cell line (Figure3.2D). 
My data so far correlate with the several reports of increased non-canonical Wnt ligands 
contributing to HSC activation. One group has suggested the alternative: that the increased 
canonical activity is important(110, 132). Canonical ligands in rat HSCs above could not be detected 
and to further investigate this possibility, mRNA expression levels  of canonical Wnt3a and Wnt10b 
were assessed in human HSCs by RT-PCR . Wnt overexpressing LX-2 cells were used as a positive 
control (Figure3.3A). Minimal expression of canonical ligands was detected when compared with the 
non-canonical Wnt5a. This was further confirmed by quantifying differences through qRT-PCR 
(Figure3.3B). These data suggests that both rat and human HSCs express a predominantly non-
canonical range of Wnt ligands. 
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Figure3.2 HSCs increase Wnt ligand expression upon activation 
(A)Wnt ligand expression was analysed and compared by RT-PCR between rat aHSCs, rat whole liver, rat brain 
(+ve) and water only (¬-ve).  Expression of Wnts 4, Wnt5a, Wnt6 only detected in HSCs. (B) mRNA levels of 
Wnt4, Wnt5a and Wnt6 were by qRT-PCR in quiescent rat HSCs (qHSC) and HSCs activated after seven days in 
culture (aHSC) (n=5) (C) mRNA levels of Wnt4 and  Wnt5a were quantified by qRT-PCR across a time course of 
HSC activation (n=3). (D)Wnt5a is detectable in both whole cell protein lysates and concentrated culture 
medium from the LX-2 cell line when analysed by Western Blot. qRT-PCR results are expressed as fold change 
normalised to control ± SEM *p<0.05, **p<0.01. Student’s t Test (unpaired).  
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Figure 3.3 Canonical ligand expression is minimal in aHSCs 
(A)mRNA expression of Wnts3a, 10b and 5a were analysed by RT-PCR in three different preparations of human 
HSCs. (B) mRNA transcript levels of Wnts3a and 10b were quantified by qRT-PCR in LX-2 and human HSCs and 
compared relative to transcript levels of Wnt5a (relative level of transcriptional difference (RLTD)).  
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3.4 HSCs express a variety of Wnt receptors 
 
Data so far demonstrates non-canonical ligand expression in HSCs. Available receptors next needed 
to be assessed. The Wnt pathway has 10 different Fzd receptors, each possessing different 
specificities of ligand binding and different associations with canonical and non-canonical 
activity(85). The literature is not consistent when defining the expression patterns of Fzds in HSCs: 
some studies suggesting uniform expression of all ten(138) while others suggest differential 
expression of a select few(110, 121). Here, RT-PCR analysis confirms expression of Fzds1,2,4,5,6 and 
8 in HSCs (Figure3.4A). Expression of a variety of Fzd receptors suggests potential for response to a 
number of different Wnt ligands despite HSCs themselves appearing to only express non canonical 
Wnts. 
How Fzd receptors respond to transdifferentiation was next quantified. Surprisingly aHSCs appear to 
downregulate the majority of Fzd receptors, significant decreases occurring for Fzd1, Fzd4 and Fzd8 
(Figure3.4B). Fzd2 is the only receptor upregulated, although the modest two fold increase was not 
statistically significant. Fzd2 is one of the better characterised Fzd receptors, and frequently 
associated with non-canonical ligands in comparison with the canonical associated Fzd1(139-142). 
This fits with the predominantly non-canonical expression profile of aHSCs. Based on this, I next 
looked at expression of the non-canonical associated Wnt receptors and co-receptors: ROR1, ROR2, 
Ryk, Ptk7(87), predicting a similar increase in expression due to the non-canonical associations seen 
so far. Expression of all four receptors was detected in HSCs by RT-PCR (Figure3.4C). However, 
transdifferentiation was associated with a reduction in expression, similar to the majority of the Fzds 
(Figure3.4D). 
I next asked when this decrease in receptor expression occurs: whether it is early and a contributing 
factor to the activation of HSCs or later on, a possible consequence of HSCs becoming refractory to 
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Wnt signalling. I quantified the expression patterns of the most significantly decreased receptors 
Fzd4 and Fzd8 in more detail across a time course of activation (Figure3.5A) . The decrease in 
expression appears to occur early, reduced substantially by day 3 with expression remaining low 
throughout the time course. Western Blot analysis confirms a decrease in protein expression with 
activation (Figure3.5B). Despite a decrease in expression, the majority of Fzds are still noticeably 
present in aHSCs when visualised by RT-PCR and presumably still able to function in Wnt signalling. 
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Figure 3.4 HSCs decrease Wnt receptor expression upon activation 
(A) mRNA expression of Fzds 1,2,4,5,6 and 8 can be detected in both quiescent (qHSC) and active( aHSCs) HSCs 
by RT-PCR. BActin serves as a loading control. Water only (-ve) serves as a negative control. (B)  mRNA levels of 
Fzd receptors were then quantified in quiescent rat HSCs (qHSC) and HSCs activated after seven days in culture 
(aHSC) by qRT-PCR. (n=4) (C) mRNA expression of ROR1, ROR2, Ryk and Ptk7 can be detected in both quiescent 
and aHSCs by RT-PCR. βActin serves as a loading control. Water only (-ve) serves as a negative control. (D) 
mRNA levels of non-canonical receptors were then quantified in quiescent (qHSC) and active (aHSC) HSCs by 
qRT-PCR (n=3). qRT-PCR results are expressed as fold change normalised to control ± SEM *p<0.05, 
***p<0.001. Student’s t Test (unpaired).  
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Figure 3.5 Decrease in Fzd expression occurs early in activation 
(A) mRNA levels of Fzd4 and  Fzd8 were quantified  by qRT-PCR across a time course of culture activation of rat 
HSCs (n=3). (B) Protein expression of Fzd4 and Fzd8 was analysed by Western Blot across a time course of 
culture activation of rat HSCs. GAPDH serves as a loading control. qRT-PCR results are expressed as fold change 
normalised to control ± SEM   
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3.5. HSCs increase expression of extracellular interactors 
 
Expression and function of extracelluar interactors of Wnt such as the sFRPs or the Dkk families has 
not been fully explored in either HSCs or the liver as a whole. In contrast to the decreased expression 
of  Fzd receptors , mRNA expression of sFRPs 1,2 and 4 and Dkk3 in aHSCs significantly increased in 
HSCs (Figure3.6A and B) . Expression of sFRPs was undetectable in qHSCs by RT-PCR (Figure 3.6A), 
again suggesting that sFRPs function only in aHSCs.  Dkk1, Dkk2 and Dkk4 expression could not be 
detected in either qHSCs or aHSCs while sFRP5 expression was highly variable. sFRP4 appears to be 
the most extensively upregulated sFRP. Analysis of protein expression across a time course further 
confirms this, with expression substantially increased by day 3 (Figure3.6C). 
As mentioned previously, the role of these Wnt interacting proteins has not yet been resolved and 
there is evidence for them either promoting or repressing  Wnt signalling depending on cell 
context(92, 93). Significant increases in expression with HSC activation have not yet been reported 
and I aimed to explore their effect on HSC biology and behaviour more thoroughly. Sources indicate 
that the enhancing or inhibitory effect of these proteins may be influenced by concentration(99, 
143). They are proposed to function as biphasic modulators of Wnt signalling: inhibitory at high 
concentrations and stimulatory at lower. Based on this, I treated LX-2 cells with low concentrations 
of recombinant sFRPs and Dkks, aiming to stimulate WNT signalling. 
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Figure 3.6 HSCs increase expression of several extracellular interactors of Wnt. 
(A) mRNA expression of sFRP family members and Dkk3 was analysed in both quiescent (qHSC) and active( 
aHSCs) HSCs by RT-PCR. βActin serves as a loading control. Water only (-ve) serves as a negative control. 
(B)mRNA expression levels of sFRPs and Dkk3 were then quantified in quiescent rat HSCs (qHSC) and HSCs 
activated after seven days in culture (aHSC) (n=4) (C) Protein lysates across a time course of in vitro activation 
were immunoblotted for sFRP4 expression. GAPDH serves as a loading control. qRT-PCR results are expressed 
as fold change normalised to control ± SEM *p<0.05 Student’s t Test (unpaired).   
 
  
(A) (B) 
(C) 
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I began with Dkk3 treatment at time points of two or six hours and used Dvl2 phosphorylation as an 
indicator of increased Wnt activity.  Dkk3 is a considered a divergent member of the predominantly 
inhibitory Dkk family with evidence suggesting its ability to enhance Wnt signalling (96, 97). Here, 
treatment of LX-2 cells with 5nM recombinant Dkk3 appeared to increase hyper-phosphorylated Dvl 
expression at the two hour time point (Figure3.7A). I decided to use 5nM as a concentration 
potentially able to promote Wnt stimulation. 
Serum starved LX-2s were treated for 24 hours with 5nM Dkk2, Dkk3, sFRP1 or sFRP5 and qRT-PCR 
used to assess effects on transcript levels of fibrogenic markers such as α-Sma, CollagenI or TGFβ or 
downstream markers of canonical Wnt signalling . Dkk2 treatment resulted in no significant change 
in either set of markers. A small but significant upregulation of β-Catenin canonical targets Axin2 and 
cMYC occurred upon Dkk3 treatment along with a small upregulation of Collagen1 expression 
(Figure 3.7C). This could imply upregulation of Wnt activity, corresponding with the increased 
phosphorylation of Dvl observed by Western Blot. sFRP treatment appeared to have an opposite 
effect. Although sFRP1 treatment had no consistent trend, sFRP5 treatment suppressed all 3 
fibrogenic markers analysed as well as cMyc and CyclinD expression (Figure 3.7B). sFRP5 expression 
in HSCs was highly variable, significantly increased in some preparations whereas unchanged in 
others suggesting it may not be a consistent factor in HSC activation. From this it appears that these 
secreted factors have opposing effects on fibrotic potential of HSCs. As aHSCs express substantially 
more sFRPs than Dkk3 it could be concluded that their role in primary cells is one of inhibition. 
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Figure 3.7 sFRPs and Dkks promote opposing effects on HSC gene expression. 
(A) Protein lysates from either untreated controls or LX-2 cells treated with 5nM recombinant Dkk3 for 2 or 6 
hours were immunoblotted for Dvl2 expression. GAPDH serves as a loading control. mRNA of fibrogenic 
markers or Wnt targets genes were were quantified in LX-2 cells treated for 24 hours with 5nM sFRP1 and 
sFRP5 (B) or Dkk2 and Dkk3 (C) (n=3) qRT-PCR results are expressed as fold change normalised to control ± 
SEM *p<0.05 Student’s t Test (unpaired).  
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sFRPs were originally identified as SARPs ( secreted apoptotic related proteins) able to modulate the 
apoptotic response in cells(100). Based on this I questioned whether their role could be mediation of 
apoptosis in HSCs. I aimed to stimulate apoptosis in LX-2s and either pre-treat or co-treat with 
recombinant sFRPs and Dkks. I chose sFRP1 and Dkk3 as they are reliably increased in aHSCs and 
used a range of concentrations  between 1 – 50nM. 50µM cyclohexamide in low serum medium 
(0.5%) for 16 hours was used as a stimulator of apoptosis, quantifying apoptosis using acridine 
orange assay. Firstly, LX-2 cells were pre-treated for 6 hours with sFRP1 or Dkk3 before 
cyclohexamide mediated induction of apoptosis. Apoptotic cell percentage appeared to vary with 
concentration(Figure 3.8A). Both Dkk3 and sFRP1 appeared to induce apoptosis upon low dose ( 
5nM) whereas the higher dose (50nM)  treatment reduced apoptosis percentage, although changes 
did not reach statistical significance. Simultaneous treatment of cyclohexamide and Dkk3 did not 
show the same trend. Simultaneous sFRP1 and cyclohexamide resulted in a similar reduction at 
50nM (Figure 3.8B). This may propose a role for sFRP1 in modulating response of HSCs to apoptotic 
stimulus instead of directly affecting fibrotic gene expression. 
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Figure 3.8 sFRP1 and Dkk3 treatment mildly influences apoptotic response 
Apoptosis was induced in serum starved LX-2 cells by 50µM cyclohexamide (CHX) treatment . Effect of varying 
concentrations of recombinant Dkk3 and sFRP1 on the apoptotic response was analysed by acridine orange 
staining in two separate treatments. Cells treated with 1, 5 or 50nM recombinant protein either 6 hours before 
((A) Pre-treatment ) or in conjunction with 50µM CHX ((B) Simultaneous) (n=2) 
  
(A) 
(B) 
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Figure 3.6B identifies sFRP4 as the most significantly upregulated secreted factor, both at mRNA and 
protein level.  As a first step in identifying its function in HSCs I attempted to deplete expression via 
siRNA transfection. A combination of siRNAs specific to sFRP4 were transfected into primary rat 
aHSCs using Inteferin  meditated transfection. However, despite multiple attempts using a variety of 
concentrations and conditions successful knockdown could not be achieved (Figure 3.9A). 
Transfection via electroporation was also attempted but resulted in highly stressed cells and no 
significant knockdown (Figure 3.9B). siRNA mediated knockdown of sFRP4 was therefore not further 
pursued. 
 
I next attempted overexpression of sFRP4 protein in LX-2s reasoning that this may be a more 
permanent source of stimulus. Overexpressing cells will consistent produce sFRP4 rather than   
undergoing a brief stimulus with recombinant protein. LX-2s transfected with 1µg of sFRP4 
expression vector clearly upregulate sFRP4 protein expression, as demonstrated by Western Blot 
analysis (Figure 3.10A). The expression vector used promotes translation of sFRP4 proteins tagged 
with a FLAG epiptope. This provides a simple way of demonstrating successfully secretion of sFRP4 
by performing FLAG IPs on medium collected from overexpressing cells. Figure 3.10B demonstrates 
substantial expression of FLAG in medium from SFRP4 overexpressing cells. Despite this increased 
sFRP4 protein expression and secretion, no significant alterations in fibrogenic gene expression or 
canonical Wnt targets were observed when analysed by qRT-PCR  (Figure 3.10C). 
I next questioned whether sFRP4 overexpression may provide a similar protective effect upon 
induction of apoptosis as suggested by sFRP1 recombinant protein treatment. I used similar 
experimental conditions: low serum medium  (0.5%)  combined with 50µM Cyclohexamide 
treatment. However sFRP4 overexpression resulted in no change in apoptotic response (Figure 3.11) 
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Figure 3.9 Attempted siRNA knockdown of sFRP4 
(A) Western blot analysis of sFRP4 expression in primary rat aHSCs transfected with increasing concentrations 
of sFRP4 targeting siRNA via Interferin mediated transfection. GAPDH serves as a loading control. (B) Western 
blot analysis of sFRP4 expression in primary rat aHSCs  transfected with sFRP4 targeting siRNA by 
electroporation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10  sFRP4 overexpression in LX-2 cell line has minimal effect. 
(A) Protein expression of sFRP4 was analysed by Western blot in control (-) and sFRP4 overexpressing LX-2 cells 
(+). GAPDH serves as a loading control. (B) FLAG IP of medium from in control (-) and sFRP4 overexpressing LX-
2  cells (+)analysed by Western Blot. mRNA levels of fibrogenic markers (C) or Wnt targets (D) quantified by 
qRT-PCR in sFRP4 overexpressing LX-2 cells compared to empty vector controls (n=3). qRT-PCR results are 
expressed as fold change normalised to control ± SEM 
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Figure 3.11  sFRP4 overexpression has minimal effect on apoptosis 
% Apoptosis as assessed by Acridine Orange staining compared between control (-) and SFRP-4 overexpressing 
LX-2 cells (+) treated for 24hrs with 50µM cyclohexamide (CHX) under serum free conditions (n=3). 
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3.6 Discussion 
 
Increased Wnt activity in myofibroblasts is implicated in numerous models of fibrosis, suggested to 
be one of the developmental signalling pathways reactivated upon injury (107, 111, 112). Early 
studies in HSCs also support a role for Wnt signalling in contributing to the transdifferentiation of 
qHSCs. Evidence from this Chapter agrees with all current literature, demonstrating increased Wnt 
activity and ligand expression in aHSCs as well as increased activity of the downstream marker Dvl . 
aHSCs express a variety of Wnt ligands, receptors and extracellular interactors, suggesting the 
potential for Wnt signalling to regulate activation of HSCs. The absence of Dvl expression and low 
levels of Wnts in quiescent HSCs suggests HSC derived Wnt signalling is minimal in healthy liver, as 
observed for other morphogens. 
This Chapter offers several unexpected findings. Firstly, the predominantly non-canonical range of 
ligands expressed by LX-2 cells and HSCs. Figure 3.3 highlights the extremely limited expression of 
the canonical Wnts 3a and 10b when compared to the highly expressed Wnt5a. This appears to 
contrast with several previous studies, Cheng et al.  for example purport that the canonical  Wnt3a 
and Wnt10b are significant contributors to HSC activation(110). However this study also reported a 
greater upregulation of non-canonical ligands at the mRNA level:  Wnt4 and Wnt5a increased by  12 
fold rather than the 3 fold observed for Wnts 3a and 10b. Functional study of β-Catenin /Canonical 
Wnt signalling is facilitated by numerous techniques allowing direct read out of β-Catenin activity 
and a greater number of targeted reagents. This may explain why many of the studies pursued 
canonical signalling rather than the more convoluted non-canonical pathways. Despite this lack of 
canonical ligand expression,  HSCs still express a variety of canonical associated receptors and 
therefore the potential to respond to canonical Wnts via paracrine signalling. Figure 3.2 indicates 
that peak expression of different Wnts occurs at different times. This may translate into different 
functions:  Wnt4 expressed early and contributing to initiation of activation whereas the later 
expressed Wnt5a may enhance behaviour of activated myofibroblasts. Wnt expression during 
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development is subject to strict temporal regulation. During liver development for example, early 
time points are associated with high expression of Wnt3 and Wnt6 whereas later time points are 
associated with Wnt2 and Wnt5a(144). Temporal differences in Wnt expression during HSC 
activation is therefore a significant possibility.  Ideally, analysis of protein expression levels would 
have been conducted to further confirm this. Unfortunately, due to poor cross reactivity of Wnt 
antibodies for rat protein samples this could not be achieved. 
HSCs express eight out of ten Fzd receptors identified in mammals as well as a variety of non-
canonical associated receptors. Another surprising finding was the significant downregulation in 
mRNA and protein expression for the majority of receptors. Visualisation of Fzd mRNA by RT-PCR still 
shows high expression of Fzd1, Fzd5 and Fzd8 however, despite the significant decrease when 
quantified by qRT-PCR. This suggests that Fzds are still present at a reduced level in aHSCs, As 
overactive Wnt signalling is associated with cancer and numerous other pathologies(67), this 
downregulation may be a regulatory mechanism, a way of modulating response to Wnts produced, 
preventing over stimulation. The non-canonical associated Fzd2 is the only Fzd which appears 
upregulated albeit not to a statistically significant extent. Downregulation of accompanying Fzds may 
be a mechanism of directing Wnt signalling through this receptor alone. Wnt5a is commonly 
attributed as a binding partner of Fzd2 and increased expression of these two pathway components 
again supports the non-canonical theme of Wnt signalling in HSCs. 
Decreased Fzd expression occurs early in activation by day 3 as demonstrated by Figure 3.5, implying 
that high expression of Fzds is associated with quiescent cells only. This appears contradictory as 
minimal levels of Wnt ligands are present at this time. As mentioned in the Introduction, Fzd 
receptors are able to bind numerous ligands through their CRD domain, not merely restricted to Wnt 
ligands(84). Functional data outlining Wnt independent Fzd behaviour is limited but the high Fzd  
expression in quiescent, non-Wnt signalling cells may imply the possibility of Wnt independent 
function. 
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The increased expression of several extracellular interactors of Wnt is a novel finding, not previously 
reported in aHSCs. High expression of sFRPs and Dkks has been observed during early mouse 
development in whole liver tissue and is significantly reduced at later stages(144).  Increased 
expression occurring upon HSC activation further supports the idea of reactivated developmental 
pathways contributing to fibrosis. How these proteins influence HSCs however cannot be confidently 
determined from this data. 
One simple suggestion could be that increased expression serves as a regulatory mechanism, 
accompanying the decreased expression of Fzd receptors to prevent over- stimulation of Wnt. 
Hepatocellular carcinoma (HCC) is one cancer particularly associated with increased Wnt activity, 
with 25% of HCCs contain at least one activating β-Catenin mutation(145).  Methylation mediated 
inactivation of sFRPs is a distinguishing feature of HCC cell lines and was detected in 42 – 63% of 
nineteen primary patient samples analysed, supports a role for sFRPs in liver having a Wnt/β-catenin 
inhibitory role(146). Here, treatment of LX-2 cells with recombinant protein suggests potential Wnt 
enhancing roles for Dkk3 and inhibitory roles for sFRP1 and sFRP5. However as the endogenous 
concentrations of sFRPs and Dkk3 in primary HSCs are not known, it is difficult to determine whether 
the 5nm treatment outlined in Figure 3.7 is physiologically relevant. 
Little effect on classic fibrogenic targets were observed upon sFRP and Dkk treatment and other 
aspects of the active myofibroblasts phenotype were examined instead. Alterations in apoptosis 
response were observed upon sFRP1 treatment with higher concentrations of recombinant sFRP1 
(50nM) potentially conferring mild protection upon apoptotic stimulus with effect more pronounced 
with pre-treatment. This would correspond with the original role of sFRPs, identified as apoptosis 
related proteins(100). Clearance of HSCs by apoptosis is essential for fibrosis resolution and the 
survival of HSCs during fibrogenesis is dependent on matrix derived survival signals(59). sFRP 
secretion may be one of these factors promoting HSC survival. 
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Although the significant upregulation of expression with HSC transdifferentiation is exciting, further 
in-depth study of these proteins may be difficult. Interactions between individual members are not 
known and stimulus or depletion of one member could promote compensatory behaviour in the 
others(147). Moreover, there is possibility of functional redundancy between members and over 
expression or deletion of multiple members may be required before functional effect is observed.  
Another difficulty in studying extracellular Wnt modulators is that concentrations produced by HSCs 
are not known. Differences in mRNA expression are not necessarily translatable into the amounts of 
functional protein secreted.  An extensive characterisation of sFRP and dkk concentration at each 
stage of a time course of HSC activation would be ideal before continuing study. This would allow 
identification of the most highly secreted proteins as well as giving indication as to their function:  
lower expression may suggest enhancement of Wnt signalling. Until the mechanics of these proteins 
have been more thoroughly elucidated, they remain a highly convoluted system to approach. 
 
One of the aims of this Chapter was to identify a possible target for further study of the Wnt 
pathway in HSCs.  Of the three Wnts expressed by aHSCs, Wnt5a is the most extensively studied and 
is a well-defined non-canonical ligand(103). It possess great potential for regulating behaviour of 
HSCs as it has been shown to regulate proliferation, migration, apoptosis resistance and contractility 
in fibroblasts from numerous sources(148). Wnt5a therefore appeared to be an attractive target for 
further study of the non-canonical pathway in HSCs. Despite no apparent canonical ligand expression 
detectable in HSCs, the possibility for canonical activity through paracrine stimulus cannot be 
ignored. Exploration of non-canonical and canonical behaviour in HSCs will be the next step to build 
on data presented in this Chapter. 
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3.7 Conclusions 
 
In summary, this Chapter demonstrates: 
 Increased Wnt activity accompanying HSC activation 
 A non-canonical ligand expression profile in aHSCs 
 Decreased Fzd receptor expression in aHSCs 
 Increased expression of sFRP1, sFRP2, sFRP4 and Dkk3 in aHSCs 
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Chapter 4: Canonical vs Non-Canonical 
Signalling 
4.1 Introduction 
 
Chapter 3 identified multiple ligands, receptors and extracellular interactors  present in HSCs, 
depicting a complex Wnt environment. This Chapter aims to determine how Wnts function in HSCs 
by exploring markers of canonical or non-canonical activity. As aHSCs express non-canonical ligands 
and increase expression of the non-canonical receptor Fzd2, signalling through non-canonical 
effectors is the predicted mechanism. Several canonical associated receptors are also expressed, 
requiring investigation of the potential for canonical  signalling also. 
4.2 HSCs express components of the canonical pathway 
 
As mentioned in the previous chapters, canonical signalling is the most extensively described branch 
of the Wnt pathway. The majority of studies correlating Wnt and fibrosis focus on fibroblasts 
upregulating active β-Catenin.  This chapter therefore begins with profiling the canonical pathway in 
HSCs. 
HSCs express the necessary components of the canonical pathway as demonstrated by RT-PCR, with 
expression of destruction complex components (GSK3β, Axin and APC), canonical co-receptors (Lrp6) 
and downstream targets (Axin2). (Figure 4.1A). Differential expression upon activation was then 
determined by qRT-PCR. mRNA expression of β-Catenin is significantly upregulated by approximately 
3.5 fold. Surprisingly, this is accompanied by significantly decreased expression of its downstream 
transcriptional target Axin2. (Figure 4.1B) Changes in co-receptor and destruction complex 
components were limited. However, as these are regulated by post-translational modifications 
changes may not be reflected at the mRNA level. Across a time course of activation a substantial 
 75 
 
increase in protein expression of β-Catenin and downstream TCF/LEF targets can be visualised by 
Western Blot (Figure 4.1C). 
Despite limited canonical ligand expression, HSCs clearly express major components of the canonical 
pathway along with canonical associated Fzd receptors as demonstrated by Figure 3.4. In order to 
verify whether HSCs can respond to exogenously produced Wnts, I incubated LX-2 cells with 
conditioned medium taken from Wnt3a and 10b overexpressing LX-2 cells. A three hour treatment 
significantly increased expression of β-Catenin and downstream target TCF4, suggesting canonical 
responsiveness in HSCs (Figure 4.2). 
4.3 Canonical pathway appears inactive in HSCs 
However the presence of β-Catenin does not equal active canonical signalling. β-Catenin must 
translocate to the nucleus and bind with target transcription factors in order to stimulate 
upregulation of target genes(12). The best known  β-Catenin targets are  members of the TCF/LEF 
transcription factor family(73). I used transfection of the TOPFLASH luciferase reporter as a marker 
of  TCF/LEF dependent transcriptional activity. LX-2 cells were transfected with the TOPFLASH 
expression vector and either Wnt3a or Wnt10b as a canonical stimulus. A Renilla luciferase 
expression vector was also co-transfected as a control of transfection efficiency and data are 
presented as a ratio of firefly to Renilla luciferase activity. Endogenous luciferase activity in LX-2s 
was limited and did not increase upon with canonical Wnt stimulation (Figure4.3A). Wnt 
overexpression in HEK293 cells served as a positive control with a significant increase in TOPFLASH 
activity in comparison to LX-2s. Furthermore, transcript levels in LX-2 cells of Axin2, a classic β-
Catenin target(117), were unchanged upon Wnt overexpression in LX-2 cells but significantly 
increased in Wnt overexpressing HEK293 cells (Figure4.3B). LX-2s therefore appear unresponsive to 
canonical Wnt stimulus. 
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Figure 4. 1 Canonical pathway expression in HSCs.  
(A) mRNA expression of canonical pathway components is detectable in both rat in quiescent HSCs (qHSC) 
and HSCs activated by seven days in culture (aHSCs) by RT-PCR. (B) Canonical pathway mRNA levels were 
quantified by qRT-PCR in qHSC and aHSC (n=4) (C) Western Blot for protein expression of β-Catenin and its 
target TCF4 across a time course of rat HSC culture activation (7 days in culture). βActin serves as a loading 
control. qRT-PCR results are expressed as fold change normalised to control ± SEM. *p<0.05 Student’s t 
Test (unpaired).      
Figure 4. 2 HSCs upregulate β-Catenin in response to stimulus.  
Western Blot for protein expression of β-Catenin and its target TCF4 in LX-2 cells treated for three hours 
with conditioned medium taken from LX-2 cells overexpressing canonical Wnt 3a (3a+), Wnt10b (10b+) 
or an empty control expression vector (-) . GAPDH serves as a loading control  
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I next attempted a more direct source of stimulus and overexpressed a constitutively active form of 
β-Catenin, with a serine to alanine mutation at the serine 37 (Ser37) position, a GSK3β 
phosphorylation site. This mutant will be resistant to GSK3β mediated phosphorylation and 
subsequent degradation and will therefore always be able to localise to the nucleus and to bind 
TCF/LEF targets(134). TOPFLASH luciferase activity in β-Catenin overexpressing LX-2s and rat HSCs 
remained unchanged while HEK293 and control primary cells (rat dermal fibroblasts) significantly 
increased luciferase activity. (Figure 4.4A) Ser37 β-Catenin overexpression induces a robust response 
in HEK293s, increasing luciferase activity over 20 fold, demonstrating its efficacy as a method of 
stimulus.  Overexpression of mutant β-Catenin increases active β-Catenin protein levels in LX-2s to a 
similar extent of that in HEK 293s when visualised by Western Blot, demonstrating no difficulties in 
LX-2s overexpressing active β-Catenin (Figure 4.4B). Transcript levels of the β-Catenin target Axin2 
was again unchanged in LX-2s while substantially increased in HEK293s (Figure 4.4C). Finally I 
assessed the effect of canonical stimulus on the expression of fibrogenic markers such as alpha 
smooth muscle actin (α-Sma) and type I Collagen. However, neither Wnt10b nor active β-Catenin in 
LX-2s generated significant differences. (Figure 4.4D). From this, aHSCs appear again  unresponsive 
to canonical Wnt stimulus. 
One study suggests that canonical signalling may instead be active in maintaining quiescence and 
links the stem cell like phenotype of quiescent HSCs to β-Catenin’s role in regulating pluripotency 
and self-renewal(122, 133). I explored this further by attempting a TOPFLASH assay in early rat HSCs,  
at  day 2 of an in vitro time course. No TOPFLASH luciferase activity could be detected.  However, 
Renilla luciferase activity acting as a control of transfection efficiency was measureable 
(approximately 20 relative light units (RLU)) indiciating that transfection of early HSCs was low but 
still successful. Protein expression of β-Catenin is minimal in quiescent day 0 HSCs, only detectable 
at day 1 and active, dephosphorylated β-Catenin cannot be detected at either of these early time 
points (Figure4.5). These data strongly suggest that β-Catenin does not play a role in maintaining 
quiescence 
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Figure 4. 3 Canonical stimulus of HSCs does not result in a transcriptional response. 
(A) LX-2 and HEK293 cells were transfected with a TOPFLASH luciferase expression vector and co-transfected 
with Wnt 3a or 10b as a canonical stimulus. Cotransfection  of Renilla luciferase served as a positive control. 
Data presented as fold change of firefly to renilla ratio (F/R) ± SEM. (n=2) (B) Axin2 mRNA expression levels 
Wnt10b overexpressing LX-2 or HEK293 cells compared by qRT-PCR (n=3) qRT-PCR results are expressed as fold 
change normalised to control ± SEM. *p<0.05 Student’s t Test 
Figure 4. 4  βCatenin stimulus of HSCs does not result in a transcriptional response. 
(A) LX-2 and HEK293 cells or rat HSCs and dermal fibroblasts (rDFs) were transfected with a constitutively 
active βCatenin (Ser37) or empty control expression vector.  Cotransfection  of Renilla luciferase served as a 
control of transfection efficiency. Data presented as fold change of firefly to renilla ratio (F/R) ± SEM. (B) 
Expression of Active and total β-Catenin analysed by Western Blot in protein lysates from control or 
βCatenin(Ser37) overexpressing LX-2 and HEK293 cells.GAPDH serves as a loading control. (C) Axin2 mRNA 
expression levels of Ser37 βCatenin overexpressing LX-2 or HEK293 cells compared by qRT-PCR (n=3). (D) 
mRNA expression  levels of fibrogenic makers compared by qRT-PCR in βCatenin (Ser37) or Wnt10b  
overexpressing LX-2 cells. qRT-PCR results are expressed as fold change normalised to control ± SEM. *p<0.05 
Student’s t Test (unpaired).  
 
 79 
 
4.4 β-Catenin is correctly localised to the nucleus of HSCs 
From these findings it appears that canonical signalling is deficient in LX-2s and primary HSCs even 
under conditions able to effectively stimulate a canonical response in other cell types. The 
complexity of the Wnt pathway gives rise to many potential points at which a defect could occur. I 
first addressed whether active β-Catenin was able to correctly localise in HSCs. 
In order for nuclear localisation to occur, the phosphorylation of β-Catenin by the kinase GSK3β 
must be disrupted. In the absence of Wnt signalling β-Catenin is phosphorylated by the destruction 
complex and degraded. Wnt signalling promotes destabilisation of the destruction complex, 
preventing phosphorylation and enabling translocation of β-Catenin to the nucleus(12). I first 
assessed whether HSCs may have a deficiency in GSK3β inhibition. Day7 HSCs were treated with CT 
99021 , a commercially available inhibitor of GSK3β,  reasoning that increasing inhibition of GSK3β 
would yield  a larger pool of non-phosphorylated,  potentially active β-Catenin. Western Blots for 
active and total β-Catenin demonstrate several points. Firstly that again no active or total β-Catenin 
can be detected in Day 0 quiescent cells. By Day 7 however an upregulation of both total and active 
β-Catenin is observed (Figure4.6A). This suggests that there is a potentially active pool of non 
phosphorylated β-Catenin present in HSCs . Treatment of Day7 aHSCs with CT99021 did not increase 
mRNA expression of fibrogenic genes or β-Catenin  target Axin2 (Figure4.6B). This suggests that the 
canonical pathway deficiency is not at the point of destruction complex inhibition. 
β-Catenin binds to TCF/LEF transcription factors confined to the nucleus. Correct nuclear localisation 
of β-Catenin is therefore critical to its canonical Wnt signalling function.  I separated protein lysates 
from LX-2 cells into cytoplasmic and nuclear fractions and assessed the expression and location of β-
Catenin by Western Blot. p84 and αTubulin were used as markers of nuclear and cytoplasmic purity 
respectively. LX-2s express high levels of β-Catenin, located both in the cytoplasm and in the 
nucleus. Furthermore, expression in both compartments is increased upon overexpression of β-
Catenin (Figure 4.7) From this HSCs appear to correctly target β-Catenin to the nucleus. 
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Figure 4. 5 Active β-Catenin is not detectable in qHSCs 
Protein lysates from freshly isolated HSCs (Day 0) and after 24 hours of culture (Day 1) immunoblotted 
for active and total β-Catenin expression. Total βCatenin only expressed after 24 hours of culture. 
GAPDH serves as a loading control.  
Figure 4. 6 GSK3β inhibition does not stimulate canonical response 
(A) aHSCs (seven days in culture (D7)) were treated with 2µM of CT99021. Active and total β-Catenin 
expression was compared  by Western Blot between quiescent (D0) and active (D7) HSCs treated with 
either vehicle control (-) or 2µM CT99021 (+) for 24 hours. HEK293 cells overexpressing constitutively 
active β-Catenin (S37) were used as a positive control for active β-Catenin expression. GAPDH serves as 
a loading control.  (B) mRNA levels of fibrogenic markers and the β-Catenin target Axin2 were 
compared by qRT-PCR between vehicle control (DMSO) or  CT99021 treated aHSCs (24hrs) (n=2). qRT-
PCR results are expressed as fold change normalised to control ± SEM. 
 
(A) (B) 
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4.5 Nuclear Interactors of β-Catenin 
Once in the nucleus, the stability of β-Catenin and its ability to bind TCF/LEF targets depends on 
interaction with a multitude of other proteins. I next hypothesised that HSCs may have a deficiency 
in a key nuclear interactor of β-Catenin and thus impair binding to TCF/LEF targets. 
Pygopus and BCL9 are two nuclear proteins implicated in a 'scaffolding role', required to tether β-
Catenin to TCF family members (149-151). Deficiencies in these scaffolding proteins can lead to 
impaired signalling and they are considered essential for correct canonical function(152, 153). 
Expression of their different forms (Pyg1, Pyg2, BCL9, BCL92) was analysed by RT-PCR in LX-2 cells 
with HEK293 cells again used as a positive control. However, LX-2 cells displayed no obvious 
deficiency in mRNA expression (Figure 4.8A). 
 
Repressors of β-Catenin activity are also active in the nucleus. Chibby is one well documented such 
repressor, able to bind β-Catenin  and compete with TCF/LEF targets(154).  RT-PCR analysis suggests 
an increased amount of Chibby expression by LX-2s, although this could not be verified by qRT-PCR 
(Figure4.8B). Chibby expression over a time course of rHSC activation was next established, 
hypothesising that an increase in expression may occur to counteract increased β-Catenin (Figure 
4.8C). However, again mRNA expression decreases with activation.  This expression data suggests 
that there are no obvious deficiencies in mRNA expression of several key β-Catenin nuclear 
interactors. Ideally protein expression of Pyg, BCL9 and Chibby would also have been assessed to 
strengthen these findings. However due to poor quality of antibodies this could not be achieved. 
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Figure 4. 7 βCatenin is targeted to the nucleus of HSCs   
Protein lysates from LX-2s transfected with constitutively active mutant β-Catenin (Ser37 +) or empty 
control expression vectors (-) separated into cytoplasmic ( C) or nuclear (N) fractions. β-Catenin 
expression detected in both fractions by Western Blot. P84 and αTubulin serve as controls of nuclear and 
cytoplasmic purity respectively.  
Figure 4. 5Expression of key βCatenin interactors detectable in HSCs 
(A)mRNA expression of key βcatenin interacting proteins detectable by RT-PCR in both LX-2 
and HEK cells. ( B) mRNA expression levels of βcatenin inhibitor Chibby compared between 
four different samples of LX-2 and HEK cells. No significant difference observed. (C) mRNA 
expression of Chibby analysed across an in vitro activation time course of three separate 
preparations of rat HSCs. Significant decrease occurs with activation.     
8 -Catenin interactors detectable in HSCs 
 mRNA expression of key β-catenin interacting proteins detectable by RT-PCR in both 
LX-2 and HEK293 cells. (B) mRNA expression levels of β-catenin in i itor Chibby compared 
between LX-2 and HEK293 cells (n=4). (C) mR A expression of Chibby analys  across an in 
vitro activation t me course of rat HSCs (n=3). qRT-PCR results are expressed as fold change 
normalised to con rol ± SEM. 
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4.6 HSCs appear deficient in TCF/LEF expression. 
β-Catenin’s direct targets are members of the TCF/LEF transcription factor family comprising 
TCF1,3,4 and LEF1. β-Catenin triggers their activation by displacement of the repressor Groucho/TLE, 
forming an activation complex, enabling  binding to target genes.  The literature is highly 
contradictory as to the exact roles of TCF/LEF members. TCF1, 4 and LEF1 are generally considered 
to activate β-Catenin target genes(73) whereas TCF3 is suggested to have a repressive role(155-157). 
I next investigated whether HSCs may have a deficiency in expression of TCF/LEF member. Firstly, I 
analysed expression of TCF1, TCF3,TCF4 and LEF1 in LX-2s by Western Blot using HEK293s as a 
control. LX-2s express substantiallyy less TCF1, TCF4 and LEF1 compared with HEK293s along with 
similar levels of TCF3. (Figure 4.9) 
 
I next aimed to increase the ability of LX-2 cells to respond to canonical stimulus by increasing 
expression of the TCF/LEF1 family. LEF1 appears to be substantially decreased in LX-2 cells and was 
overexpressed in LX-2 cells either singly or in conjunction with active β-Catenin. However, TOPFLASH 
activity was not stimulated instead appearing to decrease upon LEF1 overexpression (Figure 4.10). 
Furthermore, there was minimal effect on fibrogenic markers. This appears to be the first source of 
deficiency in the canonical pathway identified in HSCs.  However, as simply increasing expression of 
TCF/LEF family members was ineffective there are likely more factors influencing canonical activity. 
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Figure 4. 9 Expression of TCF1, TCF4 and LEF1 decreased in LX-2 cells  
Western Blot analysis of TCF1, TCF3, TCF4 and LEF1 expression compared between LX-2 and HEK293 
cells. Decreased TCF1, TCF4 and LEF1 expression apparent in LX-2s. GAPDH serves as a loading control.     
Figure 4. 10 LEF1 overexpression does not stimulate a canonical response  
(A) LX-2 and HEK293 cells were transfected with a TOPFLASH luciferase expression vector and 
cotransfected with  either constitutively active β-catenin (Ser37), LEF1 or empty control expression 
vector. Cotransfection  of Renilla luciferase served as a control of transfection efficiency. Data presented 
as fold change of firefly to renilla ratio (F/R) ± SEM. (B) mRNA expression of fibrogenic markers analysed 
in of LX-2s overexpressing LEF1 either singly or in conjunction with β-Catenin (Ser37) (n=3). ). qRT-PCR 
results are expressed as fold change normalised to control ± SEM. (C) Western Blot analysis of LEF1 
expression in control and LEF1 overexpressing LX2s. GAPDH serves as a loading control.  
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4.7 Wnt Interactors and β-Catenin 
In Chapter 3 I demonstrated that aHSCs significantly upregulate  expression of Wnt interactors such 
as sFRP members and Dkk3  however a specific  function  was not isolated. How they influence Wnt 
signalling has not yet been resolved and appears to be highly cell specific. Several sources suggest 
roles in inhibition of β-Catenin/TCF activity (158, 159) and the ability to inhibit canonical Wnt 
signalling even in the presence of activating β-Catenin mutations(160). Furthermore, epigenetic 
inactivation of sFRPs is a frequent occurrence in numerous cancers  (146, 161, 162). I next explored 
the possibility that HSCs may inhibit canonical activity through production of these secreted 
inhibitors. 
For this, I used HEK293 cells overexpressing active β-Catenin as a positive control for canonical 
activity. Medium taken from LX-2 cells and incubated with HEK293 cells for six hours appeared to 
decrease TOPFLASH activity approximately 30% in comparison to medium taken from HEK293 cells 
(Figure 4.11). This suggests the possibility that LX-2s may secrete factors able to negatively influence 
canonical signalling. I next tested whether sFRP overexpression could have a similar negative 
influence on canonical signalling.  I co-transfected β-Catenin overexpressing HEK293 cells with a 
sFRP4 expression vector and again observed a similar reduction in TOPFLASH activity. This could be a 
preliminary suggestion as to how HSCs prevent canonical signalling, despite the presence of all 
necessary downstream components. 
 
  
 86 
 
 
  
Figure 4.11 sFRP4 and canonical inhibition.  
β-Catenin overexpressing HEK293 cells co-transfected with TOPFLASH expression vector were 
treated with HEK293 cell conditioned medium, LX-2 cell conditioned medium or co transfection 
with sFRP4. Renilla luciferase served as a positive control. Data presented as fold change of 
firefly to renilla ratio (F/R) ± SEM. Significant decrease in TOPFLASH activity observed upon LX-2 
conditioned medium treatment or sFRP4 co transfection. *p<0.05 Student’s t Test (unpaired)  
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4.8 Non Canonical Activity in HSCs 
So far this chapter has demonstrated that HSCs show limited endogenous canonical activity, despite 
abundant expression of β-Catenin and canonical components. Furthermore, they appear resistant to 
canonical stimulus even under conditions that provoke a response in other cell types. Reasons for 
this remain unclear although I have been able to identify a decreased expression of β-Catenin target 
and an increased expression of potential Wnt inhibitors in HSCs. 
As HSCs express a variety of non-canonical ligands I next turned to establishing the presence of non 
canonical signalling. Two major effectors of the non-canonical branches of Wnt signalling are JNK as 
part of the PCP pathway and CamKii as part of the Wnt/Ca2+ pathway.  JNK mediated activation of 
AP1 components is well established in contributing to HSC activation(163) and increased calcium 
signalling is important in mediating increasing contractility of aHSC(164). Non-canonical effectors 
therefore have high potential for regulating HSC behaviour.  I tested response of these effects upon 
Wnt stimulation in HSCs. 
Wnt conditioned medium stimulation in primary rat HSCs  and overexpression of Wnt in LX-2 cells 
both stimulate a marked increase in JNK phosphorylation (Figure 4.12A and C respectively), This 
suggests the potential for Wnt to activate JNK signalling in HSCs. Expression of the Ca2+ pathway 
mediator CamKii was also elevated upon Wnt stimulus (Figures 4.12B and D). Response  of non-
canonical effectors and the predominantly non-canonical Wnt ligand expression profile suggest that 
non-canonical signalling is the main branch active in aHSCs. 
As non-canonical Wnt activity has been shown to inhibit canonical/β-Catenin activity(139, 165, 166) I 
again aimed to increase the ability of LX-2 cells to respond to canonical stimulus through non-
canonical inhibition. LX-2 cells overexpressing active β-Catenin were treated with either SP600125 to 
inhibit JNK phosphorylation or Cyclosporin A, an inhibitor of calcineurin, a downstream effector of 
CamKii. However, again no upregulation in TOPFLASH activity was observed with inhibitor treatment 
(Figure 4.13) 
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Figure 4.13 Non Canonical Inhibition in HSC  
LX-2 cells were transfected with a TOPFLASH luciferase expression vector and cotransfected with either Ser37 β-Catenin 
mutant or empty control expression vectors. Renilla luciferase served as a control of transfection efficiency. Data 
presented as fold change of firefly to renilla ratio (F/R) ± SEM.  Cells were treated with  SP600125 (50µM ) or 
Cyclosporin A (50µM)  for 24 hours.  
Figure 4.11 Non-Canonical Effectors in HSCs  
 
Figure 4.12 Non-Canonical Effectors in HSCs  
rHSCs (A) and (B) or LX-2s (C) and (D) were stimulated by 24 hours Wnt conditioned medium (CM) or 48 hours Wnt 
Transfection respectively.  Protein lysates were immunoblotted for expression of Phospho-JNK, (PJNK), total JNK 
(TJNK) and CamKii. GAPDH serves as a loading control.  
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The transcription factor family associated with calcium signalling is the NFAT family (NFAT 1 -4)(167). 
To establish whether activity of non-canonical associated transcription factors was present, rat HSCs 
and LX-2s were transfected with a total NFAT luciferase reporter. Endogenous NFAT activity was far 
greater in LX-2s and rat HSCs than TCF transcriptional activity (Figure 4.14A) RT-PCR analysis 
demonstrates expression of all four NFAT transcription factors in rat HSCs, with NFAT3 particularly 
abundant (Figure 4.14B).  However, NFAT3 does not appear to be differentially expressed upon HSC 
activation (Figure 4.14C) and non-canonical stimulus through Wnt5a overexpression does not 
increase NFAT luciferase activity in LX-2s (Figure 4.14D). This suggests that high levels of NFAT 
activity in HSCs may not be attributed to increased Wnt signalling. One of the significant issues of 
working with the non-canonical pathway is that there is no functional read out specific to Wnt 
signalling, no non-canonical version of the TOPFLASH assay for example. Numerous factors have the 
potential to influence JNK and CamKii and attributing alterations in function directly to Wnt 
signalling can be difficult. 
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Figure 4.14 NFAT Activity in LX-2s and HSCs 
(A) Rat HSCs and LX-2s were transfected with a total NFAT luciferase reporter or an control 
promoterless luciferase vector for 48 hours. Renilla luciferase served as a positive control. Data 
presented as firefly to renilla ratio (F/R) in relative light units (RLU). (B) mRNA Expression levels of 
NFAT family members detected in aHSCs by RT-PCR, with water only (-ve) serving as a negative 
control. (C) mRNA expression levels of NFAT3 compared between three separate preparations of 
quiescent (qHSC) and active (aHSC) rat HSCs. No significant difference observed. (D) LX-2s were 
transfected with a total NFAT luciferase reporter and co-transfected with either a Wnt5a or empty 
control expression vector. Renilla luciferase served as a control of transfection efficiency. Data 
presented as fold change of firefly to renilla ratio (F/R) ± SEM.  
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4.8 Discussion 
 
This Chapter aimed to explore the activity of canonical and non-canonical effectors in HSCs, 
attempting to determine which branch was functional. Canonical activity has been demonstrated as 
pro-fibrogenic in HSCs and in fibroblasts across numerous fibrosis models.  The main finding from 
this Chapter contradicts this identifying an apparent defect in canonical β-Catenin/TCF dependent 
signalling. 
 
HSCs express all necessary components of canonical pathway and correctly localise β-Catenin upon 
stimulus. If aHSCs are regulated by activity of Wnt3a and Wnt10b, high levels of canonical activity 
would be expected even without stimulus.  Under endogenous conditions however, no 
transcriptional activity could be measured either through TOPFLASH activity or analysis of 
downstream transcriptional targets. Stimulus through either Wnt overexpression or active mutant β-
Catenin overexpression successfully elicited response in the HEK293 cells used as a positive control. 
HSCs and LX-2 cells however remained unresponsive.  As β-Catenin is correctly localised, the defect 
is likely to be at the nuclear level: either β-Catenin unable to associate with its TCF/LEF targets or 
TCF/LEF transcription factors unable to bind to their target genes. 
 
From this Chapter, two possible causes of transcriptional defect are highlighted.  Firstly, the reduced 
protein expression of canonical TCF/LEF targets observed in LX-2 cells in comparison to HEK293 
controls. Target availability for β-Catenin would therefore be reduced, although this is more likely to  
decrease in canonical signalling rather than cause a total absence. Furthermore, overexpression of 
LEF1 did not promote TOPFLASH activity or expression of target genes, despite significant increases 
in protein expression. Therefore a simple defect in protein expression is unlikely to be the major 
cause. 
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LX-2 cells do not appear to uniformly express TCF/LEF members.  This appears similar to problems 
encountered in Chapter 3, multiple TCF/LEF family members with interactions and functional 
redundancy levels not fully outlined. LEF1 and TCF1 expression is markedly reduced. In contrast TCF3 
expression is marginally increased in LX-2s in comparison to HEK293s. TCF1, TCF4 and LEF1 members 
behave similarly upon β-Catenin binding with TLE/Groucho repressors displaced and transcriptional 
activating complexes  formed(73). TCF3 however is considered a divergent member of the family, 
associated with a repressive role. Wu et al (157) demonstrate that endogenous levels of LEF1 activity 
are reduced  upon transgenic overexpression of TCF3 and that β-Catenin promotes LEF1 activity 
through inhibition of TCF3 repression. β-Catenin is thought to relieve the repressive effect through 
binding and targeting TCF3 for degradation(156). In mouse models, early depletion of TCF3 
disrupted gastrulation and caused defects which phenocopied models of canonical Wnt 
overactivation (168). Here, depletion of TCF3 in LX-2 and removing its possible repressive effect 
could be a method of stimulating canonical activity. 
 
Establishing functional β-Catenin-TCF/LEF binding will be essential in clarifying the canonical defect. 
High TCF3 protein levels in LX-2s could indicate a lack of β-Catenin mediated degradation and 
therefore inefficient β-Catenin/TCF binding. However attempted Immunoprecipitation (IP) assays to 
determine binding between β-Catenin and TCF/LEFS as well as attempted Chromatin IP (ChIP) assay 
to determine binding between TCF transcription factors and target genes were unsuccessful. Further 
optimisation of conditions to provide conclusive data about β-Catenin, TCF/LEF and target gene 
binding interactions will be invaluable in continuing study. 
 
Inhibition of β-catenin by sFRPs is another possibility for canonical defect as sFRPs are able to 
decrease canonical signalling even in the presence of activating β-Catenin mutations(160).  
Additionally,  in breast cancer cells, TCF/LEF activity was increased only when siRNA depletion of 
sFRP1 accompanied mutant β-catenin expression(162). Here, sFRP4 overexpression in HEK293s 
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stimulated with β-Catenin significantly decreased TOPFLASH activity by 30%. This could serve as an 
explanation for the greatly increased expression of sFRPs upon HSC activation: they are factors 
secreted to repress canonical signalling rather than directly influencing the fibrogenic phenotype. 
This is a very preliminary finding and will require extensive investigation into potential mechanisms. 
 
The possibility that HSCs have a particular nuclear interactor involved in β-Catenin repression is an 
attractive one. However, β-Catenin has known ability to interact with over 80 different proteins in 
the nucleus. Expression profiles of nuclear β-Catenin interactors varies widely with cell type and 
their function as repressors or interactors can be highly context specific. Furthermore, interactions 
between different nuclear components are not well known. Identifying a HSC specific β-Catenin 
repressor is therefore likely to be an arduous task. One promising candidate is SOX9, a member of 
the  SRY-related high-mobility-group box (SOX) family of transcription factors. SOX9 is able to 
compete with TCF/LEF targets for β-Catenin binding and promote its degradation(169, 170).  SOX9 is 
highly expressed in aHSCs with its nuclear localisation demonstrated by immunofluorescence(171). 
In HSCs it is able to in regulate collagen expression: induction of SOX9 by TGFB treatment led to 
increased collagen expression while siRNA depletion caused a reduction. Increased expression of  
SOX9 associated with HSC activation could therefore disrupt β-Catenin /TCF interaction in the 
nucleus of HSCs provoking defective canonical signalling. IP assays to demonstrate SOX9/ β-Catenin 
interactions followed by siRNA depletion of SOX9 to determine whether canonical signalling can be 
induced would be necessary to further explore this possibility. 
 
This Chapter has revealed an absence of canonical/ TCF driven signalling in HSCs and proposes 
several mechanisms by which it may occur (Figure 4.15). This appears at first to contradict data from 
previous studies. Previously published data along with results here from section 4.1 clearly 
demonstrate increased expression of total and active β-Catenin in aHSCs and decreased fibrogenic 
activity upon its suppression. However, these studies do not conclusively show β-Catenin functioning 
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through TCF/LEF family members. Furthermore, downregulation of β-catenin is accompanied by  
decreased activity of effectors such as Smad3(123), PDGF, Akt (129) and TGFβ(128) and not classic 
canonical Wnt effectors.  The ability of the canonical inhibitor Dkk1 to promote reversion of aHSC to 
more quiescent phenotype in vitro as well as amelioration of a cholestatic liver injury model has 
been used as evidence of canonical Wnt activity in HSCs(110). Dkk1 functions through binding and 
inhibiting the canonical associated co-receptor Lrp6(93). However, in addition to  Wnt stimulation, 
Lrp6 activity can also be independently stimulated by multiple profibrogenic pathways such as TGFβ, 
CTGF and PDGF, all disrupted through Dkk1 treatment (172). Dkk1 treatment of HSCs could 
therefore be inhibiting activity of these pathways instead of Wnt to modulate HSCs behaviour. 
 
β-Catenin is able to act as a transcriptional activator independent of Wnt/TCF stimulus, although 
examples are few in comparison to its role in regulating canonical Wnt signalling. Evidence so far 
supports a TCF independent role for β-Catenin in HSCs which requires much further exploration. 
TGFβ  is one alternative inducer of β-Catenin activity. TGFβ treatment frequently is observed to 
stimulate β-Catenin nuclear translocation and complex formation with the Smad family of 
transcription factors in the absence of Wnt signalling(173-175). In renal tubular epithelial cells,  TGFβ 
promoted β-Catenin to act as a transcriptional co-activator  of Smad3, upregulating Smad3 reporter 
activity but no concurrent upregulation in  TOPFLASH activity(176). This demonstrates 
transcriptional activity of β-Catenin without reliance on its better known TCF binding partners.  
Another study demonstrated a complex of Smad3/ β-Catenin directly binding to αSMA promoter and 
regulating transcription, again in the absence of  TCF activity(177). TGFβ is a major profibrogenic 
cytokine and secreted in abundance by HSCs and other cells in the injured liver. TGFβ mediated β-
Catenin signalling could therefore be one potential role for β-Catenin in aHSCs. Several studies  
require exogenous TGFβ stimulus before β-catenin function is observed. The β-catenin 
overexpression experiments in Figures 4.4 and 4.10 were conducted under standard culture 
conditions. Addition of recombinant TGFβ stimulus may have enabled greater β-catenin activity. 
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Whether non-functional β-Catenin /TCF signalling is due to a defect in signalling machinery or 
through active repression cannot be determined from this data. Abnormal β-Catenin signalling is 
associated with numerous cancers and other pathologies: active β-Catenin mutations can be 
detected in 25% of HCCs for example(145). Minimal levels of canonical Wnt signalling may serve as a 
regulatory mechanism preventing the dysregulated proliferation and cell signalling associated with 
overactive β-Catenin mutations. 
 
Canonical Wnt signalling through TCF/LEF mediated transcription therefore appears to be absent in 
HSCs. Instead HSCs and LX-2s upregulate non-canonical effectors such as Jnk and CamKii in response 
to Wnt stimulus as demonstrated by Figure 4.12. Based on this as well as the expression of non-
canonical ligands and receptors in aHSCs, it can be proposed that non-canonical Wnt signalling is the 
active branch. Non-Canonical Wnt signalling has been shown to regulate proliferation, migration and 
contractility in numerous cell types. These are typical traits of the profibrogenic myofibroblast 
therefore non-canonical signalling has much possibility for regulating HSC behaviour. 
  
 96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 Points of inhibition of Canonical/TCF mediated Wnt signalling 
This study has highlighted six possible points of canonical Wnt inhibition occurring in HSCs. (A) (1) 
Predominantly non-canonical ligand expression. Non canonical signalling is inhibitory to canonical 
signalling(139) (2) Decreased Fzd receptor expression, reducing response to canonical ligands 
secreted by other cells (3) Increased sFRP expression (4) Increased expression of other morphogens 
such as Notch, able to directly inhibit β-Catenin(178)  
(B) In the nucleus, HSCs express higher levels of the repressive TCF3 in comparison to the other 
TCF/LEF family members associated with transcriptional activation(5) (6) Transdifferentiation is 
associated with upregulation of SOX9, direct inhibitor of β-Catenin activity (171) 
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4.9 Conclusions 
 
In summary, this chapter demonstrates: 
 Absence of canonical β-Catenin/TCF mediated transcriptional activity, 
even under effective canonical stimulus 
 Decreased expression of TCF/LEF targets in 
 Response to Wnt stimulus through non-canonical effectors 
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Chapter 5: Role of Wnt in HSC 
Behaviour 
5.1 Introduction 
 
Chapter 3 identified active Wnt signalling in HSCs. Chapter 4 explored which branch of Wnt could be 
operating, identifying flaws in the canonical pathway and highlighting non-canonical Wnt as the 
most likely mechanism. This Chapter focuses on how exactly non-canonical signalling contributes to 
HSC behaviour. 
Previous studies have identified expression of non-canonical ligands in HSCs yet their function 
remains relatively unexplored. This Chapter intends to build on these studies and identify a specific 
role for Wnt ligands. Based on findings in previous chapters, Wnt5a was selected as a suitable 
candidate for further study. 
 
5.2 Inhibition of Wnt signalling influences activation of HSCs 
 
Firstly, as an initial method of determining the role of Wnts in HSCs, I attempted a simple depletion 
of Wnt activity via commercially available inhibitors.  There are a large number of inhibitors selective 
for Wnt signalling, targeting numerous points in the pathway. However, as for many other reagents, 
most focus on the disruption of the canonical pathway. Reliable inhibitors targeting the non-
canonical pathway only are not widely used. Three inhibitors were chosen, each targeting a different 
stage in the signalling cascade: IWP2, a  Dvl-PDZ domain inhibitor (Dvl-PDZ) and ICG001. 
IWP2 is an antagonist of porcupine (Porc), the upstream component responsible for the 
palmitoylation of Wnt ligands and essential for secretion (80, 179).  Disruption of Porc function will 
therefore prevent release of Wnt ligands, halting signalling at the beginning of the pathway. The Dvl-
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PDZ inhibitor targets the central PDZ domain of Dvl proteins, preventing Dvl association with Fzd 
receptors and  transduction of Wnt signal(180). Both of these are inhibitors act upstream of the 
separation of canonical and non-canonical pathways and should function as ‘pan-Wnt inhibitors’, 
affecting both pathways equally. ICG001 is an inhibitor of β-Catenin, preventing association with one 
of its co-activators CBP(181). Active β-Catenin is clearly present in aHSCs as demonstrated by Figure 
4.6 Disruption of its activity may provide further clues as to its function. 
The efficacy of IWP2 treatment can be clearly demonstrated by decreased expression of  
hyperphosphorylated Dvl with increasing doses of IWP2 (Figure 5.2A). Dvl-PDZ inhibitor is able to 
significantly decrease common downstream Wnt targets such as Sox9 and Axin2 (Figure 5.2B) 
Finally, ICG001 can be shown functional as it significantly decreases TOPFLASH activity in active β-
catenin overexpressing HEK293 cells (Figure 5.2C). 
Initially, day 7 rat cells were treated for 24hrs with doses commonly used in the literature: IWP2 at 
5µM, Dvl-PDZ inhibitor at 15µm and ICG001 at 5µM. Morphologically, IWP2 and Dvl-PDZ inhibitor 
treated HSCs appear identical to controls when assessed by bright field microscopy. In contrast, 
ICG001 treatment dramatically alters morphology with cells appearing smaller, rounder and fewer in 
number (Figure 5.3A). Canonical Wnt/β-Catenin inhibition in HSCs has previously been alleged to 
promote reversion to a quiescent phenotype(110). ICG001 administration has also proved successful 
in reducing fibrosis with treatment of alveolar epithelia cells in a pulmonary fibrosis model able to 
suppress TGF-β induced αSMA and collagen expression(182, 183). Data here however do not 
correspond to this. Despite the dramatic change in appearance, no significant reduction occurs in 
expression of myofibroblast markers such as αSMA (Figure 5.3B).Furthermore,  β-Catenin inhibition 
promotes no increase in expression of PPARγ, the adipogenic master regulator and typical marker of 
quiescence (Figure 5.4A).  The number of apoptotic cells increases approximately two fold with 
ICG001 treatment in comparison to over vehicle control. This offers an alternative explanation for 
the abnormal cell appearance (Figure 5.4B). 
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Figure 5.1 Wnt pathway in HSCs targeted at three different points of signalling pathway  
Figure 5.2 IWP2, Dvl-PDZ domain, and ICG001 act as effective Wnt inhibitors in HSCs  
(A) Western Blot analysing Dvl2 expression upon 24 hours treatment with increasing doses of IWP2. βActin serves as a 
loading control.  (B) qRT-PCR analysis of WNt target genes in  rat aHSCs treated with either 15µm Dvl-PDZ domain inhibitor 
or vehicle control (n=3)  (C) HEK293 cells overexpressing active βcatenin (Ser37) were transfected with a TOPFLASH 
luciferase reporter (n=2). Renilla luciferase served as a control of transfection efficiency. Data presented as fold change of 
firefly to renilla ratio (F/R) ± SEM. qRT-PCR results are expressed as fold change normalised to control ± SEM. *p<0.05 
Student’s t Test (unpaired) 
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Figure 5.3 Wnt inhibitors and HSCs.  
Rat aHSCs (7 days in culture)  were treated with either 15µm Dvl-PDZ inhibitor, 5µM IWP2, 5µM ICG001 or 
vehicle control (DMSO). (A) Changes in cell morphology were assessed by bright field microscopy (B) mRNA 
expression of fibrogenic markers was analysed by qRT-PCR for each inhibitor treatment (+) compared with 
vehicle contol  (n=3). qRT-PCR results are expressed as fold change normalised to control ± SEM. *p<0.05 
Student’s t Test (unpaired) 
 
Figure 5.4 ICG001 does not appear to promote reversion of HSCs to quiescent phenotype.  
Rat aHSCs (7 days in culture) were treated for 24 hours with 5µM ICG001. (A) qRT-PCR analysis of mRNA 
expression of β-Catenin target Axin2 or the quiescence marker PPARγ in ICG001 and vehicle control (DMSO) 
treated aHSCs (n=3). (B) Acridine Orange staining was used to measure apoptosis in ICG001 and vehicle 
control treated aHSCs (n=3) *p<0.05 Student’s t Test (unpaired) 
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In contrast, treatment with IWP2 or the DVl-PDZ inhibitor suppressed expression of fibrotic markers. 
Dvl-PDZ treatment significantly decreases mRNA expression of both αSMA and Collagen 1. IWP2 
similarly decreased Collagen1 expression but not to a statistically significant level (Figure 5.3B). This 
further supports a pro-fibrogenic role for Wnt signalling independent of β-Catenin. 
IWP2’s striking decrease of Dvl phosphorylation was chosen as the more reliable marker for Wnt 
inhibition. From Figure 5.2, IWP2 appears effective across several doses from 5µm to 20µm, 
reducing expression of the higher weight, hyperphosphorylated form. At the 5µM dose used above, 
minor expression of hyperphosphorylated Dvl can still be detected. I next attempted treatment with 
a higher dose of 20µM and extended treatment time, administering two doses of IWP2 over a 48 
hour period, attempting to further increase Wnt inhibitory potential. Two time points were chosen: 
quiescent HSCs (treated at days 1 and 2) and active HSCs (treated at days 7 and 8), allowing 
assessment of Wnt function during both initiation of HSC activation and perpetuation of the active 
phenotype. IWP2’s suppression of Wnt signalling was assessed through analysis of downstream 
markers. Firstly, expression of Evi mRNA, the direct downstream component of Porc and another 
component necessary for Wnt secretion(184), is reduced by approximately 40%. This is further 
accompanied by significant reductions in commonly used markers of Wnt activity such as NFAT3 and 
SOX9(Figure 5.5A). SOX9 profibrogenic role is well known(171), and its decrease further supports a 
profibrogenic role of Wnt signalling in HSCs.  Phosphorylated  Dvl is also markedly decreased  in 
treated cells at Days 7/8 compared to controls when analysed by Western Blot. (Figure 5.4B) 
As predicted, a 48 hour treatment with IWP2 significantly decreased αSMA and Collagen1 expression 
in aHSCs (Figure 5.5C), supporting the hypothesis that Wnt signalling contributes to HSC activation. 
Surprisingly, the opposite results are apparent upon early treatment, marked increases TIMP1 and 
Collagen1 transcript levels observed (Figure 5.5C). This suggests temporal differences in Wnt activity: 
potentially inhibitory early in activation and stimulatory later on. As IWP2 treatment blocks both 
canonical and non-canonical signalling, discerning from this which Wnts may be active at an early 
time point is not possible. 
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Figure 5.5 IWP2 successfully inhibits Wnt signalling and decreases expression of fibrogenic targets in aHSCs. 
Primary rat HSCs were treated with two doses of 20µM IWP2 or vehicle control (DMSO) over a 48 hour period. (A) 
mRNA expression of Wnt pathway components and targets was analysed by qRT-PCR (n=4). (B) Western Blot 
analysing protein expression of Dvl2 after 48 hours in IWP2 or vehicle control (DMSO) treated aHSCs. βActin serves as 
a loading control. (C) mRNA of fibrogenic markers was analysed by  qRT-PCR in aHSCs treated with IWP2 or vehicle 
control (DMSO) at Days 1 and 2 of culture or Days 7 and 8. (n=4). qRT-PCR results are expressed as fold change 
normalised to control ± SEM. *p<0.05 Student’s t Test (unpaired)   
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5.3 Overexpression of Wnt 
Pan-Wnt inhibition therefore significantly alters the fibrogenic potential of HSCs. I next aimed to 
identify function for specific Wnt ligands, primarily using non-canonical Wnt5a as a target. 
Accomplishing specific depletion of Wnt5a is likely to be difficult. Commercial inhibitors selective for 
Wnt5a are not available and reliable siRNA knockdown would be complicated by the poor cross-
reactivity of Wnt5a antibodies in rat. Instead, Wnt overexpression was first attempted in the easily 
transfectable LX-2 cell line. To begin, LX-2s were transfected with constructs for either  Wnt10b or 
Wnt5a ligands, questioning whether there would be a difference in  response to canonical and non 
canonical Wnts. Overexpression was highly effective with mRNA increasing by approximately 160 
fold for Wnt5a and 70 fold for Wnt10b (Figure 5.6A).  Phosphorylation of Dvl is markedly increased 
in LX-2s cells upon Wnt overexpression, to a similar extent for both canonical (Wnt10b and Wnt3a) 
and non-canonical ligands (Wnt5a) (Figure 5.6B). This again demonstrates the initial robust response 
to both types of Wnt ligand. Wnt overexpression does not significantly alter viability of LX-2 cells as 
measured by MTT assay (Figure 5.6C) nor causes any overt differences in morphology (Figure 5.D). 
Wnt inhibition in aHSCs in the previous section decreased transcript levels of fibrogenic markers. 
Wnt overexpression here was expected to enhance expression of fibrogenic markers. Figure 4.4 
demonstrated that Wnt10b overexpression did not stimulate increased expression of fibroblast 
markers in LX-2s. Here, a similar lack of response is observed in Wnt5a overexpressing cells (Figure 
5.7) 
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Figure 5.6 LX-2s readily respond to overexpression of canonical and non-canonical Wnts.  (A) LX-2 cells were transfected with a 
Wnt5a, Wnt10b or empty control expression vector. After 48 hours, mRNA expression of Wnt5a and Wnt10b was analysed by qRT-
PCR in three separate transfections. WNt5a and  Wnt10b are significantly increased upon transfection. (B) Western Blot analysis of 
LX-2 cells overexpressing Wnt3a, WNt5a or Wnt10b demonstrates significant upregulation of Dvl2 phosphorylation in comparison 
to control cells. Wnt5a or 10b overexpression causes no significant differences in  viability of two separate transfections of LX-2 cells 
as measured by MTT assay  (C) and causes no change in cell morphology assesed by bright field microscopy.     
Figure 5.7 Overexpression of non-canonical Wnt5a does not affect expression of fibrogenic genes.  
mRNA expression of fibrogenic genes analysed by qRT-PCR in LX-2 cells overexpressing Wnt5a for 48 hours (n=3) qRT-PCR 
results are expressed as fold change normalised to control ± SEM 
i re 5.6 LX-2s readily respond to ove xpression f c no ical and non-canonical Wnts. 
(A) LX-2 cells we e transfec ed with a W t5a, Wnt10b or empty control expression vector. After 48 hours, mRNA 
expression of Wnt5a and Wnt10b was nalysed by qRT-PCR (n=3) qRT-PCR results a e expressed as fold change 
norma i ed to control ± SEM. (B) Western Blot analysis of Dvl2 expression in LX-2 cells o erexpressing W t3a, Wnt5a r
Wnt10b compared to empty control vector. GAPDH serves as a loading control (C) Viablity of  Wnt5  or 10b 
over xpressing LX2 cells determined via MTT assay (n=2) (D) Cell morphology of Wnt overexpressing LX-2s assessed by 
bright field microscopy.     
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The majority of Fzd receptors were seen to decrease upon HSC activation (Figure 3.4) 
Overexpression of Fzd receptors was next attempted in LX-2 cells, hypothesising that a deficiency in 
receptors may prevent a response to Wnts being secreted. Overexpression of the significantly 
decreased Fzd4, Fzd8 and ROR2, the classic non-canonical receptor, was successful in LX-2s, with 
mRNA expression increased by approximately 200, 800 and 600 fold respectively (Figure 5.8). Again 
however, overexpression of receptors did not stimulate transcriptional change in any of the 
fibroblast markers analysed. 
From these overexpression experiments, LX-2s display an initial robust response to Wnt stimulus 
with phosphorylation of the signal mediator Dvl. However, no downstream transcriptional effects 
are apparent. LX-2s are considered representative of fully differentiated myofibroblasts. One 
possibility is that they may be ‘too activated’ in phenotype for increased Wnt signalling to provoke 
further effect.  Wnt stimulation of primary cells is therefore likely to be more valuable in 
investigating function of HSC expressed Wnts. 
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Figure 5.8 Overexpression of Wnt receptors does not alter fibrogenic gene expression.  
(A) Wnt Receptors Fzd4, Fzd8 and ROR2 were overexpressed in LX-2 cells for 48 hours and receptor 
mRNA expression analysed by qRT-PCR (n=3). mRNA levels of fibrogenic markers were then analysed in 
Fzd8 (B), Fzd4 (C) and ROR2 (D) overexpressing LX-2 cells compared to controls. qRT-PCR results are 
expressed as fold change normalised to control ± SEM 
 
(A) (B) 
(C) (D) 
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5.4 Wnt Stimulation of Primary Cells: Fibrogenic Markers 
Overexpression of Wnt ligands in primary HSCs was considered unlikely to be an effective stimulus 
as they are typically a difficult cell type to transfect(185). Instead, Wnt overexpressing LX-2s were 
used to produce medium conditioned with Wnt ligands, similar to a method used previously(166) 
and summarised in Figure 5.9. LX-2s were transfected with 1µg of Wnt expression vector for the 
standard 48hour transfection period. Medium was then collected and used to treat primary rat 
HSCs. Medium from LX-2s transfected with an empty expression vector was used as a control. This 
method enables treatment of rat HSCs with cell produced Wnt ligands, having undergone the post-
translational modifications such as palmitoylation necessary for secretion and function. 
 
 
 
 
 
 
 
 
Primary rat HSCs were incubated in medium conditioned with either canonical (Wnt10b) or non-
canonical (Wnt5a) ligands for 24 hours. Dvl2 phosphorylation substantially increased in response to 
both canonical and non-canonical ligands (Figure 5.10A), comparable with the response of LX-2s to 
Wnt overexpression (Figure5.6B). This again demonstrates the ability of HSCs to initially respond to 
both canonical and non-canonical stimulus. Conditioned medium treatment brought about no overt 
change in cell morphology (Figure 5.10B) and no significant differences in viability as measured via 
MTT assay. (Figure 5.10C) 
 
Figure 5.9 Method of Wnt conditioned medium treatment of primary HSCs   
LX-2s were transfected with 1µg of either an empty control or Wnt expression vector in 16% medium (Wnt TF). 
Medium was collected after 48 hours and used in treatment of primary rat HSCs 
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Figure 5.10 Primary HSCs respond to stimulus with both canonical and non canonical ligands.  
(A) Western Blot analysis of Dvl2 expression in  protein lysates from rat aHSCs treated for 24hours with 
conditioned medium (CM) from LX-2s over expressing Wnt5a, 10b or an empty control expression vector. 
GAPDH serves as a loading control. (B) Cell morphology of 24 hour Control or  Wnt5a CM treated rat HSCs 
assessed by bright field microscopy  (C) Viability of  Control or Wnt5a CM treated rat HSCs determined via MTT 
assay (n=2)  
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After establishing the Wnt stimulating effect of conditioned medium, two treatment points were 
then chosen: Day 3 when cells are early in activation, before a significant increase in Wnt expression 
occurs and Day 7 when cells are approaching full activation and Wnt signalling is already established.  
These two time points allow either an early induction of Wnt signalling or enhancement of Wnt 
already present. 
 
Day 3 cells stimulated for 24 hours did not respond as predicted. No significant effect on fibrogenic 
markers was observed, the typical myofibroblast marker α-SMA is increased by approximately 3 fold 
but with great variability (Figure 5.11A). Other key fibrogenic markers such as Collagen1, TGFβ, 
TIMP1 and MMP9 remain unchanged. Day 7 treated HSCs modestly increased TGFβ and α-SMA 
mRNA expression by approximately 2.5 fold, although not to a statistically significant extent (Figure 
5.11A). Wnt5a and TGFβ are well documented interactors and whether Wnt5a treatment influenced 
downstream TGFβ signalling was next questioned. However, no increase in mRNA expression levels 
of TGFβ receptors, the Smad transcription factor family or the downstream target CTGF was 
detected (Figure 5.11B). Furthermore, no increase in TGFβ protein expression was observed when 
assessed by Western Blot or ELISA.  (Figure 5.11C and D) 
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Figure5.11 Wnt CM stimulus does not significantly alter fibrogenic gene expression  
Primary rat HSCs were treated for 24 hours with control or Wnt5a conditioned medium (CM).  (A) mRNA expression of 
fibrogenic markers was analysed by qRT-PCR in rat HSCs treated at Day 3 or Day 7 in culture (n=4) (B) Further analysis 
of mRNA expression of TGFβ signalling components in rat aHSCs (Day 7 in culture) (n=3) (C) TGFβ Protein levels were 
analysed by ELISA in medium harvested from control or Wnt5a CM treated aHSCs (n=2) (D)  TGFβ Protein levels were 
analysed by Western Blot in protein lysates from control or Wnt5a CM treated aHSCs. βActin serves as a loading 
control.  qRT-PCR results are expressed as fold change normalised to control ± SEM 
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These findings once more demonstrate HSCs responding strongly to Wnt stimulus but without 
downstream effects on fibrosis associated targets. Two possible conclusions can be drawn from this. 
Firstly, that Wnt signalling has limited effect on typical fibrogenic gene expression in HSCs and may 
influence behaviour through other mechanisms. Alternatively, HSCs may secrete Wnts for the 
benefit of neighbouring cells. 
Wnt5a is a well-known modulator of macrophage behaviour(186-188). Based on this, I next 
attempted stimulus of rat Kupffer Cells, the resident liver macrophages, with conditioned medium 
produced by LX-2s. Here a more marked response was observed. Expression of TGFβ and MCP1 
mRNA expression increased significantly, accompanied by increased expression of TGFβ protein 
when visualised by Western Blot (Figure 5.12A and B)  This may support the theory that Wnts 
produced by HSCS do not function as autocrine signallers but instead work in a paracrine manner, 
influencing behaviour of other cells. 
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Figure 5.12 Wnt CM stimulus significantly increased TGFβ expression in Kupffer cells.  
(A) mRNA expression of fibrogenic and inflammatory markers were analysed by qRT-PCR in rat Kupffer cells treated 
for 24 hours with control or Wnt5a CM (n=4). (B) Western Blot analysis of Dvl2 and TGFβ protein expression in control 
or Wnt5a CM treated rat Kupffer Cells. βActin serves as a loading control. qRT-PCR results are expressed as fold 
change normalised to control ± SEM. *p<0.05 Student’s t Test (unpaired)   
   
 
(B) 
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5.5 Wnt Stimulation of Primary Cells: Proliferation and Migration 
 
 
Wnt5a stimulus therefore promotes limited effect on fibrogenic markers in HSCs.  I next questioned 
its influence on other characteristic myofibroblast traits. Wnt3a treatment of several different 
pulmonary fibroblast lines in one study for example was sufficient to induce nuclear localisation of β-
Catenin but had no downstream effect on targets of fibroblast activation. Instead increased 
proliferation of fibroblasts was observed(109). Wnt5a has also been implicated in regulation of 
proliferation in fibroblasts(148). MTT assay can be used as a crude measure of proliferation and as 
shown in  Figures 5.6C and 5.10C, neither Wnt overexpression nor Wnt conditioned medium 
treatment resulted in significant change. I next briefly assessed expression of proliferation markers 
known to be Wnt targets such as Cyclin D and cMyc (189). Neither Wnt overexpressing LX-2s nor 
Wnt CM treated rat HSCs increase protein expression of these markers when analysed by Western 
Blot (Figure 5.13A). mRNA expression of proliferation markers was not significantly altered in 
primary rat HSCs treated with Wnt CM or 20µm IWP2. However, modest changes in CyclinD are 
suggested: a slight decrease upon IWP2 treatment and slight increase upon Wnt CM treatment. 
From this, opposite effects of Wnt overexpression and inhibition can be inferred (Figure5.13B). 
 
 
 
  
 115 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5.13 Wnt stimulus or inhibition does not alter markers of proliferation in HSCs. 
 (A) Western Blot analysis of Cyclin D1 and cMyc expression in protein lysates from Wnt 
overexpressing LX-2s or primary rat HSCs stimulated with control, Wnt 5a or Wnt 10b conditioned 
medium (CM) for 24 hours (B) mRNA expression of cMyc and Cyclin D was analysed by qRT-PCR in  24 
hour control or Wnt5a CM treated primary rat aHSCs ( 7 days in culture) (n=3) (C) mRNA expression of 
cMyc and Cyclin D was analysed by qRT-PCR in primary rat aHSCs treated with 20µM IWP2 or vehicle 
control (DMSO) for 24 hours (n=2). qRT-PCR results are expressed as fold change normalised to 
control ± SEM. 
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Transdifferentiation of HSCs is associated with increased migratory potential, induced by increased 
exposure to growth factors such as PDGF, EGF and TGFβ in the injured environment(23). Wnt5a has 
been implicated in migration of fibroblasts, able to regulate the activity of Rho GTP and ROCK, key 
players in controlling convergent extension and cell contractility (115, 190, 191). Treatment of rat 
HSCs with inhibitors of ROCK is able to decrease migration and reduce activation as well as 
improving fibrosis in CCl4 models (192, 193). Based on this, I hypothesised that increased expression 
of Wnt5a may enhance migration in HSCs. To test this, LX-2 cells were stimulated through 
overexpression of Wnt5a or treatment with conditioned medium and a simple scratch wound assay 
conducted.  Wound width was measured at 6, 8 and 24hrs but no significant differences in wound 
closure were observed at any time point. (Figure 5.14). Next, cells were treated with 20µm IWP2, 
questioning whether inhibition of all Wnts rather than overexpression of a single ligand would be 
more effective, predicting a decrease in rate of wound closure in HSCs. However, again wound 
widths at 6, 8 and 24 hours were similar between control and IWP2 treated cells. (Figure 5.14) 
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Figure 5.14Wnt stimulus or inhibition has minimal effect on migration of HSCs.  
Confluent LX-2s were stimulated by Wnt5a overexpression (48hour transfection), Wnt5a Conditioned 
medium treatment (24hours) or IWP2 treatment (20µm) (24hours). Cells were injured with a single 
scratch and wound width measured over a 6 8 and 24 hour period. IWP2 treatment and Wnt5a CM 
treatment was simultaneous with injury.  
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5.6 Wnt Stimulation of Primary Cells: Apoptosis 
 
Wnt5a expression is also able to modulate apoptosis resistance, as demonstrated in lung 
fibroblasts(148) and its effect in HSCs was next explored.  Under standard culture conditions i.e. 
medium containing 10% FBS,   Wnt5a overexpression in LX-2s did not alter numbers of apoptotic 
cells, as measured by Acridine Orange assay (Figure 5.15A). I next tested whether it may play a 
protective role in cells undergoing stress. Apoptosis was induced in LX-2s overexpressing Wnt 5a 
either by incubation in serum free medium alone or serum free medium combined with hydrogen 
peroxide (H2O2) treatment. A sixteen hour serum free medium incubation appeared sufficient to 
induce a mild apoptotic response, control cells increasing apoptosis percentage from six to 
approximately twenty percent (Figure 5.15A). Wnt5a overexpression significantly decreased this 
induction of apoptosis with levels remaining at approximately nine percent.  This protective effect 
was not maintained under the greater stress of H2O2 treatment however with number of apoptotic 
cells increased in both control and Wnt5a overexpressing cells to 40-50%. 
Next it was tested whether this mild protective effect was specific to Wnt5a or occurred with 
overexpression of all Wnts.  Wnt10b overexpression however stimulated the opposite effect: serum 
free conditions inducing a significant upregulation of apoptosis, from approximately twenty to forty 
seven percent. This is the first example described here of LX-2 cells responding differentially to 
canonical versus non-canonical ligands. Specificity of this protective effect to Wnt signalling was 
confirmed using IWP2. Wnt anatagonism via IWP2 treatment abolishes Wnt5a’s protective effect: 
Wnt5a overexpressing cells under serum free conditions treated with IWP2 display a marginally 
increased apoptosis percentage when compared to control cells (Figure 5.15B 
Work in primary cells appears to further confirm these findings.  Day 7 rat HSCs pre-treated with 
Wnt5a conditioned medium showed a similar decrease in apoptotic cell percentage under serum 
free conditions when compared to control treated cells albeit to a less significant extent (Figure 
5.15C). This may be attributed to conditioned medium stimulus being more transitory than 
overexpression in LX-2s. 
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Figure 5.15 Wnt stimulus may modulate resistance to apoptosis in HSCs  
(A) LX-2 cells were transfected with either a Wnt5a, Wnt10b or empty control expression vector. 24 hours after 
transfection cells were cultured in standard 10% medium or stimulated for 16 hours with either serum withdrawal 
(Serum Free Medium) or serum withdrawal with 1mM H2O2 treatment. Percentage apoptosis was analysed by 
Acridine Orange assay (n=4)  (B) LX-2 cells were transfected with either a Wnt5a or an empty control expression 
vector. 24 hours after transfection cells were stimulated by serum withdrawal and treatment with either vehicle 
control (DMSO) or 20µm IWP2. Apoptosis percentage was analysed 16 hours after stimulus by Acridine Orange 
assay (n=3). (C) Primary rat HSCs were pretreated with either control or Wnt 5a conditioned medium for 24 hours 
before stimulus with 16 hours serum withdrawal (n=2) * p <0.05 ** p <0.01 Students t Test (unpaired).  
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How this protective effect might be regulated was next assessed. NFAT activity has been linked with 
Wnt5a in regulating apoptosis in pancreatic cancer cells(194) and Chapter 4 demonstrates high 
levels of endogenous NFAT activity in LX-2s along with abundant expression of NFAT family members 
in primary HSCs (Figure 4.11). Based on this, I investigated whether NFAT activity may be regulating 
the protective effect of Wnt5a overexpression. I co-expressed Wnt5a and the total NFAT luciferase 
reporter in LX-2 cells either in standard serum containing medium (10% FBS) or serum free 
conditions. Wnt5a expression did not alter NFAT luciferase activity under either condition (Figure 
5.16). I next expressed Wnt10b in conjunction with the NFAT luciferase reporter, hypothesising that 
Wnt10b may reduce NFAT activity, disrupting its protective effect and leading to the increase in  
apoptosis percentage observed upon serum free medium treatment. Surprisingly, expression of 
Wnt10b under standard conditions appears to increase NFAT luciferase activity by approximately 
two fold. Furthermore, serum free medium treatment significantly reduced NFAT luciferase activity 
in Wnt10b overexpressing cells (Figure 5.16). Limited NFAT response to Wnt5a stimulus therefore 
suggests against an NFAT mediated protective effect. There is little evidence in the literature for Wnt 
10b regulating NFAT activity and the response of Wnt10b overexpressing LX-2s here is surprising. 
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Figure 5.16 Protective effect of WNt5a is not mediated through NFAT.  
LX-2s were transfected with a total NFAT luciferase reporter and co-transfected with either a Wnt5a, 
Wnt10b or empty control expression vector (n=3). NFAT activity was measured under standard 
culture conditions (10% FBS) or after 16hours serum starvation (Serum Free). Renilla luciferase served 
as a control of transfection efficiency. Data presented as fold change of firefly to renilla ratio (F/R) ± 
SEM. * p <0.05  Students t Test (unpaired). 
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5.7 Discussion 
 
This Chapter aimed to pinpoint the mechanism by which increased Wnt signalling affected HSCs. 
Wnt signalling has been attributed to promote differentiation of myofibroblasts from precursor cells 
during injury in numerous organs such as skin, lung and kidney and shown able to promote aspects 
of the fibrogenic phenotype such as increased contractility, increased collagen production and 
increased migration.  Functional studies concerning how Wnt regulates HSC behaviour during liver 
injury are limited for both canonical and non-canonical branches. Inhibition of canonical Wnt 
signalling in primary aHSCs through Dkk1 treatment is shown to promote reversion to a more 
quiescent like phenotype(110) while siRNA knockdown of Wnt5a in LX-2s decreases proliferation, 
supporting the importance of non-canonical signalling(130). 
 
Here, I attempted different methods of Wnt inhibition than used previously in HSCs. From Figures 
5.2 and 5.5, IWP2 appears an effective Wnt inhibitor decreasing phosphorylation of Dvl and 
suppressing expression of Wnt target genes. IWP2 treatment of Day 7 aHSCs supports the 
hypothesis of Wnts playing a profibrogenic role. Expression of αSMA, the commonly used marker of 
myofibroblast differentiation significantly decreases by approximately 50%. This is accompanied by a 
similar decrease in Collagen 1 expression, suggesting that active Wnt signalling promotes the 
fibrogenic phenotype.  Surprisingly, treatment of HSCs during the initial stages of activation, at Days 
1 and 2 of an in vitro time course appears to have the opposite effect. This is an intriguing finding, 
suggesting that there may be Wnt signalling present early in HSC activation which may be anti- 
rather than pro-fibrogenic. 
 
Kordes et al (122) suggest a model of Wnt activity whereby canonical Wnt signalling is active in 
qHSCs and maintains the quiescent phenotype. Transdifferentiation induces a shift in Wnt 
expression profile, from canonical to non-canonical ligands. IWP2 data here corresponds with this 
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model whereby early treatment inhibits secretion of canonical, inhibitory Wnts and later treatment 
inhibits secretion of non-canonical, pro-fibrogenic Wnts. Commonly known Wnts such as Wnts 3a, 4, 
5a, 6, 7b,9b, 10b or 11 could not be detected by RT-PCR in qHSCs as demonstrated by Chapter 3.  
Furthermore, protein expression of Dvl could not be detected until Day 3, suggesting an absence of 
active Wnt signalling before this time point. In order to further verify this model, expression of lesser 
known Wnts could be investigated in quiescent HSCs and during early activation. Wnt2 for example 
has recently been suggested as important in liver function with evidence in vitro using sinusoindal 
endothelial cells and in vivo using zebrafish as a model organism(195, 196). Regarding the lack of Dvl 
protein expression, here protein expression of Dvl2 has been used as an effective marker of Dvl 
activity. Although three members of the Dvl family exist in mammals, there is no evidence 
suggesting that different Wnts have different Dvl specificities and in HSCs all three Dvl members 
exhibited similar behaviour at the mRNA level (Figure 3.1). However, investigating protein 
expression of all three Dvl members in early HSCs would be necessary in order to fully rule out 
presence of Wnt signalling. 
 
Pan Wnt inhibition in the first part of this Chapter therefore supports the hypothesis that Wnt 
signalling actively promotes the fibrogenic phenotype. β-Catenin activity alone was also targeted in 
an attempt to decipher its function in aHSCs. The ICG001 inhibitor selectively disrupts interaction 
between β-Catenin and the transcriptional co-activator CBP(181). CBP/β-Catenin activity regulates 
downstream targets associated with cell survival and proliferation whereas β-Catenin/p300, the 
other major nuclear transcriptional co-activator, regulates targets associated with cellular 
differentiation(197). β-Catenin/CBP interaction is clearly important for HSCs as there is major change 
in morphology and increased apoptosis. However, results here do not recapitulate those obtained 
using ICG001 in a bleomycin injury model of pulmonary fibrosis where reduced expression of αSMA 
and Collagen1 were observed upon inhibitor treatment(183).  From this inhibition of β-Catenin in 
HSCs cannot be suggested to promote reversion to a quiescent phenotype. Instead, β-Catenin’s role 
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may be in governing cell survival. ICG001 treatment of murine hepatoblasts supports a role for β-
Catenin/CBP activity in regulating cell survival with inhibition resulting in decreased proliferation and 
survival (198). Furthermore, this effect was shown to be Wnt independent, mediated instead by Akt 
phosphorylation of β-Catenin and not dependent on the TCF transcriptional activity shown deficient 
in Chapter 4. 
 
Pan Wnt inhibition via IWP2 clearly suggests that Wnt signalling plays a role in HSC behaviour. 
Attempts at identifying the specific role of Wnt5a in HSCs however were less successful. Although 
both LX-2s and primary HSCs responded initially to Wnt5a stimulus αSMA expression levels were 
unaffected and there was no increase in profibrogenic mediators such as TIMP1 and MMP9. There 
are several possible explanations for this lack of effect. Firstly, Wnt5a may not directly regulate 
expression of fibrogenic mediators in HSCs. Instead, Wnt5a regulates other aspects of the 
myofibroblast phenotype such as the increased resistance to apoptosis demonstrated in section 5.6 
and discussed further below 
 
Secondly, in Kupffer cells, the Wnt stimulus provided by conditioned medium appeared sufficient to 
provoke a significant response. Kupffer Cell stimulation for 24 hours with LX-2 produced Wnts 
significantly increased TGFβ and MCP1 expression, key regulators in the initial response to injury. 
Two populations of macrophages function during liver injury with Kupffer cells the resident liver 
macrophages and typically associated with healthy liver(199). They are critical in the initiation of the 
inflammatory response, activated by release of damage associated molecular patterns (DAMPs) from 
damaged hepatocytes and cholangiocytes and stimulated to produce pro-inflammatory 
mediators(200). Increased expression of TGFβ by Kupffer cells will promote the transdifferentiation 
of quiescent HSCs to profibrogenic myofibroblasts. Increased expression of MCP1 (Monocyte 
Chemoattractant Protein (MCP1) also known as CCl2) will promote recruitment of circulating 
monocytes(201). As fibrosis progresses, Kupffer cell numbers decrease, replaced by macrophages 
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derived from monocytes positive for LY6C , a typical marker of inflammatory monocytes. These are 
the major pro-fibrotic macrophages, secreting proinflammatory mediators such as Il1β and TNFα as 
well as driving activation of myofibroblasts through production of TGFβ and PDGF(202). The 
importance of MCP1/CCl2 can be demonstrated by the suppressed development of fibrosis upon its 
ablation(201). Here, effect of Wnt5a on Kupffer cells suggest a role in initiation of inflammatory 
response. Whether Wnt5a has a similar effect on the LY6Chi macrophages driving fibrogenesis next 
needs to be addressed. 
 
This supports an alternative possibility that HSCs may secrete Wnts as part of a paracrine signalling 
network . HSCs are highly secretory capable of producing a diverse repertoire of cytokines, 
functioning in proliferation, regeneration, chemotaxis and promotion of fibrogenesis(26). It has been 
reported that macrophages are a major source of canonical Wnts in the liver: macrophage produced 
Wnt3a playing a significant role in the differentiation of hepatocytes from hepatic progenitor cells 
after injury. Data here could suggest that HSCs may be a source of non-canonical Wnts. Due to 
having encountered difficulties with hepatocyte culture, effects of Wnt5a conditioned medium 
treatment could not be assessed. Canonical Wnt signalling and β-Catenin activation is known to play 
a role in liver zonation and regeneration as well as the differentiation of hepatocytes from 
precursors mentioned above. Evidence of non-canonical Wnts influence on hepatocytes is extremely 
limited therefore optimising culture conditions to further pursue this may yield novel findings. 
 
The majority of cytokines produced by HSCs are thought to function in an autocrine manner. In a 
potential model of HSCs producing Wnts to function in paracrine signalling, the increased sFRP 
expression and decreased Fzd receptor expression described in Chapter 3 may be a protective 
mechanism to prevent HSCs from responding to their own ligands. 
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This Chapter intended to assess the function of a single Wnt ligand. However, stimulation of HSCs 
with Wnt5a alone was less successful than pan Wnt inhibition via IWP2 treatment. Both Wnt5a 
overexpression and conditioned medium treatment upregulated Dvl phosphorylation, therefore 
proving successful in initiating Wnt signalling.  However, in vitro conditions here may not have been 
optimal for full function of Wnt signalling. 
 
LX-2s are considered representative of fully differentiated myofibroblasts and may therefore be ‘too 
activated’ in phenotype for Wnt stimulus to provoke further transcriptional activity. Regarding the 
lack of transcriptional response in primary HSCs, Wnts function as morphogens with cellular 
response heavily dictated by concentration. Morphogens function through establishment of 
concentration gradients, cellular response dependent on amount of stimulus received, with ‘low 
threshold’ and ‘high threshold’ target genes. Furthermore, receptor expression profiles specific to 
receiving cell will further modify response.  Stimulus of primary cells with Wnt conditioned medium 
was clearly sufficient to instigate Wnt signalling in both HSCs and KCs. However, the fibrogenic 
targets analysed may have had lower thresholds of activation in KCs compared with HSCs. One of the 
caveats of working with conditioned medium as a stimulus is that Wnt concentrations cannot be 
easily modulated. A tightly regulated dose titration with recombinant Wnt proteins would be one 
method to test this. However, complications with this may involve the issues with purity and activity 
associated with use of recombinant Wnts(203) 
Furthermore, HSCs express multiple ligands and single ligand stimulus may not be sufficient. 
Overexpression or stimulus with multiple ligands may be required before a function can be 
determined. This is yet again a similar problem as witnessed in Chapters 3 and 4, encountering a 
multiplicity of Wnt ligands and interactors. A further complication is the increased expression of 
sFRPs accompanying activation. If they are indeed a protective mechanism to prevent HSCs 
responding to their own Wnt ligands, they are likely to interfere with exogenous Wnts also.  Chapter 
3 described upregulation of four secreted interactors of Wnts: sFRP1, sFRP2, sFRP4 and Dkk3. There 
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is little evidence for interaction between Wnt5a and sFRP4 or Dkk3. Interactions between Wnt5a 
and sFRP1 and sFRP2 on the other hand are well documented but the functional outcome appears to 
be highly cell context specific. Numerous references support sFRP1 and sFRP2 as inhibitory factors. 
Evidence demonstrates sFRP2 able to reduce Wnt5a mediated Dvl2 phosphorylation and impair 
migration in breast cancer cells for example or able to bind to and antagonise Wnt5a’s promotion of 
prochondrogenic differentiation. sFRP1 has similarly been shown able to disrupt Wnt5a mediated 
PCP signalling in the developing gut(204). However, there are several examples of sFRP1 selectively 
associating with canonical ligands over non-canonical Wnt5a or sFRP2 recombinant treatment 
having no influence on Wnt5a/Fzd interaction. One study demonstrates co-upregulation of Wnt5a 
and sFRP1 and sFRP2 in migrating immortalised keratinocytes, a similar situation as observed in 
aHSCs. Here, sFRP1 and sFRP2 do not appear to interact with Wnt5a but instead impair canonical 
signalling. 
 
Functional outcome of sFRP/Wnt interaction therefore appears to be highly cell context specific. The 
use of sFRPs as Wnt inhibitors should therefore be undertaken with extreme caution: concentrations 
strictly controlled and interactions in cell type of choice clearly defined. One group advocates use of 
a ‘cocktail’ of sFRPs, combining multiple sFRPs to achieve effective Wnt inhibiton. Multiple sFRPs 
upregulation may be a method of inhibiting all putative Wnt interactions in HSCs. From the literature 
described above it appears that where physical binding of sFRP1 and sFRP2 occurs, Wnt5a activity is 
inhibited. Wnt CM treatment here lacks a thorough characterisation of how sFRPs behave upon 
stimulus. To further clarify role of these proteins in HSCs, stimulus of HSCs could be repeated and 
the resulting protein interactions of Wnts and sFRPs examined. 
 
Characteristic traits of myofibroblasts include increased migration, contractility, proliferation and 
resistance to apoptosis. Of the traits analysed, manipulation of Wnt signalling in HSCs appeared to 
influence apoptosis resistance only. Contractility was not examined. However as Wnt5a is a known 
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promoter of stress fibre formation mediated by RhoA this could be a promising target. Undertaking a 
simple F-actin staining assay using Wnt CM treated rat HSCs would allow further investigation of 
this. 
 
Wnt5a overexpression in LX-2 cells appeared to promote resistance to mild apopotic stimuli. 
Clearance of aHSCs by apoptosis is a critical during fibrosis resolution, selectively targeting αSMA 
positive cells for apoptosis significantly improves fibrosis resolution(60). During injury, HSCs are 
maintained by anti-apoptotic signals derived from injured environment or autocrine production of 
TIMP1. Upon cessation of injury and a change towards normal liver architecture, these survival 
signals are removed and HSCs undergo apoptosis(23). Data here suggests possibility that increased 
Wnt5a may act as one of those survival signals. Rather than directly enhancing fibrogenic activity, 
Wnt5a may play a role in modulating HSC apoptotic response. 
 
How exactly Wnt5a is mediating this protective effect cannot be determined from this data. From 
Figure 5.16 NFAT appears an unlikely contender as total NFAT luciferase reporter activity appeared 
unresponsive to Wnt5a treatment.  Interaction between Wnt5a and NFκB is one possibility. 
Upregulation of NFκB activity mediatied by Wnt5a has been described in several studies using 
macrophages and lymphocytes(205, 206)  with decreased expression of NFκB regulated prosurvival 
genes such as Bax and Bcl2 observed upon Wnt5a siRNA knockdown(206).  NFκB plays a critical role 
in mediating survival of HSCs(207) therefore linking these two pathways in HSCs is an intriguing 
possibility. 
 
Another attractive candidate is Wnt5a/ PKC signalling with protein kinase C (PKC) is a known 
promoter of apoptosis resistance. Upon irradiation induced apoptosis in fibroblasts, phosphorylation 
of PKC mediates a protective effect through upregulation of pro-survival signals such as CREB 
phosphorylation along with anti-apoptotic markers such as BAD phosphorylation(208). Wnt5a is a 
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well-established activator of PKC in governing cell motility and recent evidence shows Wnt/PKC 
signalling enhancing survival of murine mesenchymal stem cells upon exposure to H2O2 (209, 210). 
Further work exploring Wnt5a’s influence on apoptotic mechanisms in HSCs is now required. 
Investigating its potential effect on PKC downstream effectors and potential role in apoptosis with 
further aid establishing a mechanism of Wnt5a function and survival signals it produces 
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5.8 Conclusions 
 
This chapter aimed to identify the exact role Wnt ligands are playing in HSC 
activation and behaviour and has demonstrated: 
 
 Inhibition of Wnt signalling in aHSCs decreased fibrogenic markers 
 Wnt5a stimulus did not increase fibrogenic markers in aHSCs instead 
promoting profibrogenic and proinflammatory cytokine expression in 
Kupffer Cells 
 Wnt5a treatment of LX-2s and primary HSCs appears to confer 
resistance to mild apoptotic stimuli 
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Chapter 6: H2A.Z’s Role in Influencing 
DNA Methylation in Early Zebrafish 
Embryos  
6.1.Introduction  
H2A.Z's role in influencing DNA Methylation in early zebrafish embryos 
 
This chapter serves as an initial exploration of how changes early in development may impact injury 
response in the adult, mediated through epigenetic mechanisms. As mentioned in the introduction, 
a  recent study has explored multigenerational adaptation to liver fibrosis where ancestral injury 
conveyed a protective effect upon subsequent generations(211). A reduced fibrotic response was 
associated with differential methylation levels of key fibrotic markers: high methylation of 
profibrotic TGFβ and low methylation of antifibrotic PPARγ. How this adaptation is transmitted 
between generations is not clear. Chromatin modifications in sperm were investigated as a potential 
mechanism and ChIP analysis demonstrated enrichment of the histone variant H2A.Z at the PPARγ 
promoter in sperm of injured rats. 
6.1.1 Canonical and Variant Histones 
Chromatin is the complex of DNA and packaging proteins,  with twice the protein mass of DNA 
alone(72). Chromatin exists in two states: heterochromatin, a highly condensed form, associated 
with low transcriptional activity or euchromatin, a more open conformation, allowing access of 
transcriptional machinery to DNA(37). Histones are the protein family responsible for packaging DNA 
and consist of four core members:  H2A, H2B, H3 and H4 and the linker histone H1. Core histones 
dimerise to form an octomer around which 147bp of DNA is wrapped, this is termed a nucleosome 
and is the basic unit of chromatin (Figure 6.1A).  
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Figure 6.1 Summary of Nucleosome Structure (A) Histones are the protein family responsible for packaging DNA and 
consist of four core members:  H2A, H2B, H3 and H4 and the linker histone H1. Core histones dimerise to form an 
octomer around which 147bp of DNA is wrapped. This is termed a nucleosome and is the basic unit of chromatin (B) 
Modifications to histones result in alterations in chromatin structure and alterations in transcription. Modifications 
include methylation, acetylation and phosphorylation of histone tails or exchange of variant histone forms.  
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The N terminal tails of histones are significant sites for modifications. Classic histone modifications 
include methylation, acetylation and phosphorylation(212). These changes can result in either  
altered contacts between nucleosomes, thus altering chromatin state or promoting recruitment of 
non-histone proteins which can influence transcription of genes(212). Different histone 
modifications are therefore associated with either transcriptional promotion or repression. 
Chromatin structure can also be changed through incorporation of variant histones forms. Canonical 
histones (H2A, H2B, H3 and H4) are solely involved in DNA packaging and their deposition is tightly 
coupled with DNA replication. Variant histone expression is less strictly regulated and their 
deposition can occur independent of the cell cycle(72). Furthermore, structural differences of variant 
histones in comparison to their canonical forms enable function beyond DNA packaging(213). 
Histone H2  has the largest number of variants including H2A.Z, macroH2A, H2A-Bbd, H2AvD, and 
H2A.X (214) Some variants such as H2A.Z and H2A.X are conserved throughout evolution while 
others such as macroH2A are restricted to mammals. H2A.Z has the highest level of conservation, 
more similar across species than even the canonical H2A itself(215). H2A. Z is termed a replacement 
histone and exchanges with H2A at specific points during development and differentiation with its 
deposition driven by the Swr1 chromatin remodelling complex(216) 
Structurally, H2A.Z is relatively similar to H2A. One key divergence is the presence of an extended 
acidic patch on the nucleosome surface. Mutations of this patch lead to disruption of H2A.Z function  
in developing Xenopus embryos, demonstrating its functional importance(72). One hypothesis is this 
acidic patch changes interaction with neighbouring nucleosomes, altering chromatin 
architecture(217). 
H2A.Z is implicated in a diverse range of functions. It is shown to localize to transcriptional start sites 
and is associated with promotion of gene activation and initiation of transcription. In mammals, 
H2A.Z is predominantly associated with actively expressing genes(218) and studies in embryonic 
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stem cells suggest H2A.Z is enriched at genes associated with developmental regulation(219). The 
necessity of H2A.Z is clear from depletion studies. RNAi mediated knockdown  of H2A.Z leads to 
missegregation of chromosomes(220) and failure to differentiate while knockout in mice causes  
failed gastrulation and early embryonic lethality(215). 
Another potential role for H2A.Z recently identified is in the antagonism of DNA methylation(222, 
223). Enrichment of H2A.Z at the PPARγ promoter in the sperm of injured rats suggests it might play 
a role in transmission of hereditary information, influence methylation levels of genes in offspring. 
 
6.1.2 DNA Methylation dynamics during development 
 
Changes in methylation patterns are a key contributing factor to embryogenesis. During 
development, pluripotent cells become differentiated, requiring tightly controlled regulation of 
transcription factors(211). Epigenetic changes during development are likely to be one of these 
regulatory factors. DNA methylation has been shown to have roles in genomic imprinting, 
transposon silencing, X-inactivation and gene repression(221) 
During embryogenesis, methylation patterns are highly dynamic. Global demethylation occurs upon 
fertilisation, followed by a gradual reannotation of methylation patterns mediated by Dnmt3a(40). 
The paternal genome is rapidly and actively demethylated, whereas maternal demethylation occurs 
passively during cleavage, dependent on replication (222) This reprogramming of methylation is 
thought to aid developmental transitions. A key developmental event is the midblastula transition 
(MBT), the point at which the zygotic genome transcription becomes active. This is a period of 
significant chromatin remodelling and dynamic DNA methylation patterns are crucial at this point. 
Genes involved in regulation of processes such as metabolism and protein synthesis are 
hypomethylated whereas genes involved in later developmental processes or terminal 
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differentiation are hypermethylated(223). Disruption of methylation dynamics at this early stage 
leads to dysregulated transcription and severe consequences for development (224, 225) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2 Methylation dynamics during embryogenesis 
 
Schematic illustrating dynamic nature of methylation during embryogenesis. 
Demethylation of gametes occurs upon fertilisation with active demethylation of paternal 
genome and passive demethylation of maternal genome. There is a gradual reannotation 
of methylation patterns as development proceeds.  
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6.1.3 H2A.Z and DNA Methylation 
 
H2A.Z and DNA Methylation therefore appear to have opposing roles: H2A.Z associated with active 
transcription and DNA methylation associated with repression. Whether a functional relationship 
exists between H2A.Z and methylation was first explored in the model plant organism Arabidopsis 
thaliana(226). Whole genome mapping of DNA methylation patterns and H2A.Z location revealed an 
anti-correlative relationship with H2A.Z excluded from regions of DNA methylation. Loss of function 
mutations in Met1, the Arabidopsis DNA  methyltransferase,   dysregulated  methylation patterns 
across the genome. In these plants, distribution of H2A.Z was also altered: H2A.Z was decreased in 
regions of increased methylation while increased H2A.Z enrichment accompanied decreased 
methylation. Further experiments using loss of function mutations in PIE1, a component of the 
complex involved in deposition of H2A.Z, resulted in genome wide hypermethylation and decreased 
H2A.Z distribution. From this, the authors proposed a mechanism where methylated regions exclude 
H2A.Z, further ensuring repression of transcription. Conversely, regions of H2A.Z enrichment prevent 
methylation and further promote gene activation. 
Based on these findings we wanted to explore the possibility that H2A.Z enrichment in sperm could 
modulate gene expression in the adult through influencing methylation. The first step was to 
investigate the role of H2A.Z in governing methylation during early embryogenesis. We aimed to 
deplete H2A.Z and investigate subsequent effect on genome wide methylation levels. The rodent 
model used previously presents significant obstacles as H2A.Z is essential for embryonic 
development. As mentioned, H2A.Z knockdown is early embryonic lethal in mouse models and 
H2A.Z’s presence is essential for the differentiation of embryonic stem cells(215, 227). In order to 
circumvent this, the zebrafish was chosen as a model organism. 
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6.1.3 Zebrafish as a model organism 
 
The use of zebrafish in medical research is significantly increasing.  Homology between zebrafish and 
human is high with at least one zebrafish ortholog existing for 71% of human genes. Moreover, 82% 
of disease related genes in humans have at least one zebrafish ortholog (39).Using zebrafish as a 
model organism has a great number of benefits. Genetic manipulation in zebrafish is relatively 
simple with diverse methods such as targeted mutagenesis, transient knockdown of expression and 
conditional gene expression facilitating identification of gene function. Furthermore their small size 
and low associated husbandry costs make large scale screens attractive and affordable(228). 
Existing disease models in zebrafish include models for myopathies, muscle degeneration, 
neurodegeneration, carcinogenesis and metabolic disorders to highlight a few(40, 229, 230). 
Focusing on liver disease, the zebrafish liver is fully mature by four days post fertilisation (dpf) and 
can be used as a model of hepatic disease(233). Treatment of zebrafish with ethanol is a robust 
model of alcoholic liver disease, with treated embryos displaying metabolism of alcohol, oxidative 
stress and the development of steatosis and hepatomegaly(55, 231). 
One of the major advatanges of zebrafish as a model organism is their rapid embryogenesis, with 
major organs fully formed by 5dpf. Furthermore, zebrafish develop externally and early embryos are 
transparent, allowing for significant developmental milestones such as axis polarity specification and 
gastrulation to be observed without need for specialist equipment or invasive imaging(27). Early 
stages of development are summarised by Figure 6.4, with the embryonic period lasting until 
approximately 72 hours post fertilisation, after hatching of larvae (232) 
The first cleavage occurs approximately 40 minutes after fertilisation. Embryos pass rapidly through 
cleavage and blastula stages. Epiboly, the first major cell movement involving the thinning and 
spreading of the blastodisc over the yolk cell begins at approximately and is commonly used to stage 
early embryos(233). Embryos complete gastrulation, the formation of the primary germ layers of 
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ectoderm, mesoderm and endoderm by approximately 10 hours post fertilisation (hpf). The period 
of segmentation (10 – 24 hpf) is the period during which primary organogenesis occurs and can be 
staged by the number of developing somites, paired blocks of mesoderm along the anterior 
posterior axis, from which skeletal muscle, cartilage and bones of the spine and ribcage develop. The 
period between 24 and 48 hpf is termed the Pharyngula period. During this time there is further 
development of the nervous system with the brain differentiating into distinct lobes as well as the 
circulatory system as the heart begins to beat. Embryos normally hatch independently after 
approximately 72hpf. At this point organogenesis of most systems is complete and animals display 
tactile sensitivity and independent movement. Hatching marks the end of the embryonic period. 
During development, zebrafish undergo similar wave of demethylation and remethylation as 
observed in mammals(234). The genome is hypothemethylated until the early blastula stage, the 
wave of de novo methylation beginning approximately at the mid blastula stage and continuing until 
6hpf or the beginnings of gastrulation. 
 
 
  
Figure 6.3 Methylation Dynamics  during zebrafish embryogenesis 
As in mammals, DNA methylation levels during zebrafish embryogenesis are also highly dynamic. 
Demethylation occurs upon fertilisation, de novo methylation begins approximately at the mid blastula 
stage (3hpf) and continues until 6hpf (the beginnings of gastrulation) 
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[figure 6.2 EMBRYO DEVELOPMENT OF ZEBRAFISH) 
  
Figure 6.4 Summary of early zebrafish development  
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The ortholog of H2A.Z in zebrafish is H2afv. One previous study mutated H2afv during a mutation 
screen, with mutants characterised by significant curvature of the trunk and defects in pharyngeal 
arch development. Total mortality was observed by 13 days after fertilisation(235). Although this 
mutant is an efficient method of H2afv depletion it would not be suitable for the purposes here.  As 
we intended to observe the effects of H2A.Z depletion early in embryonic development, H2afv 
depletion through morpholino knockdown was decided upon. 
Morpholino oligonucleotides (MOs) are the most common form of anti-sense knockdown deployed 
in zebrafish(236).  Morpholinos are approximately 25 base oligomers which recognise and pair with 
target RNA. Two types of morpholino exist: splice blocking which disrupt pre-mRNA processing 
through inhibition of spliceosome components or translation blocking which prevent ribosome 
function(237). Titration of morpholino dose should enable partial knockdown of H2afv protein 
expression, preventing lethality of null phenotypes observed in mice and drosophila yet allowing 
investigation of this histone variants role on embryonic development and methylation status. 
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6.3  Initial morpholino titration  
 
The first step was to identify an effective dose of morpholino (MO), the ideal dose being one to 
provide a characteristic phenotype yet not so severe to impede correct development. I initially 
injected a titration of three doses: 6.7, 3.3 and 0.67ng and followed survival and development over 
the first five days after fertilisation (Figure 6.5A). Representative images at 4dpf of each dose 
compared with standard control injected fish are illustrated in Figure 6.5B. Morpholino knockdown 
was effective at all 3 doses, clearly demonstrated by Western Blot (Figure 6.5C).  All three 
concentrations cause distinct phenotypic differences with severity increasing with increased dose. 
6.7ng of morpholino causes substantial deformities with only a 40% survival rate and was therefore 
considered too strong. 3.3 and 0.67ng result in similar survival rate of 75-85%. 
I went on to further characterise phenotypic abnormalities. Again fish were injected with either 0.67 
or 3.3ng of h2afv MO or a standard control MO. Morphant morphology was assessed at two and 
four days post fertilisation and morphants were categorised as normal, mild or severe in phenotype. 
Representative images of each category are shown in Figure 6.6A along with phenotype percentage 
scores (Figure 6.6B). Each dose was injected into a minimum of three clutches. Although injection 
with 3.3ng of morpholino results in a similar survival rate to that of 0.67ng, severe phenotype 
percentage is increased. This results in a large number of highly deformed fish, making the study and 
characterisation of phenotype much more difficult. 0.67ng was selected as a suitable dose and used 
for all subsequent experiments. 
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Figure 6. 5 Morpholino injection successfully suppresses H2afv expression. 
(A) Kaplan-Meir curve demonstrating survival of h2afv morphants across the first 4 days of development compared to Std 
control MO injected fish. Three different doses of h2afv MO is used (0.67, 3.3 or 6.7ng ). (B) Bright field images of fish 
injected with 0.67, 3.3 or 6.7ng h2afv MO compared to controls (C) Western Blot analysis of H2afv protein levels in lysates 
isolated from fish injected  0.67, 3.3 or 6.7ng h2afv MO compared to controls 
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6.4 Morphant phenotype 
Morphants in Figure 6.6 can be characterised by distinct phenotypic abnormalities in comparison to 
standard control injected fish. Morphants present with ventral curvature of trunk, abnormalities in 
pigment, smaller eyes and a reduction in head length. Severe morphants are more exaggerated in 
these traits. Figure 6.7 further highlights their smaller size in comparison to control fish as well as 
the presence of down curved heads (a), under utilisation of yolk (b) and abnormal tail yolk 
extension(c). At later time points (4 to 5dpf) morphants show poor swim bladder development as 
well as moderate deformities in organ development. LiPan transgenic fish express dsRed and GFP 
under liver specifc (fabp10) and pancreas specific (ela3l) markers respectively. Injecting into this line 
therefore allows visualisation of liver (Figure 6.8A) and pancreas development (Figure 6.8B). Both 
morphant livers and pancreases appear reduced in size and misshapen in comparison to control fish. 
Another distinct characteristic displayed by morphants is reduced swimming ability and abnormal 
response to tactile stimulus. Touch response was quantified by a simple motility assay demonstrated 
by Figure 6.9A. 2dpf fish were used as it is the first timepoint at which they are sensitive to touich 
stimulus. Fish were placed into the centre of a dish with concentric rings labelled Zone 1, Zone 2 and 
Zone 3. They were lightly touched once on the head and scored based on the zone they swam into.  
Only h2afv morphants catagorised as mild in phenotype were assessed as extreme ventral curvature 
of severe morphants prevented sufficient movement for measurement. h2afv morphants responded 
poorly in comparison to controls, with 40% unable to move beyond Zone 1 (Figure 6.9B). 
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Figure 6. 6 Morphants display distinct phenotypic abnormality when scored at 2 and 4dpf. 
(A) Bright field images comparing Std control and h2afv MO injected fish at 2 and 4dpf. h2afv morphants 
classified as mild or severely affected. (B) Percentage phenotypes of Std control and 3.3 or 0.67ng h2afv MO  
injected fish 
 
 145 
 
 
  
Figure 6. 8 Organ defects present at later developmental stages. 
5dpf morphants fail to develop swim bladders (black arrows). Reduced size and irregular shape of morphant livers (A) 
and pancreases (B) can be visualised using fish transgenic for liver specifc (fabp10) and pancreas specific (ela3l) 
markers.   
Figure 6. 7 Further phenotypic characterisation of h2afv morphants at 3dpf  
h2afv morphants are noticeably decreased in size in comparison to Std Control fish. In addition, they present 
with down curved heads (a), under utilisation of yolk (b) and abnormal tail yolk extension(c)  
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1 2 3 
Figure 6. 9 Morphants respond abnormally to touch  
(A) Diagram illustrating set-up of touch response assay. Fish were placed into the centre of a dish with concentric 
rings labelled Zone 1, Zone 2 and Zone 3 and their destination recorded upon stimulus (B) Percentages of h2afv 
morphants or control fish reaching each zone.   
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One caveat of working with morpholinos is the risk of non specific effects. Activation of the tumour 
suppressor p53 is one of the most common observed off target effects, leading to excessive 
apoptosis(238) To investigate the potential of off target cell death, apoptosis was investigated by 
acridine orange staining . At 24hpf, no significant differences between morphant and controls can be 
observed (Figure 6.10). To further control for off target p53 activation, I coinjected h2afv and  p53 
targeting MOs in two separate clutches of fish and scored for phenotype at 2dpf. Co-knockdown of 
p53 and H2afv produced similar levels of phenotypic abnormality when compared to H2afv 
knockdown alone, with morphants still presenting with misshapen heads, curvature and reduced 
size. (Figure 6.11 A and B) 
To further establish specificity of knockdown, rescue of phenotype was attempted by injection of 
h2afv mRNA.  Fish were co-injected with when mCherry tagged h2afv mRNA and h2afv MO and 
morphants scored at 2dpf.Visually mRNA and MO co-injected fish appear similar to controls (Figure 
6.12A). When scored across four separate clutches, phenotypic abnormality was reduced in co-
injected fish from approximately 60% affected to 40% affected. (Figure 6.12B).  Furthermore, 
Western blot confirmed that the exogenous H2afv-mCherry was well expressed but this did not 
restore expression of the endogenous H2afv. Phenotype was apparent in approximately 30% of 
mRNA only injected fish. However, developmental defects associated with h2afv mRNA injection 
have previously been reported in Xenopus(239).  
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Figure 6.10 h2afv MO injection does not cause excessive apoptosis at 24hpf  
24hpf Std Control and h2afv MO injected embryos were stained with Acridine Orange and 
visualised under fluorescence. No significant difference in number of apoptotic cells can be 
observed.   
Figure 6.11 Co-knockdown of H2afv and P53  does not reduce phenotypic abnormality at 2dpf  
Embryos were injected with Std control, h2afv MO or h2afv MO and p53 MO and scored at 2dpf. Bright 
field images demonstrate phenotypic abnormalities in h2afv MO and h2afv + p53 MO injected fish.  
Similar % of phenotypic abnormality observed in both h2afv MO injected and co-injected groups.   
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Figure 6.12 Injection of h2afv mRNA rescues phenotypic abnormality at 2dpf  
Fish were injected with h2afv mRNA either singly or coinjected with h2afv MO and scored at 2dpf. (A) 
Bright field images demonstrated phenotypic rescue of coinjected fish. (B) Phenotype percentage scores 
at 2dpf (C) Western Blot analysis of H2afv protein levels at 2dpf in Control, h2afv mRNA, h2afv MO and co 
injected groups    
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6.5 H2afv at Early Developmental Stages 
 
These data clearly demonstrate the importance of H2afv for early development in zebrafish as even 
injection of such a low dose of morpholino causes multi-system defects. I next aimed to determine 
when phenotypic differences were first noticeable. Std Control and h2afv MO injected fish were 
observed over the first 24 hours of development and scored at Shield, Bud, 15-17 Somite and Prim 5 
developmental stages, with a minimum of three clutches observed at each stage (Figure 6.13). No 
significant differences in phenotype or mortality are observable at Shield or Bud stage. By mid-
somatogenesis (15 – 17 somite stage) morphants can be categorised as mild or severely affected, 
again appearing reduced in size and with abnormalities in head development. By Prim5 a significant 
difference in mortality is apparent. Further deficiencies in head development are noticeable, with an 
apparent delay in formation of the midbrain-hindbrain boundary . Again traits are exaggerated in 
severely affected morphants, with significant disruption of head development. These data 
demonstrate that defects arising from h2afv deficiency can be observed at an early developmental 
time point. 
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Figure 6. 13 Developmental abnormality first observed at the 15 – 17 somite stage  
 (A) Bright field images comparing Std control and h2afv MO injected fish at Bud, 15-17 somite 
and Prim5 stages. h2afv morphants classified as mild or severly affected. (B) Percentage 
phenotypes of Std control and h2afv MO injected fish at Bud, 15-17 somite and Prim5 stages 
 
(A) 
(B) 
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Further exploration of transcriptional disruption due to H2afv deficiency was next required.  As 
H2A.Z depletion has previously been associated with gastrulation defects in mice and Xenopus(73, 
216), I first asked whether a deficiency in a specific germ layer could be detected. For example, later 
morphants display moderate defects in endoderm derived organs such as pancreas and liver 
therefore disruption of early endodermal markers could precede this. RNA was isolated from whole 
embryos at the 15-17 somite stage,  post-gastrulation and at the developmental stage where 
phenotype differences are first apparent. 
qRT-PCR analysis markers specific for endo-,exo- and mesoderm was conducted in  a minimum of 
three clutches (Figure 6.14). Expression changes were modest and no pattern specific germ layer 
disruption is apparent. Small but significant differences occur for several markers: sox9a, pitx3, snail, 
sox17, ntla. sox9a, pitx3 and snail are noteworthy as their expression is significantly associated with 
neural regions while ntla is one marker particularly sensitive to methylation. 
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Figure 6. 14Limited disruption of endoderm, mesoderm and ectoderm specific markers.  
mRNA levels of endoderm, mesoderm and ectoderm specific markers were analysed at the 
15-17 somite stage by qRT-PCR in Std Control and h2afv MO injected fish (n=4). qRT-PCR 
results are expressed as fold change normalised to control ± SEM. *p<0.05 Student’s t Test 
(unpaired)   
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6.5 Characterisation of nervous system defects 
 
It was next hypothesised that h2afv morphants may  present with nervous system defects. 
Morphologically, morphants display visibly misshapen heads, smaller eyes and poor motility along 
with moderate differential expression of neurally expressed genes at 15-17 somite stage. H2afv 
expression is predominantly localised to the CNS when mCherry tagged h2afv mRNA is 
overexpressed by injection at the 1 – 4 cell stage (Figure 6.15). Enrichment of H2A.Z at promoters of 
genes regulating neural development has been reported in human ESCs and interestingly, analysis of 
the zebrafish sperm genome identified enrichment of H2afv at genes associated with hindbrain 
formation (225, 227). Based on this, I hypothesised that genes involved in neural development and 
differentiation may be particularly susceptible to H2afv depletion. To explore this possibility of 
neural development defects, H2afv expression was first knocked down in the ngn1GFP transgenic 
line. 
 
Ngn1 is a transcription factor which acts as a proneural marker.  Expression of ngn1 begins at 
gastrulation and remains until adulthood. It initially marks broad regions of cells with potential to 
adopt neuronal fate while later expression marks sensory and dorsal root ganglia(240). Ngn1:GFP 
transgenics were injected with Std Control or h2afv MO and GFP expression pattern observed across 
a time course of development.  No differences in patterning in brain or somites were obvious at 19-
21 somite stage or later at 1dpf (Figure 6.16A and B). This suggests that no differences in proneural 
differentiation driven by ngn1 occur. However at later time points of 2 and 3dpf, ectopic dorsal root 
ganglia neurons can be observed in the trunks of morphants (Figure 6.14C). 
 
At later time points, ngn1 serves as a maker of sensory neurons, not motor neurons(241). Due to 
poor motility and movement of morphants, I hypothesised that a defect in motor neuron 
development could be occurring. To investigate this, I used a different transgenic line where GFP 
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expression is driven by isl1. Isl1 is a LIM/Homeobox gene family member and expressed by primary 
motor neurons early in development(242).  Again, early expression of isl1 was not disrupted in h2afv 
morphants in comprarison to controls. By 36hpf however, there were significant differences in 
patterning of expression, particularly in faciobranchial motor neurons (Figure 6.17). This may suggest 
disruption of motor neuron development arising from H2afv deficiency. 
  
 156 
 
 
  
 
Figure 6. 15H2afv is localised to the CNS  
Fluorescent microscopy visualisation at 24hpf of mCherry tagged h2afv mRNA. Robust expression can be 
observed in the CNS. No fluorescent signal is observed in control injected fish.   
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Figure 6. 16 ngn1 expression in morphants at 19-21 somites, 1 dpf and 3dpf.  
ngn1GFP transgenics were injected with h2afv MO or standard control. (A) and (B) Fluorescent and Bright field images 
of fish at 19-21 somites or 1 dpf show no detectable differences in patterning (C) By 3dpf, ectopic expression of trunk 
ngn1 positive neurons can be visualised to approximately 70% of morphants (white arrows) 
(A) 
(B) 
(C) 
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Figure 6. 17 Disrupted isl1 expression visible in morphants. 
Std Control and h2afv MO injected isl1:GFP transgenics were visualised at 36hpf. Disrupted 
isl1 patterning can be observed in h2afv MOs (white arrows).  
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6.6 Assessment of methylation in early h2afv morphants 
I have so far been able to demonstrate effective knockdown of h2afv resulting in characteristic 
phenotypes, detectable from an early developmental stage. Having established the importance of 
h2afv for correct development, I next wanted to investigate its potential effects on methylation. As 
mentioned previously, h2afv is thought to be anti-correlative to methylation, shown using the model 
plant organism Arabidopsis(226). From this I predicted increased levels of DNA methylation would 
be detectable in H2afv deficient fish in comparison to controls. 
I investigated global levels of DNA methylation by quantifying  levels of methylated cytosine (5 MeC) 
Genomic DNA was isolated from whole embryos at early developmental stages (Shield, Bud, 15-17 
Somite and Prim5) and immunoblotted using a 5MeC specific antibody. Separate samples blotted in 
parallel were stained with 0.2% Methylene blue in 0.3M NaOAc to detect total DNA. 5MeC levels 
were determined by normalising to total DNA. A minimum of three clutches was used for each 
developmental stage. Morphants appear consistently hypermethylated across early development, 
difference reaching statistical significance at 15- 17 somite stage (Figures 6.18A, B and C). This 
correlates with hypothesis and confirms differences observed previously in plant models. 
Hypermethylation can only be observed during these early developmental time points. No 
differeneces in 5MeC  levels are apparent at later stages such as 1dpf and 4dpf (Figure 6.18D and E). 
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Figure 6.18 h2afv morphants are hypermethylated at early stages of development.  
(A) Genomic DNA was isolated from whole embryos at the Shield, Bud, 15-17 Somite and Prim 6 
developmental stages and levels of 5MeC analysed by immunoblot. Morphants are consistently 
hypermethylated at early developmental timepoints, reaching statistical significance at the 15-17 somite 
stage (B) and (C) Representative immunoblots. At later time points of 24hpf (D) and  4 dpf (E) no increased 
methylation could be detected. * p <0.05 Students t Test (paired).  
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I next asked how this hypermethylation may be mediated. In Zilberman et al, MET1 the Arabadopsis 
homolog of dnmt1 was shown able to regulate DNA methylation patterns and subsequently alter 
H2A.Z distribution(226). Here, behaviour of the zebrafish holomog dnmt1 was investigated upon 
H2afv knockdown. Protein expression of Dnmt1 was unchanged upon H2afv knockdown at 1dpf 
(Figure 6.19A). Next it was questioned whether knockdown of Dnmt1 could reduce 
hypermethylation in morphants and therefore reduce the phenotype. Co-injection of h2afv and 
dnmt1 MOs successfully knocked down dnmt1 protein levels (Figure 6.19B) and reduced 5 MeC 
levels in three clutches of morphants (Figure 6.19C and D). However, there was no improvement in 
phenotype of co-injected morphants over the first 4 days of development. Instead, phenotypes of 
co-knockdown appeared additive, resulting in a higher percentage of severely affected animals 
(Figure 6.19E).  This suggests that hypermethylation and morphant phenotype is not driven by over 
activity of dnmt1. 
Finally, a brief analysis of histone methylation was undertaken. Methylation of histone 3 at common 
sites such as Lysine 9 (H3k9me3) and Lysine 27  (H3k27me3), associated with transcriptional 
silencing was investigated by western blot. Again no differences were observable. This suggests 
disruption of DNA methylation only occurs upon H2afv knockdown (Figure 6.20). 
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Figure 6. 19Dnmt1 does not appear to mediate hypermethylation  
(A) Dnmt1 protein expression analysed in lysates from h2afv MO and Std control injected fish. (B) Dnmt1 
protein expression reduced in protein lysates from fish injected with dnmt1 MO and coinjected with h2afv  
and dnmt1 MO . (C) and (D) Analysis of 5MeC levels in genomic DNA from Std control or dnmt1 and h2afv 
MO injected fish. (E) Phenotypes of  single MO or coinjected fish were scored until 96hpf. Coinjection did 
not reduce phenotype of h2afv morphants 
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Figure 6.20 h2afv MO does not alter expression of histone marks at 24hpf 
Western blot analysis of H2afv, H3K27me3, H3K9me3 and γH2AX protein expression in lysates 
from 24hpf control and h2afv morphant fish. αTubulin serves as a loading control.  
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6.7 Discussion 
H2A.Z has previously been suggested as a factor involved in passage of non-mendelian hereditary 
information between generations: its incorporation in particular loci in sperm leading to decreased 
methylation of promoters in offspring(48). This chapter aimed to explore whether H2A.Z may be 
able to influence early methylation patterns using the embryonic zebrafish as a model organism. The 
anti-correlative relationship between H2A.Z and DNA methylation has been previously explored in 
the model plant organism Arabidopsis(226)  and in vitro culture studies(243) however data from in 
vivo animal models remain lacking. Data from this chapter has served as a first step in establishing 
this. 
Here I have been able to effectively knockdown the zebrafish homolog of H2A.Z (H2afv)  during the 
first five days of embryonic development. Similar to previous reports, this chapter demonstrates the 
importance of H2A.Z for embryonic development with morpholino injected animals displaying 
significant mortality and physiological defects. The hypothesis of H2afv influencing DNA methylation 
is supported by simple analysis of global methylation levels. Immunoblotting for total levels of 
methylated cytosine in whole embryos suggests increased levels of DNA methylation during the 
early stages of development. DNA methylation levels are highly dynamic during early 
development(222). Genome wide demethylation occurs upon fertilisation, with gradual 
remethylation occurring  as development precedes. In zebrafish, reannotation of the genome begins 
at approximately 4hpf(244). Here we demonstrate hypermethylation of morphants throughout this 
reannotation period and beyond until 24hpf. 
Future work comparing methylomes of control and morphant samples through next generation 
sequencing will enable further insight into patterning of methylation differences. Another step will 
be to determine how this hypermethylation is mediated. The effects of H2afv depletion on Dnmt1, 
the maintenance methyltransferase, were investigated here. No differences in Dnmt1 expression 
could be observed upon H2afv depletion and no rescue of phenotype was observed upon co-
knockdown. This may suggest that hypermethylation is not mediated by Dnmt1. As a maintenance 
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methyltransferase,  Dnmt1 is  limited to copying patterns of hemimethylated DNA. A next step 
would therefore be to look at the de novo methyltransferases functional during the period of 
reannotation(222). Multiple homologs exist in zebrafish, with dnmt3 most closely resembling 
mammalian dnmt3b(245). 
Morphological defects observed such as malformed heads, smaller eyes, delayed brain development 
and poor motility particularly suggest defects in nervous system development. This is further 
suggested by preliminary work using fish lines transgenic for markers of motor (isl1) and sensory 
neurons (ngn1). The developing nervous system is acutely sensitive to changes in DNA 
methylation(246). Neurons undergo highly specified cycles of specification, differentiation and 
maturation, dependent on specific methylation profiles. Developmental disorders such as fetal 
alcohol syndrome have been strongly associated with disruption of DNA methylation in the CNS(247) 
and altered methylation patterns have been linked with neurodegenerative disorders such as 
Alzheimer’s disease(248, 249). Furthermore, other models inducing hypermethylation at early 
developmental stages have reported nervous system abnormalities (250, 251).  This coupled with 
the localisation of H2afv expression to the nervous system makes the possibility of nervous system 
defects highly likely. The observations using ngn1GFP transgenic fish suggest there is no abnormality 
in neural specification as patterning is similar between morphants and controls at the early stages of 
19 – 21 somites and 1 dpf. Early observations using isl1GFP transgenics also show no difference 
between morphants and controls. It is only at later time points: 36hpf for isl1:GFPs and 2 and 3dpf 
for ngn1:GFP that differences are observable. This suggests that there may be a defect in the 
maturation or activity of post-mitotic neurons rather than neuron specification. A critical next step 
will be to identify the effect of H2afv depletion on the signalling pathways critical in regulating this 
time point. 
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6.8 Conclusions 
 
 H2afv is necessary for correct development for zebrafish  
 H2afv depletion leads to hypermethylation during early developmental 
stages, consistent with previous results in plant and in vitro models 
 Phenotypic defects upon H2afv depletion suggest a role in CNS 
development and differentiation.  
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Chapter 7: Final Discussion  
The process of wound repair after injury is reminiscent of developmental events such as cell 
migration, redifferentiation and proliferation(9). Events modulating this in the early embryo may 
therefore be important regulators in adult tissue repair. This thesis combined two projects exploring 
different aspects of this. Firstly, how reactivation of developmental signalling pathways might be 
contributing to regulation of myofibroblast transdifferentiation and behaviour in liver fibrosis. 
Secondly, how altering early DNA methylation pattern through inheritance of epigenetic marks 
might affect response to injury in adult, using zebrafish as a model organism for study.  
7.1 Wnt Signalling in HSCs 
 
Chapters 3 through 5 focused on reactivation of the Wnt morphogen family in hepatic 
myofibroblasts and its potential effect on fibrosis progression.  Wnt signalling had previously been 
suggested as a promoter of HSC transdifferentiation. However, information regarding the exact 
ligands involved and the mechanisms they regulate was unclear. This suggested that further in depth 
characterisation of how Wnts influence HSC biology was required 
 
Chapter 3 succeeded in identifying activation of Wnt activity accompanying transdifferentiation of 
quiescent HSCs to fibrogenic myofibroblasts. I demonstrated upregulation of predominantly non-
canonical ligands in aHSCs, suggesting that non-canonical signalling is the active branch. Chapter 4 
demonstrated a lack of β-Catenin/TCF mediated response to Wnt stimulus. Instead,  HSCs responded 
to stimulus through non-canonical effectors, further implying activity of non-canonical signalling. 
Inhibition of Wnt signalling in Chapter 5 through pan-Wnt inhibition successfully decreased markers 
of activated fibroblasts. These results suggest active Wnt signalling present in HSCs and playing a 
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profibrogenic role. Single ligand stimulus of HSCs with non-canonical Wnt5a appeared to govern 
survival response of mildly stressed aHSCs as well as paracrine stimulus of Kupffer cells (KCs).     
7.1.1 Wnt Environment in HSCs 
Several issues raised by this study need to be addressed. Firstly, single ligand stimulus with Wnt5a 
did not appear to affect HSCs as potently as KCs, with limited changes in gene and protein 
expression of fibrogenic markers. This lack of response could be due to several limitations. Issues 
with strength of stimulus and ligand multiplicity are already discussed in Section 5.7. Another 
consideration is that the microenvironment in a monoculture of HSCs is not truly representative of 
an in vivo, injured environment. Single Wnt ligand stimulus in a monoculture of HSCs may have been 
too simplistic a system, missing a critical component for effective stimulus. Exogenous TGFβ 
treatment for example was shown necessary to promote β-Catenin/Smad activity in several studies. 
Co-culture of in vitro activated HSCs with Kupffer cells or exposure to LPS is able to shift gene 
expression pattern of cultured cells to one more representative of those activated in vivo (252). 
From this, it could be hypothesised that more complex cellular interactions may have been 
necessary for optimal Wnt signalling. Future work to explore this could involve Wnt treatment of 
multicellular systems such as that of precision cut liver slices, allowing study of an environment more 
representative of that in vivo. Study of Wnt in co-culture environments,  HSCs with KCs or HSCs with 
hepatocytes may have been more informative.  
Leading on from this, another limitation of this study is that the influences of other morphogen 
pathways have not been considered. During development, morphogens co-operate as part of a 
signalling network with strict spatial and temporal regulation of expression(10). Activity in adult 
tissue is subject to the same regulations and altering activity of one pathway is likely to have 
significant effects on other pathways, for example the Hh/Notch cross talk shown previously 
important in HSCs(66). 
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Morphogen pathways should therefore not be regarded in isolation and the idea of a wider network 
kept in mind when considering cellular response.  Hh activity in HSCs is one morphogen pathway 
already well described. Interaction with and promotion of Wnt signalling by Hh is one possibility and 
has been reported in cancer models(253). However, Hh is better described as an anatagonist of Wnt, 
with opposing effects on cellular differentiation in numerous instances during embryonic 
development and adult tissue homeostasis(254, 255). In vitro, Hh has also been implicated in Wnt 
activity suppression through upregulation of sFRP1(256, 257). Notch1 is also able to mediate 
canonical Wnt signalling through direct post-translation modification, binding the active form of β-
Catenin and targeting it for degradation(178). Canonical Wnt/ Notch antagonism also regulates fate 
specification of hepatic progenitor cells: high levels of β-Catenin activity promoting hepatocyte fate 
while high Notch activity specifies cholangiocyte fate(258). 
These data suggest that the aHSC may be a hostile environment for Wnt to function with decreased 
Fzd receptors expression, increased sFRP expression and elevated levels of other potentially 
antagonistic morphogen pathways (Figure 4.15). Single ligand stimulus of Wnt in overexpression/ 
conditioned medium experiments may therefore not have been sufficient to overcome this 
inhibition.  
7.1.2 β-Catenin and HSCs 
The second issue requiring consideration is β-Catenin’s role in HSCs. The limited effect of β-Catenin 
overexpression here is at odds with the pro-fibrogenic canonical Wnt emphasis in current 
literature(104). However, several of these studies infer functional canonical TCF mediated signalling 
from upregulated β-Catenin expression and nuclear localisation. Here, I have also observed 
significant upregulation of β-Catenin protein expression in aHSCs, both total and active non-
phosphorylated form. HSC β-Catenin responds initially to Wnt stimulus, correctly localising to the 
nucleus. It is TCF dependent downstream transcriptional activity here that appears to be lacking. 
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As summarised in the introduction, β-Catenin activity is well established in models of fibrosis in the 
lung, kidney and skin. Particularly in models of lung and kidney fibrosis, β-Catenin is considered pro-
fibrogenic through promotion of epithelial to mesenchymal transition (EMT)(106, 177).  EMT is the 
process by which epithelial cells transition towards a mesenchymal phenotype and involves loss of 
epithelial markers such as E-cadherin and a gain of mesenchymal markers such as vimentin(259). 
This β-Catenin/ EMT association may offer explanation for the numerous reports in other models of 
β-Catenin’s profibrogenic activity, but the lack of effect observed here. 
EMT is alleged to be one source of myofibroblasts during fibrosis, particularly EMT driven by TGFβ 
/Smad signaling(259). Active β-Catenin mediating TGFβ/Smad induced EMT is implicated in 
numerous reports of idiopathic pulmonary fibrosis and renal fibrosis.  In the case of liver fibrosis, 
HSCs are suggested to be mesenchymal in origin, therefore transdifferentiation to active 
myofibroblasts will not require EMT. In vitro evidence has suggested that cultured hepatocytes 
exposed to TGFβ are able to transdifferentiate into myofibroblast like, collagen producing cells(260). 
Taura et al (261)have since demonstrated in vivo that hepatocytes and their derived cells do not 
express α-SMA or other mesenchymal markers and are unable to produce collagen, suggesting that 
EMT in the case of liver fibrosis is an artefact of culture. β-Catenin in HSCs therefore is unlikely to be 
pro-fibrogenic through this mechanism. 
Despite a lack of pro-fibrogenic stimulus, the presence of β-Catenin is clearly important for HSCs. 
siRNA knockdown in previous studies significantly decreases proliferation for example and I have 
demonstrated here that inhibition of β-Catenin/CBP activity impairs survival of HSCs. Similar to 
Wnt5a above, it is possible that β-Catenin signalling may not directly mediate fibrogenesis in HSCs 
but regulate alternative pathways such as cell survival. As TCF/LEF1 activity in HSCs has been shown 
defective this is likely to be mediated through TCF independent activity. Although β-Catenin /TCF 
signalling is the default model for Wnt function, β-Catenin is still able to operate independent of Wnt 
stimulus and downstream TCF function. Rather than trying to force TCF dependent signalling in an 
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unsuitable environment, it may be more beneficial to focus future work on the possibilities of TCF 
independent signalling in HSCs.  
Firstly, this study was limited in analysis of β-Catenin protein expression, focusing solely on its total 
form or that of its active form, dephosphorylated at the Ser37 or Thr41 position. However, β-Catenin 
can be phosphorylated at several positions. Phosphorylation at Y654 suggests TGFβ induced activity 
(174, 262) with pY654-β-Catenin not promoting TCF dependent transcriptional activity(262). 
Phosphorylation at the Ser552 position suggests activity stimulated by Akt phosphorylation and 
promotion of cell survival, corresponding with the data obtained with β-Catenin /CBP inhibitor (198, 
263). Determining phosphorylation patterns of β-Catenin in aHSCs may give clues as to its function. 
TGFβ/Smad signalling is one possible route of Wnt independent β-Catenin function, with detailed 
examples given in the discussion section of Chapter 4. TGFβ is a critical regulator of myofibroblast 
behaviour(49). Future work exploring the interaction of β-Catenin and TGFβ in aHSCs could identify 
another means for TGFβ mediated regulation of HSC behaviour. A first step would to be establish 
how HSC β-Catenin behaves under TGFβ stimulus, whether overexpression is more effective under 
these conditions. Multiple studies demonstrate binding of β-Catenin/ Smad transcription factors to 
initiate transcription(175, 176, 182).  Immunoprecipitation assays to identify a β-Catenin/Smad 
transcriptional activating complex rather than a β-catenin/TCF complex would be solid evidence 
implying TCF independent activity of β-Catenin. Compared with the wealth of knowledge regarding 
β-Catenin /TCF activity, this area of β-Catenin function is relatively unexplored. Positive evidence of 
β-catenin regulating HSC behaviour through TCF independent mechanisms would therefore be an 
exciting finding.  
Section 4.6 investigated several key β-Catenin nuclear interactors however was severely limited in 
scope. A more thorough investigation of transcription factors present in the aHSC nucleus and able 
to interact with β-catenin is required. One candidate family worth exploring is the FOXO family of 
transcription factors. FOXO transcription factors  competitively bind β-Catenin, FOXO3 and FOXO4 in 
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particular(264). They have a higher β-Catenin binding affinity in comparison to TCF/LEFs and prevent 
β-Catenin/TCF complex formation. Foxo1 is one transcription factor upregulated upon HSC 
transdifferention and Foxo3 is shown to be involved in alcohol induced autophagy and 
hepatotoxicity (although the study focused only on hepatocytes)(265, 266). One possibility could 
therefore be an upregulation of Foxo transcription factors upon HSC transdifferentiation which 
compete with TCFs for β-Catenin binding. Further exploring this transcription family would enable 
study of another route of TCF independent signalling in HSCs.   
7.1.3 Wnt as a therapeutic target?  
Increasing understanding of how HSC behaviour is regulated is hoped to identify points of 
therapeutic intervention. The final part of this discussion explores whether the Wnt pathway in HSCs 
yields attractive targets for potential inhibition. 
Fibroproliferative disorders are a significant modern health issue yet anti-fibrotic therapy is currently 
not widely available. In the case of hepatic fibrosis and cirrhosis liver transplant is the only effective 
treatment(20). Early stages of liver fibrosis are asymptomatic with clinical complications arising from 
development of advanced fibrosis and cirrhosis, when reversion of fibrosis not possible. There is 
therefore a crucial need for pharmacological agents able to halt progression and promote fibrosis 
reversal. The activated myofibroblast, major source of excessive ECM production upon injury is an 
ideal target for this. Preclinical research has explored numerous potential targets with early phase 
clinical studies beginning. However, research is in early phases and much work needs to be done(8). 
Regarding liver fibrosis, it is essential to fully understand the signalling events which either promote 
the transdifferentiation of HSCs from quiescent pericytes to profibrogenic myofibroblasts or 
maintain this activated phenotype. This will facilitate identification of possible intervention points,  
such as preventing activation of HSCs and secretion of ECM , enhancing degradation of deposited 
matrix or promoting apoptosis and clearance of aHSCs. 
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Wnt signalling was first discovered over 30 years ago with the mapping of the canonical/ β-Catenin 
pathway and its role in promoting numerous disorders, most significantly cancer, is well 
described(12). Despite this, no therapeutic anti-Wnt targeting compounds to date are available. 
Several are currently in development but these remain in early preclinical stages(267). Disrupting 
Wnt signalling for therapeutic gain endangers its role in tissue homeostasis and areas with a high 
rate of self renewal such as the intestinal epithelium will be at risk of toxicity(268).  Overactive Wnt 
signalling is indeed reported in numerous models of fibrosis. Despite this, Wnt signalling has an 
undeniable role in cell regeneration and its blockade may have severe consequences for the repair 
process after injury(68). 
Inhibitors targeting specific Wnts are not available. Pharmacological inhibitors can be broadly 
grouped into those which prevent ligand secretion or binding, those which prevent signal 
transmission and those which directly disrupt β-Catenin activity. Inhibitors of Wnt secretion include 
the Porc inhibitors such as IWP2 used in Section 5.2 or LGK974, currently in Phase I trials(179, 267, 
269). Inhibitors of ligand binding include antagonists of Fzd receptors such as OMP-18R5 or soluble, 
sFRP like molecules such as OMP-54F28(270, 271). Signal transmission can be prevented through Dvl 
blockade such as the PDZ domain inhibitor used in Section 5.2 or stabilisation of the β-Catenin 
destruction complex through tankyrase inhibitors(180, 272). As the β-Catenin /Canonical signalling 
remains the best studied of the pathways, numerous compounds also exist to antagonise nuclear β-
Catenin function such as ICG001, also used in Section 5.2(181) 
 
In vitro, pan Wnt inhibition in aHSCs mediated by IWP2 appeared successful, significantly reducing 
expression of the myofibroblast marker α-SMA and Type 1 collagen. However in vivo administration 
of IWP2 is likely to have significant off target toxicity with trials of Wnt antagonists reporting 
detrimental effects on bone formation and turnover, haematopoiesis and disruption of intestinal 
stem cell turnover. Even targeting IWP2 specifically to HSCs is likely to have complications. Firstly, 
IWP2 would prevent only secretion of Wnt from HSCs and not response to paracrine Wnts. Secondly, 
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temporal differences in Wnt expression are suggested by Chapter 3 and differences in Wnt response 
suggested by Chapter 5 where early inhibition appears to increase profibrogenic targets. Inhibition 
of Wnt would have to be finely timed to reach specific targets. Finally, impaired Wnt secretion in 
HSCs prevents their potentially beneficial effect on other cell types. Wnts secreted by macrophages 
are important in influencing differentiation of hepatocytes from progenitors after injury, 
determining a cholangiocyte or hepatocyte cell fate(258). Only macrophage derived Wnts were 
assessed but HSC derived Wnts may also be likely to play a role. Blanket inhibition of Wnt signalling 
in HSCs may therefore have detrimental effects on repair and regeneration after injury. 
 
Treatment with Fzd antagonists or sFRP like molecules can reduce response to Wnt ligands (270, 
271). However, decreased response to Wnt appears the default state in aHSCs with significantly 
decreased receptor expression and increased sFRP expression. Therefore, treatment with these 
antagonists may have little effect on profibrogenic myofibroblasts but greater, potentially 
detrimental effects on neighbouring cells. 
 
Upregulation of sFRPs in aHSCs is an intriguing finding. sFRPs themselves have been used to target 
Wnt signalling as putative antifibrotics, recombinant sFRP treatment promoting improvement in 
instances of cardiac and kidney fibrosis(273). However, Chapter 3 suggests reasons for careful use of 
sFRPs as Wnt inhibitors, with effects appearing highly dependent on cell types and Wnt ligands 
present. As well as functioning in Wnt signalling modulation, they also possess a netrin like domain, 
implicated in matrix remodelling.  More interestingly, recent studies have shown effective reduction 
in fibrosis by treating sFRPs themselves, therapeutic antibody mediated blockade of sFRP2 improving  
a cardiac fibrosis model(274). Function of sFRPs was not resolved here, KO studies unsuccessful and 
overexpression inconclusive. As previously mentioned, careful study of sFRP/Wnt and sFRP/sFRP 
interactions as well as the possibility of functional redundancy would need to be undertaken before 
they could be considered as targets for therapeutic intervention. Similar problems are encountered 
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throughout this study: complexity of pathway, multiplicity of ligands and poorly defined interactions 
between interactors. Therapeutic intervention at the level of Wnt ligands or extracellular 
modulators is therefore unlikely to be an attractive target as the chance for interference from other 
components is great. Intervention at points further down the pathway with less chance for 
interference, such as through targeted inhibition of Dvl function, may be more effective. 
 
Several points exist at which Wnt pathway could be targeted in HSCs. The presence of multiple Wnt 
ligands and secreted interactors however significantly complicate the environment, potentially 
making it difficult to judge effectiveness of inhibitor. Furthermore, neither Wnt stimulation nor β-
Catenin upregulation appeared to have a direct profibrogenic effect although effects on survival of 
HSCs remain a possibility. From this, it could be considered that blockade of Wnt signalling in the 
liver may not be worth the potential risks to repair and homeostasis mechanisms, as significant 
reduction in fibrosis may not be achieved. 
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Figure  7.1 Summary of Summary of Wnt signalling in HSCs  
Diagram illustrating aspects of the Wnt pathway investigated in this study (A) Influence of autocrine 
Wnt5a signalling on aspects of HSC behaviour such as survival, migration, proliferation and expression of 
fibrogenic markers was investigated. Only a potential influence on HSC survival was identified (B) 
Potential for paracrine Wnt signalling between HSCs and Kupffer cells (KC) was next explored. Wnt5a 
stimulus increased expression of inflammatory markes such as TGFB and MCP1 in KCs (C) Expression of 
canonical Wnts 10b and 3a could not be detected in HSCs, implying HSCs function through non canonical 
signalling pathways (D) HSCS express abundant levels of β-Catenin despite lack of canonical Wnts 
detected and downstream TCF mediated transcriptional activity. Its function in HSCs therefore requires 
further exploration.  
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7.2 H2A.Z and DNA Methylation  
 
Chapter 6 focused on how early developmental changes may influence the wound healing response 
in adults. This chapter questioned whether altering H2afv (the zebrafish ortholog of H2A.Z) could 
alter methylation levels in early embryo. I have succeeded in showing that H2afv is critical for 
embryonic development. Its absence increases mortality, causes phenotypic abnormality, 
particularly of the nervous system and results in hypermethylation of morphants at early stages.  
These are preliminary results and many issues from this have yet to be addressed. Firstly, which 
signalling pathways does loss of H2A.Z disrupt to cause this phenotype? Analysis of the zebrafish 
sperm genome described enrichment of H2afv at loci particularly involved in development of the 
endocrine system and hindbrain as well as regulation of protein metabolism and gene 
transcription(225). Enriched genes included those of the hox, pax, pitx, dlx and nkx families, key 
regulators of embryogenesis, again supporting H2afv’s essential role in development.  The handful of 
markers analysed in section 6.5 was extremely limited. Analysis of h2afv morphants by next 
generation sequencing would significantly aid identification of pathways disrupted either directly 
through H2A.Z loss or through hypermethylation.  
Here, I have been able to demonstrate hypermethylation in morphants during early stages of 
development through immunoblotting for 5MeC levels. However this is a rudimentary method of 
analysing global methylation levels. Again, next generation sequencing would allow genome wide 
methylation profiles to be examined at the single nucleotide level. One possibility could be reduced 
representation bisulfite sequencing (RRBS), a method of sequencing that biases towards areas of the 
genome high in CpG content such as promoters and avoids the high cost and sequence depth 
required for whole genome sequencing(70). This would enable identification of which specific sites 
are hypermethylated and paired with the transcriptome analysis, would give clues as to what may be 
mediating the phenotype.  
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The translation blocking ability of a MO is usually limited to the first 5 days of development, after 
which protein translation can resume(275). For the mildly affected morphants who survive beyond 
5dpf it would be interesting to question whether H2afv is deposited at similar to sites to that of 
control fish once the morpholino has been diluted out and translation resumes. Disrupted 
methylation patterns may lead to altered deposition with potential consequences for transcriptional 
regulation later in life. Another study in Arabidopsis revealed enrichment of H2A.Z at genes 
regulating response to environmental stress and H2A.Z mutants responded poorly to stress stimuli 
such as heat or cold(276). Another question to ask could be if a similar effect is observed in 
morphants. Mildly affected morphants could be subjected to standard stressors in zebrafish models 
such as heat shock, oxidative stress or ethanol treatment. Mortality and compensatory response 
could then be observed and compared to controls.   
Finally, H2A.Z also has well established roles in DNA damage response and genome stability(277, 
278). Another limitation of this study was that due to time constraints these roles were overlooked 
in favour of studying methylation. Levels of DNA damage in morphants could be initially assessed 
through whole mount staining for the DNA damage marker γH2AX(279).  Genome stability has 
previously been examined in zebrafish through use of phosphor Histone 3 (PH3) staining as a marker 
for mitosis or metaphase spreads to analyse chromosome behaviour(280). The developing nervous 
system is highly susceptible to defects in DNA repair pathway as developing neurons undergo rapid 
phases of proliferation. If mutation occurs which is not correctly repaired this can be propagated 
through the developing nervous system, incurring serious consequences(281). Defects in the DNA 
repair pathway could therefore be contributing to the neural phenotype, especially given its slightly 
later onset (approximately 2dpf) at which point defects will have had time to accumulate.  
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